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 Abstract 
Ataxia telangiectasia (A-T) is characterised by a predisposition to the development of a range 
of lymphoid tumours of both T and B cell origin. Currently, Atm-/- mice develop an 
aggressive thymic lymphoma and die by 13 weeks of age. In order to overcome this barrier to 
long lived mice and expand the range of lymphoid tumours driven by Atm loss, I crossed the 
Atm-/- mouse with the nude mouse (nu-/-).  
The resulting Atm-/-nu-/- mice had a greater lifespan compared to the Atm-/- mice (median 
survival of 175 days versus 91 days). Of 17/69 Atm-/-nu-/- mice that developed a tumour 
sixteen were of B cell origin occurring in the spleen, liver, gut and axillary nodes. 
Histological examination of the B cell-derived tumours revealed that they were 
phenotypically heterogeneous. No tumours were observed in the control mice (Atm+/+nu-/- 
or Atm+/+nu+/-).   
Fluorescence in situ hybridisation (FISH) revealed the presence of IgH translocations in 1/6 B 
cell lymphomas and 2/6 tumours had an additional copy of Myc. M-FISH revealed clonal 
abnormalities involving chromosomes 17 and/or 18 in 5/6 tumours analysed. 
We conclude that in contrast to T cell lymphoma development in Atm-/- mice, which is 
associated with immune gene translocations and Myc amplification, the Atm-/-nu-/- model of 
A-T gives B cell lymphomas arising at different stages of B cell development and may be 
more representative of the types of B cell lymphoma in patients with A-T. 
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INTRODUCTION 
  
2 
1 INTRODUCTION 
1.1 An introduction to ataxia telangiectasia (A-T) 
1.1.1 The clinical phenotypes associated with ataxia telangiectasia 
Ataxia Telangiectasia (A-T) is an autosomal recessive disorder with multiple associated 
phenotypes. Primarily a neurodegenerative disease, A-T patients develop progressive 
cerebellar ataxia, which results in them becoming wheelchair bound by approximately 10 
years of age (Sedgwick and Boder, 1991, Swerdlow, 2008, Mavrou et al., 2008). In addition, 
patients also show both ocular and cutaneous telangiectasia (dilated blood vessels), 
immunodeficiency (Nowak-Wegrzyn et al., 2004), chromosome instability, particularly 
translocations involving chromosomes 7 and 14 in T lymphocytes (Meyn, 1999) (Chun and 
Gatti, 2004), unusual clinical (Cunliffe et al., 1975) and cellular radiosensitivity (Taylor et al., 
1975) and an increased incidence of cancer (Hecht et al., 1966) (Sedgwick and Boder, 1991). 
Patients have a median survival of 19-25 years (Crawford et al., 2006) and most patients die 
from respiratory tract infections but a significant proportion (22%) develop cancer, mostly of 
lymphoid origin (Reiman et al., 2011, Micol et al., 2011). The incidence of A-T in the UK is 
about 1 in 330,000 (Taylor et al., 1996).  
1.1.2 The ATM gene; loss of which causes ataxia telangiectasia 
 A-T is caused by biallelic mutation of the ataxia telangiectasia mutated (ATM) gene (Savitsky 
et al., 1995) located at 11q22-23 (Gatti et al., 1988). There are 62 coding exons and no 
evidence of splice variants (Uziel et al., 1996). Mutations in ATM that are found in A-T 
patients are evenly spread throughout the gene and are mostly truncating resulting in 
instability and loss of the ATM protein. These include nonsense mutations, small in frame 
deletions or insertions and splice site mutations resulting in exon skipping. Some splice site 
3 
mutations are ‘leaky’ and can result in expression of a low level of normal ATM protein. In 
addition, some small in-frame deletions or missense mutations can result in expression of 
some mutant ATM protein (Reiman et al., 2011). The ATM gene encodes a large 350kDa 
protein with kinase activity (Savitsky et al., 1995).  
1.1.3 The cellular phenotypes associated with A-T 
The most important cellular feature is that cells from patients with A-T are hypersensitive to 
ionising radiation as shown by reduced colony survival and also increased chromosomal 
damage after exposure to IR compared to normal cells. This was discovered following the 
realisation that patients were clinically radiosensitive (Morgan et al., 1968, Cunliffe et al., 
1975). The increased radiosensitivity is caused by a defect affecting both classical non-
homologous end joining (C-NHEJ) and homologous recombination (HR) repair resulting in 
unrepaired DNA DSB, as a consequence of loss of ATM in these cells. ATM loss also causes 
cell cycle defects. In cells from A-T patients there is a defect in the activation of the G1-S, 
intra-S and G2-M checkpoints in response to DNA damage. A defect in activation of the S 
phase checkpoint results in radioresistant DNA replication and cell cycle progression in the 
presence of unrepaired DSB, which are both damaging to the cell (Chun and Gatti, 2004, 
Lavin and Kozlov, 2007). 
In addition to defects in the DNA damage response (DDR) A-T cells have accelerated 
shortening of telomeres, suggesting that ATM plays a role in the maintenance of telomeres 
(Metcalfe et al., 1996). Similarly, studies of the yeast ortholog of ATM, Tel1, show that Tel1 
is required for maintenance of yeast telomeres (Ma and Greider, 2009). On the other hand, the 
chromosomes of bone marrow cells from A-T mice that lack Atm protein have normal length 
telomeres (Feldser et al., 2006). This suggests that the role of ATM in the maintenance of 
telomeres could vary between species.  
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In human primary fibroblasts, ATM is recruited to damaged telomeres and subsequently 
activates the DNA damage response.  Normally, the shelterin complex protects telomeres. 
Disruption of this complex by depletion of one of its components, TRF2, results in ATM 
activation. Overexpression of TRF2 also inhibits the ability of ATM to signal DDR. The 
inhibitory action of TFR2 on ATM is likely to prevent ATM from recognising telomeres as 
sites of DNA damage (Karlseder et al., 2004). Overall ATM plays an important role in 
detecting abnormal telomeres.  
Studying the cellular defects in A-T cells has provided some basis, although incomplete, for 
the clinical phenotype of the disease. Gross genomic instability leads to the development of 
malignancies and impaired development of the immune system in A-T (see below). On the 
other hand, it is still not clear what is the cause of neurodegeneration in these patients but 
increased oxidative stress combined with neuronal sensitivity to genotoxic stresses are all 
possible contributors.  
1.1.4 Genotype- phenotype relationships in A-T 
As mentioned previously, A-T is a both genetically and phenotypically heterogeneous. The 
relationship between the type of ATM mutation and clinical symptoms is beginning to be 
understood.  ATM mutations can be divided into those that result in loss of all ATM kinase 
activity and those that result in retention of some kinase activity (Reiman et al., 2011). Total 
loss of ATM activity is associated with the cellular and clinical features of classical A-T 
including early onset (<2 years of age), and is most commonly caused by biallelic loss of 
ATM protein. Patients with ATM mutations in whose cells residual ATM kinase activity is 
detected, either through expression of a measurable level of normal ATM protein or the 
expression of mutant ATM protein, are associated with a milder clinical phenotype (Reiman 
et al., 2011, Taylor et al., 2014). This includes a slower progression of neurological features, 
5 
longer survival and protection against tumours in childhood. An example of the first type of 
mutation is the leaky splice site mutation c.5763-1050A>G (p.Pro1922fs) which allows a low 
level expression of normal ATM protein that, of course, has the ability to phosphorylate ATM 
targets (Reiman et al., 2011). This mutation is found in one allele in a significant proportion 
of A-T patients in the British Isles and these patients usually have a second mutation that is 
truncating.  
An example of the second type of mutation, a missense mutation giving rise to mutant protein 
with activity, is the c.7271T>G (p.Val2424Gly) ATM mutation, which is usually found in 
individuals that are diagnosed as adults but had some A-T symptoms from childhood (Reiman 
et al., 2011). Generally patients homozygous for these ‘milder’ mutations have an even milder 
phenotype than those with just one such allele.  This genotype phenotype correlation is 
helpful in providing some indication to families of prognosis although this needs to be done 
with caution. 
1.2 The ATM protein kinase 
ATM is a phospho-inositide- 3 kinase (PI3K) related protein kinase (PIKK family). Other 
members of the family include Ataxia Telangiectasia and Rad 3 related protein (ATR), 
mammalian target of rapamycin (mTOR) and DNA protein kinase catalytic sub-unit (DNA-
PKcs). ATM phosphorylates target proteins on serine or threonine residues that are followed 
by a glutamine (SQ or TQ) (Shiloh, 2003). In addition to the kinase domain the ATM protein 
has a FAT domain and FATC domain. ATM binds many substrates including NBS1, BRCA1 
and p53 via an N-terminal substrate-binding site (SBS) (Difilippantonio et al., 2005, Lavin, 
2008) (Figure 1.1). Most ATM protein is located in the nucleus but some ATM expression 
has been detected in the cytoplasm of neuronal cells (Lakin et al., 1996, Ambrose and Gatti, 
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2013). A proportion of cytoplasmic ATM is localised to the peroxisomes possibly via its 
FATC domain (Guo et al., 2010).  
1.2.1 Activation of ATM 
ATM has to be activated and this occurs by autophosphorylation or transphosphorylation at 
Ser367, Ser1893, Ser1981 and Ser2996 (Lavin and Kozlov, 2007, Kozlov et al., 2011) in 
human cells. In addition to phosphorylation, ATM is acetylated on a lysine residue (K3016) 
by the acetyl-transferase TIP60 (Sun et al., 2005) (Figure 1.1).  ATM exists as an inactive 
homodimer that becomes monomerised on activation (Bakkenist and Kastan, 2003). 
Activation can occur following exposure of cells in vitro to agents that cause DNA DSB, 
including IR, various drugs such as neocarcinostatin and bleomycin as well as oxidative stress 
(Ambrose and Gatti, 2013, Taylor et al., 1983, Shiloh et al., 1982). Complete activation of 
ATM requires the MRN complex (Lee and Paull, 2005).  
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Figure 1.1 Schematic representation of ATM 
 
Schematic representation of ATM, a 3056 amino acid protein, showing the SBS, FAT, FATC and the 
important kinase domain. The four major autophosphorylation (P) and acetylation (AC) sites are 
indicated.  (Modified from (Lavin, 2008), and (Stracker et al., 2013). 
SBS= substrate binding site 
FAT= focal adhesion kinase target  
FATC = FAT C-terminal  
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1.3 Role of ATM in the DNA damage response 
1.3.1 The DNA damage response 
DNA is constantly the target of damage caused by endogenous and exogenous factors. Types 
of damage include single strand breaks (SSB), double strand breaks (DSB), DNA cross-links 
and bulky adducts (Jeggo and Löbrich, 2007) To maintain the integrity of the genome, cells 
have highly conserved DNA repair machinery that responds to genotoxic stress. This is 
important because compromised genomic integrity can lead to potentially harmful mutations 
and apoptosis (Lavin, 2008). In addition, unrepaired DSB can lead to translocations that have 
potential to cause malignancy e.g. IgH-MYC that is frequently found in B cell malignancies 
(Jackson, 2002). 
ATM is part of the DNA repair machinery. ATM is not an essential gene unlike NBN, MRE11 
and RAD50 (in the same repair pathway). In the absence of ATM, the efficiency of DSB 
repair is reduced and a subset of breaks remain unrepaired (Kühne et al., 2004). 
The first step in the DNA damage response (DDR), following DSB induction, is activation of 
the MRE11/NBS1/RAD50 complex, which in turn activates the ATM kinase. This results in 
phosphorylation of ϒ-H2AX by ATM, which facilitates the recruitment of other proteins 
involved in the sensing and maintenance of signalling to the break. Following this, MDC1 
binds to the break and is phosphorylated by ATM, which leads to the recruitment of the 
MR11, Rad50 and NBS1 (MRN) complex to the site (Stewart et al., 2003, Jungmichel et al., 
2012). NBS1, part of the MRN complex acts as an adapter protein tethering ATM to the site, 
stabilising it at the site of the DSB and allowing phosphorylation of its target proteins (Lee 
and Paull, 2005). In addition to its role as an adapter, the MRN complex acts like a scaffold to 
tether the two broken ends of DNA together via RAD50 protein (He et al., 2012, Moreno-
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Herrero et al., 2005). MDC1 also recruits RNF8 which ubiquitilates H2AX and this allows the 
binding of p53 and BRCA1 to the site and further amplification of the signal (Kolas et al., 
2007, Lavin, 2008). 
1.3.2 Down stream signaling of ATM 
If damaged DNA persists in a cell it can lead to mutagenic events that could harm the 
organism and, therefore, following recognition of DNA damage, the cell cycle pauses to allow 
time for the damaged DNA to be repaired. If the damage to the DNA is too great then the cell 
undergoes apoptosis. ATM is a key regulator of this process. On sensing DNA damage, ATM 
initiates a signalling cascade that results in activation of different cell cycle checkpoints, DNA 
repair or apoptosis (Abraham, 2001, Shiloh, 2003). 
ATM co-ordinates the G1-S checkpoint by phosphorylating p53 at Ser53, the G2/M 
checkpoint by phosphorylating Chk2 at Thr68, and the intra-S phase checkpoint by 
phosphorylating SMC1 at Ser957 and Ser966 (Ambrose and Gatti, 2013). 
1.3.3 ATM and DNA DSB repair 
DNA DSBs are repaired through one of two distinct pathways; homologous recombination 
(HR) and classical non-homologous end joining (C-NHEJ). HR is less error prone and only 
occurs immediately following S/G2 phase as it requires the presence of a homologous sister 
chromatid to be used as a template (Jackson, 2002). C-NHEJ occurs throughout the cell cycle, 
but unlike HR predominates in the G1 phase and is the main type of repair that takes place in 
non-dividing cells.  
1.3.4 Non-homologous end joining  
Classical Non-homologous end joining (C-NHEJ) repairs externally induced DNA DSB, 
mainly, in the G1 phase of the cell cycle and also in the repair of physiological breaks 
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generated in immune gene rearrangement during lymphocyte development. Repair is initiated 
by binding of the Ku hetero-dimer, which consists of Ku70 and Ku80, at the DSB. The Ku 
complex acts as a scaffold for the binding of the serine/threonine protein kinase DNA-
dependent protein kinase catalytic subunit (DNA- PKcs). On binding, DNA-PKcs undergoes 
autophosphorylation and phosphorylation by ATM (Chen et al., 2007, Weterings and Chen, 
2007).  These phosphorylation events are important for the activity of DNA-PKcs and the 
efficient completion of C-NHEJ. Targets of DNA-PKcs include other C-NHEJ proteins and 
proteins involved in the DDR response including XRCC4, KU70/80, Artemis and p53 (Burma 
et al., 2006, Burma and Chen, 2004). Depending on where the two strand breaks occurred the 
DNA ends may contain a 3’ or 5’ overhang which are not compatible for ligation and require 
shortening or filling to produce two blunt ends. DNA processing is done by DNA 
polymerase-µ and DNA polymerase-λ, as well as the nuclease Artemis, which are recruited by 
the Ku-DNA-PKcs complex (Ma et al., 2002, Lieber, 2010). Finally, repair is completed by 
ligation of the two DNA ends by Ligase IV and XRCC4 (Grawunder et al., 1997). 
1.3.5 V(D)J recombination and NHEJ  
V(D)J recombination is a process that is only undertaken in lymphocytes. It creates genetic 
diversity in the immune antigen receptors. V(D)J recombination occurs before antigen 
exposure. It is a process of recombination to generate a unique coding sequence composed of 
variable (V), diversity (D), and joining (J) segments. These gene segments are flanked by 
recombination signal sequences (RSS) that are separated by either 12-bp or 23-bp sequence. 
Recombination will only take place between two segments flanked by 12-bp and 23-bp 
spacers. This 12/23 rule prevents the joining of two similar gene segments. V(D)J 
recombination is divided into two stages; (1) cleavage and (2) repair. Cleavage is undertaken 
by the recombinase activating genes 1 and 2 (RAG1 and RAG2). These proteins, signalled by 
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the RSSs, introduce DSB between the V, D and J genes that are sensed by ATM, which 
initiates the DDR (Bredemeyer et al., 2006, Gapud et al., 2011). The RAG complex along 
with ATM are temporarily involved in stabilising the post cleavage complex before it is 
repaired by the proteins involved in NHEJ (Deriano et al., 2011). ATM also plays role in 
safeguarding against RAG mediated breaks being generated at multiple loci at the same time 
(Chaumeil et al., 2013).  RAG proteins generate a coding end, that has a covalently sealed 
hairpin intermediate which requires processing before repair and contributes to the 
diversification of this gene, and a signal end that can be fused directly (Mcblane et al., 1995). 
The processing step of NHEJ adds additional diversity to the immune gene in the following 
ways. The Artemis protein undoes the covalently sealed hairpin at the coding end of the break 
by making a cut at or near the apex of the loop, which causes nucleotide deletions or 
insertions at this position (Lieber, 2010). Once the hairpin is open, the lymphocyte specific 
polymerase, terminal deoxynucleotidyltransferase (TdT), adds further diversity to the immune 
gene by inserting non-templated nucleotides (Bollum, 1979, Gilfillan et al., 1993). Finally, 
V(D)J recombination is completed by the ligation of the two coding ends and the two signal 
ends by the XRCC4- Ligase IV complex (Malu et al., 2012, Rooney et al., 2004, Alt et al., 
2013).  
1.3.6 Homologous recombination  
Homologous recombination (HR) will repair DSB, inter –strand cross links (ICL) and in the 
recovery of stalled replication forks. In the late S/ G2 phase of the cell cycle both HR and C-
NHEJ can be used to repair DSB (Geuting et al., 2013). Although ATM is not essential for 
HR it must play a role because ATM phosphorylates the HR protein Rad51 and cells from A-
T patients have a higher frequency of recombination events (Chen et al., 1999, Morrison et al., 
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2000, Bryant and Helleday, 2006). More recently it has been shown that RPA 
phosphorylation during HRR is also ATM dependent. 
HR is a multistep process that can be broken down into three main phases: pre-synapsis, 
synapsis and post synapsis. In pre synapsis the DSB are recognised and processed. In the 
synapsis phase, Rad51 binds the single stranded overhang. The Rad51 coated filament 
performs a homology search and the invading strand generates a displacement –loop (D-loop).  
In the final phase, post-synapsis, DNA synthesis begins and second strand invasion forms a 
holiday junction. Resolution of this complex can occur with or without chromatid crossover 
(Li and Heyer, 2008, Heyer et al., 2010).  
1.4 The role of ATM in T and B lymphocyte development 
1.4.1 Lymphocyte development 
Haematopoietic stem cells (HSC) in the bone marrow are responsible for the production of all 
blood cell lineages throughout life including T and B lymphocytes. From HSC, progenitor 
cells are produced, which in turn differentiate into more specialised cells losing pluripotency 
at each stage of differentiation. The common lymphoid progenitor (CLP) has the potential to 
produce both T and B cells. The fate of each cell is determined by cytokine signalling in the 
bone marrow (Kondo et al., 1997, Kondo et al., 2001). Lymphocytes have specialised 
immune genes that encode specific antigen receptors. Lymphocyte development is centred 
around producing and selecting a high affinity T cell receptor (TCR) or B cell receptor (BCR) 
in order to recognise and respond to pathogen invaders (Cooper and Alder, 2006).  
1.4.2 The development of T cells  
The thymus does not contain any self-renewing progenitors, instead it relies on the migration 
of T cell progenitors from the bone marrow. Haematopoietic stem cells (HSCs) in the bone 
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marrow produce multipotent progenitors (MPPs), that give rise to lymphoid primed 
multipotent progenitors (LMPPs), that differentiate into common lymphoid progenitors 
(CLPs). LMPPs and CLPs leave the bone marrow and enter the circulation before settling in 
the thymus. The majority of T cell development takes place in the thymus (Zlotoff and 
Bhandoola, 2011). T cell progenitors in the thymus can give rise to cells expressing an αβ 
TCR, or less commonly a ϒδ TCR. On entering the cortex of the thymus, double negative 
(CD4-CD8-) progenitor T cells first undergo V(D)J recombination of their β/δ chain and form 
pre T cells that express a pre-TCR complex. Signalling through the pre-TCR complex 
promotes survival and further development. Double positive (CD4+CD8+) T cells then 
recombine the second receptor chain (α/γ) and express a TCR complex. In some cases, further 
rounds of receptor editing occur to reduce autoreactivity or increase affinity of the receptor to 
antigen that is expressed on the surface of cortical thymic epithelial cells. Ultimately strong 
signalling through the TCR in response to antigen leads to positive selection and prevents 
further rearrangements After positive selection, T cells move to the thymic medulla and those 
that exhibit auto reactivity are eliminated by negative selection (Sprent and Surh, 2002, 
Sprent and Kishimoto, 2002). The double positive (DP) T cells then lose expression of CD4 
or CD8 and become single positive (SP) T cells (Nemazee, 2006).  
1.4.3 The development of B cells  
B cells are part of the adaptive immune system and can be simply described a set of cells that 
express clonally diverse surface immunoglobulin that recognise specific antigens (Cooper and 
Alder, 2006). B cell development begins in the bone marrow then the cells travel to secondary 
lymphoid tissue, including the spleen, where maturation is completed. B cell development can 
be characterised by an ordered stepwise progression of gene and surface marker expression 
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(Alt et al., 1986). In the mouse, the most commonly used surface antigens used for the 
identification of B cells are C-Kit, B220, CD43 IgM, IgD (Miosge and Goodnow, 2005).  
Part of the B cell development is rearrangement and editing of the BCR through three 
processes that occur at different stages of maturation; V(D)J recombination, class witch 
recombination (CSR) and somatic hypermutation (SHM). Rearrangement at each stage is 
strictly regulated by a series of checkpoints. Cells that generate receptors that lack antigen 
affinity or are autoreactive are dismissed. Selection occurs through signalling of BCR. A high 
affinity to antigen produces BCR signalling which promotes cells survival and clonal 
selection of these cells. In addition, in the mechanism of receptor selection, BCR signalling 
switches off RAG proteins and thus stops further recombination. Those cells with a low 
affinity rearrangement will undergo further rounds of editing until a high affinity antibody is 
produced or a non productive rearrangement occurs that leads to cells death (Nemazee, 2006, 
Ehlich et al., 1994). 
1.4.4 The role V(D)J recombination in B cell development 
The recognition of specific antigens is conferred by a specific antigen receptor on the B cell 
surface. This antigen receptor, the B cell receptor (BCR), is made up of two chains, the 
immunoglobulin heavy chain (IgH) and an immunoglobulin light chain (IgL) (Nemazee, 
2006). The heavy chain of the BCR is made up of a constant region and a variable region. The 
variable region is encoded by three gene groups; variable (V), diversity, (D) and joining (J). 
In humans the V genes, J genes and D genes are randomly joined by a process of V(D)J 
recombination (See section above) (Tonegawa, 1983). The light chain has a variable region 
and a joining region only.  The quasi-random nature of recombination events ensures a high 
possibility of unique receptors being produced (Nemazee, 2006). Additional diversity is 
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created at the joining of the junctions between these genes, which adds to the variability and 
specificity of the receptor.   
The first immune gene rearrangement to take place is D-J of the IgH gene and it occurs in 
progenitor (Pro) B cells.  At the next developmental stage the V-DJ recombination takes place. 
and leads to expression of an IgH with a µ (M) constant region and a surrogate light chain that 
make the pre-BCR complex. (Ehlich et al., 1994, Allman et al., 1999). This is the first check 
point in B cell development and 75% of B cells fail to pass this checkpoint and undergo 
apoptosis (Osmond, 1991).  
After rearrangement of IgH the B cell goes on to rearrange immunoglobulin light chain (IgL). 
This gene locus lacks a D segments and therefore has much less diversity potential. V-J 
recombination along with further rounds of editing takes place and finally a BCR receptor 
with an IgH and IgL chain is expressed on the surface of the cells (IgM). These immature B 
cells then leave the bone marrow and travel to the secondary lymphoid tissues (Nemazee, 
2006).  
1.4.5 Antigen dependent B cell development 
Antigen stimulation in the secondary lymphoid tissues gives rise to further differentiation in a 
process known as the germinal centre (GC) reaction, which is characterised by clonal 
expansion and is summarised in Figure 1.2. In the germinal centre the immunoglobulin genes 
under go class switch recombination (CSR) and somatic hyper mutation (SHM) with the aim 
of increasing the affinity of the BCR to antigen (Rajewsky, 1996, Kocks and Rajewsky, 1988, 
Lebien and Tedder, 2008).  
The process of isotype switching of the constant region of the BCR is called class switch 
recombination (CSR). CSR is initiated by the protein AID (Activation-Induced (cytidine) 
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Deaminase). The constant region of the antibody determines the effector function of BCR 
signalling. The BCR constant region is switched from IgM to either IgG, IgD, IgE or IgA 
through intra-chromosomal deletion. The broken ends of DNA are repaired by C-NHEJ (see 
section 1.3.4) (Stavnezer et al., 2008). ATM is required for the efficient completion of CSR 
and consistent with this, A-T patients have reduced IgA and IgG levels (Pan et al., 2002). 
Mouse B cells also have reduced CSR when stimulated in vitro. In the absence of ATM, AID 
induced DSB can persist over several cell division and can lead to abnormal recombination 
including IgH- Myc translocations (Ramiro et al., 2006). Overall, like in V(D)J recombination,  
ATM is involved in the organisation of the repair complex and halting the cell cycle in CSR 
(Callén et al., 2007, Reina-San-Martin et al., 2004).  
SHM is a process in which point mutations are introduced into the variable region of the 
antibody with the intention to refine the specificity of the receptor to antigen (Bross et al., 
2000). High rates of transcription are required for it to occur (Peled et al., 2008). Point 
mutations are generated during the erroneous repair of uracil, introduced into the DNA by the 
deamination of cytosine by AID, by base excision repair (BER) and mis-match repair (MMR) 
(Peled et al., 2008).   
The germinal centre is the site of T cell specific immune response. The purpose of it is to 
facilitate the affinity maturation of B cells to generate long lived plasma cells with high 
affinity antigens (Mcheyzer-Williams and Ahmed, 1999). There are a series of common steps. 
Firstly the activated B cell migrates to the centre of the follicle where it begins to proliferate. 
The follicle has two distinct areas: light zone and dark zone. The follicle is mostly made up of 
T cells, B cells, macrophages and follicular dendritic cells (FDCs) that express larges amounts 
of antigen. The follicular processes of the FDCs extend into a light zone. The dark zone 
contains the closely packed proliferating B cells, and very few FDC processes. B cells in the 
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follicle can been categorised morphologically into small cleaved centrocytes found 
predominantly in the light zone, and larger round centroblasts, found predominantly in the 
dark zone (Allen et al., 2007b, Maclennan, 1994, Maclennan, 2005). Centroblasts are rapidly 
dividing B cells that do not express immunoglobulin as they are undergoing progressive 
rounds of SHM indicated by high levels of AID protein expression in this region (Cattoretti et 
al., 2006, Moldenhauer et al., 2006). When centroblasts stop dividing, they become 
centrocytes and migrate to the light zone.  Although more recently it has been proposed that 
cells in both the light and dark zone undergo mitosis and the cells move back and forth 
between the light and dark zone (Camacho et al., 1998, Hauser et al., 2010). B cells with a 
high affinity BCR that interact strongly with T cells and FDCs, are selected for in the GC. 
Those B cells with a low affinity receptor are eliminated by apoptosis. This process is termed 
affinity maturation (Kepler and Perelson, 1993, Maclennan, 1994). Positively selected B cells 
choose to either undergo further rounds of SHM or to exit the germinal centre and 
differentiate into long lived plasma cells or memory B cells (Meyer-Hermann et al., 2012).  
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Figure 1.2 The germinal centre 
 
 
The germinal centre is composed of three zones; light zone, dark zone and mantle zone.  Mature B 
cells that have encountered antigen differentiate into centroblasts in the dark zone. Here, the 
centroblasts undergo a phase of rapid proliferation. During this phase SHM of the immune gene takes 
place to generate an antigen receptor that has a high affinity. Those cells with an antigen receptor with 
weak affinity or are autoreactive undergo apoptosis. The remaining cells leave the dark zone and move 
into the light zone and become centrocytes. Centrocytes undergo further rounds of editing and 
selection of their immune genes to increase affinity to antigens presented by FDC and T cells. In the 
light zone some centrocytes undergo CSR, which changes the effector function of the antigen receptor. 
Finally the centrocytes differentiate into either a plasma cell or memory B cell and are now ready to 
leave the germinal centre.  
Diffuse large B cell lymphoma is composed mostly of centroblasts B cells. Follicular lymphoma 
contains both centroblasts and centrocyte B cells.  
SHM = Somatic hypermutation  
CSR = Class switch recombination  
FDC = Follicular dendritic cell 
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1.5 The role of ATM in tumour development  
1.5.1 Tumour development in patients with A-T 
It has long been known that patients with A-T have an increased risk of developing cancers 
(Sedgwick and Boder, 1991). Recent studies suggest between 22 and 40% of A-T patients are 
likely to develop malignancy (Reiman et al., 2011, Micol et al., 2011, Meyn, 1999). A-T 
patients develop a range of malignancies mainly lymphoid tumours, but also endocrine and 
brain tumours, breast cancer, glioblastoma, liver, uterine, ovarian and myeloid leukaemia 
(Taylor, 1992, Micol et al., 2011). The type of tumour development in A-T patients is closely 
related to the age of development (Reiman et al., 2011), with lymphoid tumours being more 
prevalent in young patients (<16 years of age). About 40% of lymphoid malignancies are non-
Hodgkin’s lymphoma, 25% are acute lymphoblastic leukaemia and 10% are Hodgkin’s 
lymphoma.  It is unclear whether A-T patients have a higher proportion of T cell lymphomas 
than B cell lymphomas. 
Bcr-Abl, Tel-AML, MLL translocations are frequently found in paediatric leukaemia in the 
general population, but the incidence of these translocations is not increased in tumours that 
develop in A-T patients suggesting that ATM loss is not involved in the development of B 
precursor ALL (Taylor et al., 1996, Reiman et al., 2011). In the general population paediatric 
B cell lymphoma usually develops from early B cells that have not yet undergone V(D)J 
recombination, whereas B cell lymphoma in young A-T patients frequently are of mature B 
cell origin. T cells from A-T patients frequently have translocations involving chromosomes 7 
and 14 with breaks within the T cell receptor genes and these are present at much higher 
levels that in the general population (Taylor et al., 1996, Reiman et al., 2011). This may be a 
consequence, either of increased occurrence of such translocations, in the absence of ATM, or 
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a reduced level of apoptosis of cells with such translocations. T cell prolymphocytic 
leukaemia (T-PLL) develops from a T cell with a translocation involving the T cell receptor 
and an oncogene and is associated with old age. However, A-T patients develop these 
tumours at an early age, probably as a consequence of the high level of the appropriate 
translocations in their T cells. It is possible that such aberrant translocations play an important 
part in the development of all lymphoid tumours (both B and T cell origin) seen in A-T 
patients although this is difficult to document. 
In older A-T patients that develop a malignancy there is an increased proportion of solid 
tumours (Reiman et al., 2011) and this can be associated with the expression of abnormal 
ATM protein, but with some kinase activity (Reiman et al., 2011), in these patients allowing 
increased longevity. A possible explanation for this is that the small amount of ATM kinase 
activity protects the patients from developing lymphoid malignancies at an early age but this 
ATM activity is not enough to prevent the development of solid tumours later in life (Reiman 
et al., 2011). The risk of A-T patient developing breast cancer is probably higher than the risk 
associated with carrying either a BRCA1 or BRCA2 mutation. 
Heterozygote carriers of an ATM mutation are at increased risk of developing cancer; in 
particular female carriers are twice as likely to develop breast cancer than a non-carrier. 
Approximately 1% of the population are carriers of an ATM mutation, which has implications 
in the monitoring and management of breast cancer in both A-T families and the general 
population (Taylor, 1992, Meyn, 1999).  
1.5.2 ATM and tumour development in the general population 
Somatic ATM mutations have been associated with cancer development, particularly chronic 
lymphocytic leukaemia (CLL) (Stankovic et al., 1999) T cell prolymphocytic leukaemia 
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(Vorechovský et al, 1997) and Mantle Cell Lymphoma (Schaffner et al., 2000), in the general 
population. Somatic ATM mutations have been detected in several other tumour types 
including lymphoid, lung and large intestine tissues. ATM missense mutations were most 
common in sporadic lymphoid tumours, in contrast to the situation with germ line mutations, 
which are most commonly truncating mutations (Cremona and Behrens, 2014). Loss of ATM 
function can also occur through deletion of chromosomal region distal 11q where the ATM 
gene is located. In a cohort of chronic lymphocytic leukaemias with an ATM mutation 
Skowronska and colleagues found that almost half also had an 11q deletion, leading to 
biallelic inactivation of ATM and consequently loss of ATM function (Skowronska et al., 
2012). The association of loss of function of ATM with the development of sporadic 
lymphoid tumours (eg T-PLL and Mantle cell lymphoma) may be related to the function of 
ATM in lymphoid cells and particularly in V(D)J recombination and formation of 
chromosome translocations, although other mechanisms may operate in CLL and other 
tumours, which remain to be elucidated. Finally, ATM has also been shown to be 
hypermethylated in colorectal tumours, although this was not shown to correlate with a 
change in ATM protein expression (Beggs et al., 2012). 
1.6 The A-T mouse  
Several mouse models have been constructed in order to examine the effect of the systemic 
loss of ATM (Barlow et al., 1996, Elson et al., 1996, Xu et al., 1996), or the consequences of 
particular ataxia telangiectasia associated mutations for cancer risk (Spring et al., 2001), or 
targeting ATM mutations in order to investigate neurodegeneration in older mice (Borghesani 
et al., 2000) and the effect of the presence of a normal level of kinase dead ATM (Yamamoto 
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et al., 2012, Daniel et al., 2012). A summary of these models is given in Table 1.1 and Table 
1.2. 
Table 1.1 Summary of Atm-/- mouse models 
Table 1.2 Haematopoietic comparison 
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1.6.1 Atm null mice  
Barlow and colleagues created the first A-T mouse in 1996 (Barlow et al., 1996). Atm protein 
expression was ablated by insertions of a PKG neo cassette into the Atm gene at position 
5790 to create a truncation mutation similar to that seen in A-T patients. This mutation was 
predicted to lead to absence of ATM protein expression in these mice and southern blotting 
was used to confirm disruption of the gene. These mice recapitulate A-T in that they are 
radiosensitive, sterile, smaller than wild type, have immunological abnormalities and a high 
susceptibility to T cell lymphoma of the thymus (thymoma). All mice develop thymoma of 
CD4+CD8+ T cell origin, and die between 2 and 4 months of age. The thymomas are 
genetically unstable and contain chromosome 6, 12, 14 and 15 translocations.  
Immunological abnormalities in the Wynshaw-Boris (Barlow) mice included reduced CD4+ 
and CD8+ T cells. Additional analysis of these mice by Loizou and colleagues (Loizou et al., 
2011) showed that pre B and immature B cells are also reduced in these mice. Abnormalities 
in the B cells in the Barlow mice also include reduced IgG expression, suggesting and 
impairment in CSR.  
No evidence of neurodegeneration can be detected in these mice by histological examination 
of brain tissues including cerebellum. However, the Barlow A-T mice faired poorly in rota-
rod tests and foot print analysis compared to wild type mice, suggesting a neurological deficit 
in these A-T mice. The mild neurological abnormalities observed in these mice are clearly not 
as severe as the progressive neurodegeneration that develops in A-T patients (Shiloh and 
Rotman, 1996). 
A-T mice were also generated with disruption of the Atm gene in several other laboratories. 
Xu and Baltimore generated mice by disrupting the conserved sequence in the kinase domain 
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that resulted in no protein expression (Xu et al., 1996, Xu and Baltimore, 1996). The Xu and 
Baltimore mice, like the Wynshaw-Boris mice, nearly all develop T cell lymphoma and die by 
the age of 4 months. Similarly they also have immunological abnormalities. Double positive 
(CD4+CD8+) and single positive (CD4+CD8- and CD4-CD8+) T cells, along with immature 
(B220medium IgM+) and follicular (B220+IgM-) B cells are reduced in the Xu and Baltimore 
mice. Unlike the Wynshaw-Boris mice, the Xu and Baltimore mice showed no signs of 
neurological abnormalities.  
The Elson (Elson et al., 1996) mice had a disruption in the Atm gene that corresponded to 
position 5460 of human cDNA. These mice produced two alternative spliced Atm mRNAs 
but no Atm protein expression (normal or abnormal), could be detected in their tissues. The 
Elson mice were similar to the Wynshaw-Boris and Xu Atm null mice in that they had growth 
retardation, hypersensitivity to ionising radiation and reproductive defects. Like the Xu and 
Baltimore mice, no neurological abnormalities have been observed in the Elson mice. 
Interestingly, the incidence of thymoma was much lower in the Elson mice compared to the 
Wynshaw-Boris and Xu and Baltimore mice as only a third (4/12) of mice developed a 
thymoma.  
Some mutations that are found in A-T patients result in the expression of an abnormal ATM 
protein that retains some activity (Reiman et al., 2011). With this in mind, Borghesani  
(Borghesani et al., 2000) generated mice with mutations that were intended to express 
abnormal Atm protein. This mouse had an insertion in the kinase domain that allowed for two 
Atm transcripts; one that had a premature stop codon and another that would theoretically 
allow for read through and production of an abnormal Atm protein that had a kinase domain. 
However no Atm transcript or protein was detected in these mice. Despite this, the 
Borghesani mice lived longer than the Wynshaw-Boris and Xu mice; 50% of Borghesani 
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mice were still alive at 10 months of age. The incidence of lymphoma development was also 
reduced compared to the Wynshaw-Boris and Xu and Baltimore mice suggesting that 
something was protecting these mice. Despite these differences the Borghesani mice were 
similar to the Wynshaw-Boris and Xu and Baltimore mice in that all three had reduced T and 
B cell numbers. Double positive (CD4+CD8+) and single positive (both CD4+CD8- and 
CD4-CD8+) thymocytes were reduced, indicating a disruption in T cell maturation. Also, 
immature B cells (B220medium IgM+) in the bone marrow were reduced but the more mature 
B cells in the spleen were comparable to that of the wild type mice. 
Unlike the Wynshaw-Boris, Xu and Baltimore, and Elson mice, the Borghesani mice had 
detectable neurological defects. In the cerebellum, the molecular layer was reduced and 
Purkinje cells had an abnormal pathology that was detectable in both young (6 weeks of age) 
and old (12 months of age) mice. No overt ataxia could be seen in bridge crossing or footprint 
analysis tests but rota rod performance indicated that the Borghesani mice had decreased 
motor learning.   
A mouse model was made by Spring and colleagues that had residual Atm protein expression 
(Spring et al., 2001). This model carried a mutation that recapitulated the c.7636del9 mutation 
found in A-T patients. Like the Atm null mice generated by Wynshaw-Boris, Xu, Elson and 
Borghesani and colleagues, the Spring mice had growth retardation, radiosensitivity, 
reproductive defects and immunological abnormalities but they are dissimilar to the models 
that had no Atm protein expression because they lived longer. Approximately, 30% of Spring 
mice were still alive at 18 months. These mice developed thymic lymphoma at a lower 
incidence than the mice with complete loss of Atm protein. The thymic lymphoma developed 
from a double positive (CD4+CD8+) and single positive (CD4+CD8- and CD4-CD8+) origin 
whereas the Atm null mice predominantly developed double positive (CD4+CD8+) thymic 
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lymphoma. In addition the Spring mice also developed malignancies of a non-T cell origin.  
Mice that died before 40 weeks of age all developed T cell lymphoma, but older mice were 
susceptible to developing B cell lymphoma as well as ovarian sex cord, epithelial and stromal 
cell tumours. 
The Wynshaw-Boris, Xu and Baltimore, Elson and Borghesani mice all had no detectable 
Atm transcript or protein expression yet the age of survival and tumour type and incidence in 
these mice differed greatly. There have been two possible reasons for this proposed; (1) 
differing husbandry methods: Reduced exposure to pathogens can reduce the incidence of 
lymphoid tumours in mice and could also be a factor in the development of lymphoid tumours 
in A-T mice (Reliene and Schiestl, 2006)  and (2) Differing background strains: The 
background strain of the mice can also affect tumour incidence (Genik et al., 2014).  
Finally, a further type of ATM mutation was modelled in mice. Mice were engineered to 
express a normal level of ATM protein that was kinase dead; these mice were not viable when 
the mutation was present in the homozygous state (Daniel et al., 2012, Yamamoto et al., 
2012). This suggested that the presence of kinase dead Atm protein was more detrimental to 
the organism than complete loss of Atm protein. In the Daniel et al work, the authors 
modelled two ataxia telangiectasia mutations c.8293 G>A; p.(Gly2765Ser) and 
c.8189A>C;p.(Gln2730Pro), which in patients gave rise to expression of a normal level of 
ATM protein but without kinase activity (Reiman et al., 2011). Homozygosity for each of 
these mutations, in mice, was embryonically lethal.  A conditional deletion allowed survival 
of the c.8189A>C;p.(Gln2730Pro) heterozygous mouse. The reason for the presence of kinase 
dead ATM protein causing embryonic lethality in mice is not known and while there are no 
known examples of human homozygotes for these particular mutations, there is a published 
case of another ATM mutation, c.9022C>T;p.(Arg3008Cys), present in a patient in the 
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homozygous state (Angèle et al., 2003). The effects, on the one hand, of kinase dead ATM 
protein and, on the other, total absence of ATM, in A-T patients remains to be fully 
investigated. 
At the same time, another group generated a mouse that also expressed an Atm protein that 
lacked Atm kinase activity (Yamamoto et al., 2012). This mouse had a D2880A/N2885K 
double mutation that corresponds to D2870A/N2875K in humans (Canman et al., 1998, 
Bakkenist and Kastan, 2003). Mice that were heterozygous for this double mutation were 
viable, normal in size, fertile and had no discernable lymphocyte abnormalities. However, like 
the Daniel mice, homozygous mutation led to embryonic lethality. It was concluded that the 
cause of embryonic lethality was not due to a dominant negative effect, as heterozygous mice 
had no defects. To overcome this lethality conditional kinase dead (KD) mice were generated. 
The defect in lymphocyte development was not enhanced in conditional Atm KD mice, as 
V(D)J recombination and CSR was similar to Atm-/- mice. Conditional KD Atm mice had 
increased genomic instability after IR compared to Atm-/- mice, which points to an inhibitory 
involvement of KD Atm in NHEJ and HR. 
1.6.2 Lymphoma in A-T mice  
A-T mice (excluding the Spring mice), develop DP (CD4+CD8+) T cell thymic lymphoma. 
These lymphoma harbour recurrent translocations involving chromosomes 12, 14, and 15. 
The translocations are present in almost all cells in a tumour population (Liyanage et al., 
2000). Translocation between chromosomes 12 and 14 (12;14)) are commonly found (Zha et 
al., 2010). The break point of this translocation on chromosome 14 is at the TCRalpha/ delta 
locus and this is juxtaposed to the centromeric portion of chromosome 12. This translocation 
causes loss of the B cell immune gene IgH. The t(12;14) is also concurrent with amplification 
of a portion of chromosome 14 to generate complex translocations called complicons (Zha et 
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al., 2010, Liyanage et al., 2000). There are several possibilities as to why chromosome 14 
frequently translocate with chromosome 12. The TCR and IgH locus are frequently co 
localised in the nucleus. This close proximity could allow for increased incidence of 
erroneous repair of DSB in each of these genes that leads to translocation. The loss of the 
distal part of chromosome 12 or the juxtaposition of 12 to 14 could also confer an advantage 
to the cell and therefore this translocation is selected for.  T cell lymphomas in A-T mice have 
another chromosomal abnormality that is likely to confer a selective advantage to the cell. 
Aberrations involving chromosome 15 frequently results in increased copy number of Myc, 
although this increased copy number does not result in increased mRNA levels in these cells 
(Liyanage et al., 2000). The chromosomal locations of immune genes and gene associated 
with lymphoid tumours in humans and mice are given in Table 1.3.  
Table 1.3 Chromosome locations of genes in humans and mice 
Human Mouse  
Name Location Name Location Description 
Immune genes 
IGH 14  Igh 12 Immunoglobulin heavy 
IGL 22 Igl 16 Immunoglobulin light  
IGK 2  Igk 6 Immunoglobulin kappa  
TRA 14  Tcra 14 T cell receptor alpha 
TRD 14  Tcrd 14 T cell receptor delta 
TRB 7 Tcrb 6 T cell receptor beta 
TRG 7  Tcrg 13 T cell receptor gamma 
Non-immune genes 
MYC 8 Myc 15 Myelocytomatosis 
oncogene 
BCL6 3 Bcl6 16 B-cell CLL/lymphoma 6 
BCL2 18 Bcl2 1 B-cell CLL/lymphoma 2 
 
This table gives the location of immune genes and non-immune genes in human and mice. The 
nomenclature for each species is taken from the NCBI Gene database.   
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1.7 The origins of B cell lymphoma 
1.7.1 An overview of the WHO classification of lymphoid neoplasms 
The WHO classification of tumours of haematopoietic and lymphoid origin aims to 
encompass the all the methodologies available to clinicians in the diagnosis of human 
tumours. These include morphological, immunophenotypic, cytogenetic and clinical features. 
The most recent review of the classification system was conducted in 2008. The classification 
stratifies neoplasms into lineage (myeloid, lymphoid or dendritic cell/ histiocytic cell) and 
aims to assign a normal cell counterpart to each neoplasm.  Lymphoid neoplasms are divided 
into two groups B and T cell/NK cells. Most T and B cell neoplasms largely resemble the 
normal cells counterpart and their classification reflects this (Swerdlow, 2008).  
To understand B and T cell neoplasm classification an understanding of lymphocyte 
development is needed. Briefly, progenitor B cells (Immunoblast B cells) in the bone marrow 
undergo V(D)J recombination and differentiate into Pre- B cells, which become 
immunoglobulin (IgM+) expressing immature B cells, that leave the bone marrow and finally 
become mature B cells expressing both IgM and IgD (Lebien and Tedder, 2008). Mature B 
cells that encounter antigen in secondary lymphoid tissues enter the germinal centre, become 
rapidly proliferating centroblasts and undergo CSR and SHM. Once they stop dividing, the 
centroblasts move to the light zone of the germinal centre (GC) and become centrocytes.  
Centrocytes leave the germinal centre and differentiate into long-lived plasma cells or 
memory B cells (Maclennan, 1994, Allen et al., 2007a). Some post-germinal centre memory 
B cells remain in the marginal zone of the follicle and others enter the peripheral blood. 
Marginal zone B cells express pan B cell markers (CD19 and CD20), IgM and low levels of 
IgD. Plasma cells travel to the bone marrow where they survive for long periods of time and 
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secrete antibody (Mcheyzer-Williams and Ahmed, 1999). Also see Figure 1.2 for an outline 
of B cell development in the germinal centre. 
There are two types of lymphoma that are of most interest here, diffuse large B cell 
lymphoma (DLBCL) and follicular lymphoma (FL). DLBCL cells morphologically resemble 
centroblasts  and centrocyte cells. In addition, DLBCL cells have evidence of somatic 
hypermutation taking place suggesting that they originate from cells that have been exposed 
to antigen and were part of the GC reaction. FL also originates from GC B cells. They are 
composed of a mixture of centrocytes and centroblasts. The proportion of each cell type 
determines the grading of the lymphomas.  Lymphoma can also arise from non-germinal 
centre B cells and include, mantle cell lymphoma, marginal cell lymphoma and plasma cell 
myeloma.  The morphological, immunological and genetic characteristics of these tumours as 
described in the WHO classification, 2008 will be described in more detail below (Swerdlow, 
2008).  
1.7.2 Classification of diffuse large B cell lymphoma 
DLBCL are a heterogeneous group of tumours and patients may be asymptomatic depending 
on the tumour location. The most recent nomenclature given to this tumour group is DLBCL, 
not otherwise specified (NOS). The common variants of this type are centroblastsic, 
immunoblastic or anaplastic type. The cells in this tumour form a diffuse pattern and are twice 
the size of a normal lymphocyte.  DLBCL, NOS usually arise de novo but can also be a 
consequence of progression of another, less aggressive type of B cell lymphoma e.g. follicular 
lymphoma.  The centroblastsic variant is the most common variant of DLBCL and is either 
composed almost entirely of centroblasts (>90% centroblasts) or is a mixture of centroblasts 
and immunoblasts (<90% centroblasts). DLBCL usually lack expression of one or more 
common B cell markers. Tumour cells usually express surface immunoglobulin, most 
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commonly IgM and less frequently IgG and IgA. Other surface markers typical of this 
lymphoma include; IRF4/MUM1, CD10, BCL6, BCL2. Genetic analysis of DLBCL shows 
that MYC and IgH are frequently translocated in these tumours. Aberrant somatic 
hypermutation of MYC, BCL6 PAX6 or RHO/ TIFF are present and suggested to be involved 
in tumourigenesis of DLBCL (Swerdlow, 2008).  
1.7.3 Classification of follicular lymphoma 
Follicular lymphoma is composed of both centrocytes and centroblasts. Most FL have a 
follicular pattern that differs to a reactive follicle as it has a smaller or non-existent mantle 
zone and tingible body macrophages are usually absent. FL is graded to aid prognosis and 
treatment. Grade 1 and 2 are low-grade lymphoma. Grade one predominately consists of 
centrocytes and 0-5 centroblasts per high power field (hpf). Grade 2 contains 6-15 
centroblasts per hpf. Both grades 1 and grade 2 are indolent and the same treatment is 
prescribed for both. Grade 3 is a high-grade lymphoma that has > 15 centroblasts per hpf. 
Grade 3 is further subdivided; grade 3A has centrocytes present and grade 3B is solid sheets 
of centroblasts only. Within a FL, diffuse areas of predominantly centroblasts are given a 
separate diagnosis of DLBCL with follicular lymphoma, grade 1-2, grade 3A or grade 3B.  
The number of centroblasts is counted or estimated, in ten neoplastic follicles, and expressed 
per 40x hpf. Follicular lymphoma usually express surface antigen (IgM+/-, IgD, IgG or IgA) 
as well as B cell associated antigens. In addition tumour cells in FL are commonly BCL2+, 
BCL6+, CD10+ CD5- CD43-. FL grade 3B cells may lack CD10 expression but still express 
BCL6. FL have rearranged immunoglobulin gene and SHM can be ongoing. BCL2 
translocations are frequently found in FL, and are more common in grade 1-2 than grade 3 
(Swerdlow, 2008).  
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1.7.4 Classification of marginal zone and mantle cell lymphoma 
Splenic marginal zone lymphoma (MZL) is composed of small-medium sized cells that 
resemble those in the follicular marginal zone. Marginal zone tumour cells replace the white 
pulp and infiltrate the red pulp. Tumour cells in MZL commonly express surface IgM and 
sometimes IgD. Most MZL are BCL2 positive, approximately 50% of cases are CD43+ and 
MZL tumour cells are negative for CD10, BCl6, CD5 and CD23 expression. 50% of cases in 
MZL tumour cells have a mutated IgH gene suggesting that they have been exposed to 
antigens but otherwise a specific cell type has not been assigned to this type of tumour yet.  
Mantle cell lymphoma (MCL) accounts for 10% of NHL in humans.  MCL resemble small to 
medium sized lymphocytes with an irregular nucleus. MCL cannot be distinguished from 
MZL morphologically and require immunophenotypic analysis to confirm diagnosis. MCL 
tumour cells express IgM and IgD. In addition they are BCL2+, CD5+, CD43+, CD10-, 
BCL6, Cyclin D1+. MCL tumour cells have a rearranged IgH but do not have evidence of 
SHM so are likely to develop from a pre-germinal centre B cell.  In general, MCL tumours 
have Cyclin D1 translocations and an additional number of non-random translocations 
(Swerdlow, 2008).  
1.7.5 Classification of Burkitt lymphoma  
Morphologically, Burkitt lymphoma is composed of medium irregular shaped tumour cells 
with round nuclei and prominent nucleoli.  Burkitt lymphoma has a high proliferation index 
and a large amount of visible apoptosis. The large numbers of macrophages that have ingested 
apoptotic tumour cells creates a starry sky pattern in that is characteristic of Burkitt 
lymphoma. Burkitt lymphoma tumour cells have a rearranged IgH gene and mutations that are 
associated with somatic hypermutation (SHM). Burkitt lymphoma tumour cells express the 
common B cell antigens and also express BCL6, CD38, CD77 and CD43. Tumour cells in 
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Burkitt lymphoma are usually BCL2 negative. The most common genetic abnormality 
associated with Burkitt lymphoma is a translocation between MYC and IgH.  
In certain instances, tumours have features that align with both DLBCL and Burkitt 
lymphoma. These tumours are classified as B cell lymphoma, unclassifiable, with features 
intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. The tumour cells 
in these lymphomas can be medium sized cells or a mixture of medium and large blast cells. 
Other features of tumours in this classification include, a high mitotic index, and either with 
or without a MYC translocation. The IgH gene is clonally rearranged in these tumours and 
expressed. Tumour cells are also CD10+, BCL6+ BCL2- and IRF4/MUM1-. This is a 
heterogeneous classification group and some transformed FL can be placed in this category 
(Swerdlow, 2008).  
1.7.6 Classification of lymphoid neoplasms in mice 
In 2002 the Mouse Models of Human Cancers Consortium (MMHCC) was formed and a 
haematopathology committee were brought together to develop a scheme for the classification 
of mouse lymphoma and leukaemia that could be used by pathologists to relate murine 
malignancies to human counterparts. A goal of studying mouse lymphoid neoplasms is to 
determine if they truly recapitulated human disease. For the most part, mouse leukaemia and 
lymphoma are categorised in a similar structure to human leukaemia and lymphoma, but there 
are a few differences between human and mice that should be taken into consideration. First, 
mice have on-going haematopoiesis in the spleen throughout adult life, unlike in adult humans 
where haematopoiesis is restricted to the bone marrow (Wolber et al 2002). Second, the 
murine germinal centre structure is modestly different in the mouse compared to humans, as 
the marginal zone is smaller and less distinct. With regards to neoplasm cytology, mouse FL 
has a more diffuse pattern, whilst still maintaining a follicular character, and also has a higher 
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proportion of centroblasts than human FL. The final difference to note is murine lymphomas 
with a high proliferative index and surface Ig expression that resemble human Burkitt 
lymphoma may lack translocations involving MYC and in this instance, it is suggested that, 
they are categorised as Burkitt-like lymphoma.  With consideration of the exceptions 
mentioned above, classification of DLBCL, FL, marginal zone lymphoma, and classic Burkitt 
lymphoma is in alignment with the guidelines for the classification of human lymphoid 
neoplasms (Swerdlow, 2008).  
1.7.7 B cell lymphoma tumourigenesis 
Through understanding the development of lymphoma better, It is hoped that better tratments 
can be developed. Chromosome translocations have long been associated with lymphoid 
tumour development (Lengauer et al., 1998). Lymphoid tumours and B cell lymphoma in 
particular, have chromosomal translocations that usually involve the immunoglobulin variable 
or switch region, but non IG gene rearrangements have also be found (Robbiani and 
Nussenzweig, 2013). Translocations confer a proliferative advantage to the cell. Advantage 
can be gained through juxtaposition of a proto-oncogene next to a promoter that increases the 
transcription of this protein or gene translocations can lead to fusion of two genes and the 
production of an altered gene product that has oncogenic activity (Nussenzweig and 
Nussenzweig, 2010). The most likely cause of translocation that leads to tumourigenesis is the 
persistence of unrepaired DNA DSB. 
1.7.8 Etiology of DNA double strand breaks in lymphoma 
Chromosomal translocations are only able to form when two concurrent DSBs are present. 
DSBs occur frequently in dividing cells as a consequence of errors in replication (Bartkova et 
al., 2005). Current estimates predict that approximately 10 double strand breaks occur in 
dividing fibroblasts per day (Lieber, 2010).  The cause of these breaks can be endogenous or 
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exogenous. Programmed DSB are generated during lymphocyte development by RAG1/2 and 
AID proteins (Wang et al., 2008a).  RAG1/2 generates DSB in the variable region of the IgH 
and IgL genes in pro-B cells in the bone marrow during V(D)J recombination (Gostissa et al., 
2011). RAG1/2 targets recombination specific sequences (RSS) that flank the V, D and J 
genes. The RSS sequence consists of a conserved heptamer and an A-T rich nonamer 
separated by 12 or 23 bases. The specificity of these two signals target RAG to the correct 
gene families during V(D)J recombination. However this regulation of RAG1/2 is error prone. 
RAG1/2 also recognises some sequences that are highly similar to RSS as targets and 
generates DSB in non-immunoglobulin genes. These types of sequences are present in certain 
oncogenes, including BCL2. These off target RAG1/2 breaks can become illicit substrates for 
V(D)J recombination (Marculescu et al., 2002).  
In mature B cells AID is activated and generates DSB breaks for the processes of SHM and 
CSR. RAG1/2 targets specific sequences whereas AID is more promiscuous in its coding 
target. AID targets RGYW motifs such as AGCT and although these motifs are enriched in 
the variable region exons, they are also present throughout the genome. Consequently, non-
immunoglobulin genes are also frequently targeted by AID. Genes that are frequently found 
translocated in cancers such as Pax5, Il21r, Gas5, Ddx6, Birc3, Ccnd2, Aff3, Grhpr, MYC, 
Pvt1, Bcl2l11, Socs1, mir142, Junb and Pim1, are AID target hotspots. Translocations 
involving these genes often confer a selective growth advantage to the cell. In addition to the 
off-target action of RAG1/2 and AID, physiological factors such as errors in replication and 
transcription, and certain DNA structures can generate DSBs (Zhao et al., 2010). External 
factors also cause DSB DNA damage. Common cancer treatments such as topoisomerase 
inhibitors and IR, or oxidation can also generate DSBs (Felix et al., 2006).  
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In normal circumstances DSBs break are rapidly repaired and genome integrity is maintained 
(Robbiani and Nussenzweig, 2013).  For a translocation to occur an unrepaired DSB 
generated by one of the above mechanism must persist long enough to come into close 
proximity to a second DSB to which it can be joined. In normal cells the DDR leads to cell 
cycle checkpoint activation and repair of the break by either C-NHEJ or HR (Section 1.3.4, 
1.3.6). Impairment in this response by loss of one of the factors involved causes the 
persistence of DSBs. Unrepaired DSBs are substrates for translocations that can have severe 
consequences on the cell and organism. B lymphocytes from mice deficient in Atm, a critical 
activator of cell cycle checkpoints in response to DSBs, harbor persistent DSBs. DSBs 
generated early on in development can become substrates for translocation later on in 
development in mature B cells (Isoda et al., 2012, Callén et al., 2007). Translocations and 
tumour development associated with Atm loss will be discussed below.  
1.7.9 Mechanisms promoting translocation in lymphoma 
After DSB have been formed and in order for these to result in translocation two DSBs must 
be brought together and joined. Either two DSBs are generated spatially close together in the 
nucleus or mobility of the damaged DNA ends brings two distant DSBs proximal allowing for 
them to be aberrantly joined (Misteli and Soutoglou, 2009). There are several factors that 
increase the possibility that two DSB will be generated in close proximity and that they may 
be aberrantly joined. Actively transcribed regions of DNA are localized in the nucleus 
together. Transcription is error prone, plus AID targets single strand DNA. Both of these 
factors increase the possibility of co-localised DSB formation occurring. The genome is not 
randomly organized. The higher organization of DNA into chromatin can lead to certain 
genes being colocalised with others. In mice two genes that frequently translocate together, 
IgH and MYC, are frequently localised near to each other in the nucleus, thus increasing the 
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possibility of a translocation between the two regions of the genome (Zhang et al., 2012, 
Klein et al., 2011). In addition mis-repair of DSB on chromosomes of a similar size is also 
possible.  
The mobility of a chromosome can also determine the propensity for translocation. Changes 
to the chromatin properties such as relaxation, can affect the motion of chromatin and are 
critical for translocation (Dimitrova et al., 2008, Roukos and Misteli, 2014).   
1.7.10 DSB repair and translocation ligation 
Once two DSBs are co-localised they need to be ligated together for the translocation to be 
complete. The key question is what mechanism is responsible for the wrongful joining of 
these two DSB? DSB generated by RAG1/2 and AID in lymphocyte development are 
repaired by C-NHEJ.  This repair pathway does not require a template and therefore can 
facilitate the joining of two non-homologous chromosomes such as in V(D)J recombination, 
SHM, CSR and aberrant translocations. Translocations occur in normal cells but occur at a 
higher rater in cells deficient for C-NHEJ factors. Mice have been generated that are deficient 
in each of the C-NHEJ factors and they have a reduced ability to undergo V(D)J 
recombination. When these mice are also deficient in p53 they develop tumours that harbor 
translocations (Rooney et al., 2004).  
In the absence of C-NHEJ ,breaks can be repaired by a process called alternative end joining. 
(A-EJ) and it is thought that this mechanism of repair is more prone to chromosomal 
translocations than C-NHEJ (Chiarle et al., 2011). DSBs joined using A-EJ tend to have 
higher degree of microhomology at the junction, but in the absence of microhomology blunt 
ends can also be joined.  The search for homologous sequence processing at the broken ends 
can result in genetic loss or insertions, altering the normal code. C-NHEJ preferentially joins 
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breaks within the same chromosome; coincidently preventing the occurrence of translocations. 
Overall, C-NHEJ plays a role in maintaining genome stability and loss of this pathway has 
severe consequences for the cell (Ferguson et al., 2000, Alt et al., 2013).  
1.7.11 The role of NHEJ in B cell lymphoma development  
Mice deficient for C-NHEJ factors show a marked decrease in V(D)J recombination, 
decreased CSR and increased neuronal cell death. Cells from these mice have a high level 
genomic instability. Activation of the p53 checkpoint prevents tumourigenesis in mice that 
lack C-NHEJ. Therefore mice deficient for both a C-NHEJ factor and p53 have a high 
predisposition to the development of lymphoid malignancies (Franco et al., 2006, Lieber et al., 
2006). 
For example, mice deficient in XRCC4 and p53 develop pro-B cell lymphomas that harbor 
IgH-Myc translocations. In addition, they also have complex translocations (complicons) that 
contain amplification of both Myc and IgH gene loci.  These complicons are initiated by 
RAG1/2 induced breaks and joined by A-EJ (Zhu et al., 2002). In mice with XRCC4 and p53 
deficiency in mature B cells, tumour development occurs via a slightly different mechanism. 
Mice developed mature B cell lymphomas that had attempted V(D)J recombination and CSR 
but lacked surface immunoglobulin expression. The tumors harbored frequent translocations 
involving IgH, Igκ and Igλ locus. Most of these tumours had reciprocal translocations 
between IgH and Myc but had no gene amplification or complicons (Wang et al., 2008b). 
Analysis of the breakpoints of these translocations showed that they arise from RAG1/2 
induced breaks and suggested that, like the XRCC4 deficient pro B cell lymphoma, the 
translocations in the mature B cell lymphoma resulted from abnormal secondary V(D)J 
recombination in the periphery (Wang et al., 2009). Both XRCC4 deficient Pro B cell 
lymphoma and mature B cell lymphoma had translocations involving Myc but the up-
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regulation of this gene is likely to be caused by different mechanisms and dependent on the 
differentiation stage of the B cell.  
Similar phenotypes were observed in mice deficient for other C-NHEJ factors. Ku80-/-p53-/-
mice developed disseminated pro-B cell lymphomas with IgH-Myc translocations and 
complicons (Difilippantonio et al., 2000). In addition, Lig4-/- p53-/- mice develop pro- B cell 
lymphomas that have amplification of both IgH and Myc (Orii et al., 2006). These models 
illustrate that loss of C-NHEJ in the absence of p53 checkpoint allows for the occurrence of 
tumorigenic translocations and the development of B cell lymphomas.  
1.7.12 The mechanisms associated with Atm loss and tumour development  
In addition to the components of C-NHEJ, factors responsible for detecting the DSB are also 
important in lymphocyte differentiation and protecting against tumour development 
(Nussenzweig and Nussenzweig, 2010, Bartkova et al., 2005). Human patients deficient in the 
DDR factors ATM, H2AX, 53BP1, MCD1, MRE11 and NBS1 have reduced lymphocyte 
development due to impaired V(D)J recombination and CSR (Franco et al., 2006).  
Loss of the DNA damage response factor, ATM, affects V(D)J recombination and increases 
tumour development in humans and mice (section 1.1.1,1.1.3). Several studies have sought to 
understand the role of immune gene rearrangement, and the mechanism for this 
rearrangement, in the development of tumours in the absence of ATM protein.  Like humans, 
Atm-/-mice have perturbed lymphocyte development and develop T cell lymphomas 
(thymomas), which frequently harbour translocations involving immune genes (Zha et al., 
2010). The reduced capability of successful V(D)J recombination in Atm-/- T cells inhibits 
differentiation and is the reason for the reduced levels of mature T cells in Atm-/-  mice. 
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Aberrant V(D)J recombination in Atm-/- T cells also results in unresolved DSB that 
predispose to translocations (Vacchio et al., 2007) 
The effect of Atm loss is similar in B cells and T cells. Atm-/- mature B cells have a greater 
number of unrepaired DSBs in the antigen receptor genes than wild type mature B cells in 
vitro. These breaks are not dependent on AID, which is expressed only in mature B cells, 
suggesting that the breaks persist from an earlier developmental stage. The DSBs in mature 
Atm-/- B cells are dependent on RAG1/2 expression and are likely the result of erroneous 
attempts at V(D)J recombination (Callén et al., 2007). Even though RAG1/2 induced breaks 
are not critical for tumour development in Atm-/- mice, the high frequency of RAG1/2 breaks 
and the persistence of these breaks increase the likelihood for erroneous repair of these DSBs 
and the potential for translocation (Petiniot et al., 2000).  
Tumour development in Atm deficient mice is associated with, but not exclusively reliant on 
RAG1/2 or AID induced breaks in the immune genes (Petiniot et al., 2002, Ramiro et al., 
2006). RAG2-/-Atm-/- mice still developed tumours, albeit at a lower frequency than Atm-/- 
mice. Unlike Atm-/- T cell lymphoma, RAG2-/-Atm-/- tumours did not have translocations 
involving the TCRα, or TCRδ genes. They did however have increased number of 
translocations compared to Atm-/- tumours, indicating that Atm-/- tumours develop 
translocations caused by aberrant repair of DNA DSBs in both immune and non-immune 
genes (Petiniot et al., 2000, Liao and Van Dyke, 1999).  
The persistence of DNA DSBs in Atm-/- mice is the consequence of a checkpoint defect in 
Atm-/- cells (Chun and Gatti, 2004). In the absence of checkpoint activation, a B or T cell that 
has a DSB, which is likely to be in one IgH or TCR allele, is able to undergo successive 
rounds of recombination in the second allele, until a successful V(D)J  rearrangement is made. 
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Signalling through this second IgH or TCR promotes survival of the B or T cell respectively, 
and thus propagates the DSBs through successive cell divisions and differentiation (Callén et 
al., 2007).  
1.7.13 Translocations associated with B cell lymphoma 
Knowing the genetics of a tumour is important for diagnosis and treatment of human 
malignancies. Recurrent translocations are a hallmark of certain B cell lymphomas. These 
translocations frequently involve immunoglobulin genes, most commonly the IgH gene, 
which is located on chromosome 14 (Swerdlow, 2008). The translocation partner is usually a 
proto-oncogene, for which juxtaposition to the IgH enhancers causes up regulation.  The most 
common translocations associated with DLBCL involves BCL6 (Bastard et al., 1994, Offit et 
al., 1994). BCL6 is a transcriptional repressor that is involved in B cell development. Up-
regulation of this protein via translocation prevents differentiation of the B cell, maintaining it 
as a GC B cell and predisposing it to neoplastic transformation (Ohno, 2004). The t(14;18) 
translocations involving BCL2 is present in 18-20%  of DLBCL (Hill et al., 1996). Also 
present in 85% of follicular lymphoma, the t(14;18) translocation is  the major pathogenic 
mechanism in these lymphomas through up-regulation of BCL2 (Barrans et al., 2003). 
Another gene that is frequently associated with translocation is MYC. Nearly all cases of 
Burkitt lymphoma harbour MYC translocations with an immunoglobulin gene. The 
translocation most frequently observed is t(8;14) and but sometimes t(2;8) and t(8;22), 
involving the light chain genes, are also found (Kramer et al., 1998). Translocations involving 
MYC are also found in other B cell lymphoma, including DLBCL, but in these tumours MYC 
can be found translocated to a non-immune gene (Johnson et al., 2009).  
Chromosome translocation is not the only cause of gene deregulation in B cell lymphomas. 
Mutations have been found in BCL2, BCL6, MYC, RHOH/TTF, PIM1, PAX5, IRF4, 
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ST6GAL1, BCL7A, CIITA, LRMP and SOC in DLBCL. These mutations are caused by 
aberrant SHM and are likely to be involved in lymphomagenesis in the absence of 
translocations (Khodabakhshi et al., 2012, Pasqualucci et al., 2001).  
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1.8 The nude mouse 
The athymic nude phenotype was first observed in a colony of hooded rats in 1953 at the 
Rowett Research Institute in England (Vos et al., 1980). The first nude mouse was described 
by Flanagan in 1996 (Flanagan, 1966). Homozygous mutation in the Foxn1 gene is 
responsible for the lack of hair, abrogated thymic development and reduced T cells in the 
nude mice (Nehls et al., 1994, Nehls et al., 1996) . The Foxn1 gene encodes a winged helix 
domain transcription factor named whn. A single deletion in the coding sequence of the whn 
gene causes a frame shift and a premature stop codon that prevents transcription of the protein. 
Whn is highly expressed in the thymus and skin, where is has a role in the inducing the 
expression of tissue specific genes required for thymic anlage and the hair papilla 
development (Nehls et al., 1996, Brissette et al., 1996). 
Nude mice have reduced levels of T cells in the lymph nodes and spleen and consequently do 
not reject allografts and some xenografts. Despite having reduced T cell numbers, nude mice 
a have functional ‘post-thymic’ T cell repertoire with a cytolytically active CD8+ T cell 
response. The natural killer cell response is normal, even slightly elevated in nude mice 
(Belizário, 2009). The B cell population is also normal but the IgH antibody repertoire is 
reduced (Kaushik et al., 1995).   
An observational study by Sharkey and Fogh suggests that the median survival for nude mice 
is 6 months, but this is dependent on the husbandry conditions (Sharkey and Fogh, 1979). The 
tumour incidence in nude mice is no different to that of the immunocompetent counterparts of 
the same strain (Stutman, 1978) and tumour development was observed in 6.8% of nude mice. 
Therefore nude mice do not have an increased incidence of spontaneous tumour development. 
Ninety-two per cent of tumours developed in nude mice that were over 5 months of age and 
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the median age of development was 9 months. The tumours were mostly of lympho-reticular 
origin, but a small proportion were pulmonary adenomas. Other causes of death in these nude 
mice included hepatitis and sendai virus infections (Sharkey and Fogh, 1979, Sharkey and 
Fogh, 1984).    
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1.9 Aims 
The reason for Atm-/- mice developing only T cell lymphoma, whereas A-T patients develop 
a wide range of lymphoid malignancies has been a long-standing question (Micol et al., 2011). 
In an attempt to answer this question, Spring and colleagues (2001) developed mice with a 
hypomorphic Atm mutation. Indeed, in addition to thymoma development, these mice 
succumbed to B cell and non-lymphoid malignancies, albeit at a low frequency, but no 
investigation into the development of these tumours was undertaken. There is a need, 
therefore, for a model in which aggressive T cell lymphoma development is eliminated, 
allowing the development and investigation of other phenotypes associated with A-T. This 
model for example, could enable investigation into non-T cell tumour development in the 
absence of Atm protein expression. The nude (nu-/-) mouse is athymic. If thymic 
development was abrogated in the Atm-/- mouse, by crossing it with the nu-/- mouse, it could 
be possible to prevent thymoma development and generate a long-lived Atm-/- mouse in 
which case these studies could be carried out.  
T cell malignancies in A-T patients and Atm-/- mice are associated with translocations within 
immune genes but little is known about the development of B cell malignancies in A-T 
patients (Russo et al., 1988, Liyanage et al., 2000, Taylor et al., 1996). Analysis of Atm-/- 
tumours revealed the role of defective DNA repair in the development of genetic 
abnormalities that contribute to tumour development. In these tumours loss of Atm caused 
persistence of unrepaired DSBs that result in translocations as a consequence of abnormal 
immune gene rearrangements during lymphocyte development (Zha et al., 2010). Whether 
ATM null B cell lymphomas develop by a similar mechanism remains to be elucidated.  
With these questions in mind the aims of this study were; 
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a. To generate an Atm-/-nu-/- nude A-T mouse in which early thymoma development 
and subsequent early death was abrogated and in which longer survival might reveal 
susceptibility to other tumour types. 
b. To determine the suitability of this new Atm-/-nu-/- nude A-T mouse as a model for 
A-T. 
c. To investigate the mechanisms associated with the development of any malignancies 
in these Atm-/-nu-/- nude A-T mice. 
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2 MATERIALS AND METHODS  
2.1 Generation of A-T mice 
2.1.1 Generation of Atm-/- mice 
Atm-/- mice were generated by the Wynshaw-Boris laboratory (Barlow et al, 1996). Atm 
knockout was undertaken by insertion of a PGK-neomycin gene into position 5979 of the 
murine Atm gene causing a truncating mutation.  
We obtained these mice as a breeding pair of heterozygotes from the Jackson laboratory 
(stock number 129S6/SvEvTac-Atmtm1Awb/J). These were bred to larger numbers and 
heterozygote males and heterozygote females mated to generate Atm-/-, Atm+/- and Atm+/+ 
mice. All work was approved by the Home office under the Animals (scientific procedure) act 
1986.  
2.1.2 Generation of Atm-/-nu-/- mice.  
The generation of Atm-/-nu-/- mice required a series of matings. The proximal mating pairs 
that produced these double knockout animals were Atm heterozygous nude males (Atm+/-nu-
/-) and female Atm/nude double heterozygotes (Atm+/-nu+/-). Some additional preliminary 
matings were undertaken in order to get to these proximal genotypes and these are given in 
table 2.1.  First, Atm+/-nu+/- males and Atm+/-nu+/- females were obtained by mating an 
Atm heterozygote female (Atm+/-nu+/+) with a Balbc nude male (Atm+/+nu-/-) (Mating 1). 
An Atm+/-nu+/- female from the first generation was then mated with a nude male as used in 
the first cross (Mating 2). From this mating Atm+/-nu-/- males were obtained. The third 
mating was the proximal one of male Atm+/-nu-/- with female Atm+/-nu+/-. Some of these 
offspring were Atm-/-nu-/- double knockouts. The breeding strategy is outline in Table 2.1 
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Table 2.1 Mating strategy for the generation of Atm-/-nu-/- mice 
Mating number Mating Genotypes Progeny genotype  
Mating 1 Atm+/+nu-/- (m)  x  Atm+/-nu+/+ (f) Atm+/+nu+/- 
Atm+/-nu+/- (f) 
Mating 2 Atm+/+nu-/- (m)  x   Atm+/-nu+/- (f) Atm+/+nu+/- 
Atm+/+nu-/- 
Atm+/-nu+/- 
Atm +/-nu-/- (m) 
Mating 3 Atm+/-nu-/- (m)  x  Atm+/-nu+/- (f) Atm+/+nu+/- 
Atm+/+nu-/- 
Atm+/-nu+/- 
Atm+/-nu-/- 
Atm-/-nu+/- 
Atm-/-nu-/- (m & f) 
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2.2 Atm genotyping 
2.2.1 DNA extraction  
Ear clippings from 3 weak old mice were incubated for a minimum of 5 hours, but usually 
overnight, in lysis buffer (100mM Tris-HCl pH 8.5, 5mM EDTA 0.2% SDS, 200mM NaCl, 
100µg/ml proteinase K). Digested tissue samples were centrifuged for 15-20 minutes at 
13000rpm. The supernatant was added to 1.5ml micro centrifuge tubes containing 350µl of 
propan-2-ol. DNA was precipitated by inverting several times and then was centrifuged at 
13000rpm for 15-20 minutes. The supernatant was discarded and 500µl of 70% ethanol was 
added to wash the pellet. The DNA pellet was centrifuged again for 10-15 minutes at 
13000rpm/18000g. Once more, the supernatant was discarded and the DNA pellet was air-
dried. When completely dry the DNA pellet was resuspended in 20-50ul of 10mM Tris-HCl, 
1mMEDTA pH8.0 depending on pellet size, and finally heated at 70-80°C for 10-15 minutes 
to resuspended the DNA in the buffer.  
2.2.2 Atm PCR for identification of Atm-/- mice 
Atm knockout in these Atm null mice was caused by the insertion of a PKG neomycin gene 
into the Atm gene. Mice with the Atm knockout gene were identified using primers between 
the remaining Atm sequence and the inserted PKGneomycin gene; Atm-A (5’ gac  ttc  tgt  cag  
atg  ttg  ctg  cc  -3’) and Atm-Neo (5’ggg  tgg  gat  tag  ata  aat  gcc  tg -3), that produced a 
441-bp PCR product. Wild type Atm was detected using primers between the portion of the 
Atm gene present in the knockout and the part of the Atm that was deleted in the knockout; 
Atm-A (5’ gac  ttc  tgt  cag  atg  ttg  ctg  cc  -3’) and Atm-B (5’ cga  att  tgc  agg  agt  tgc  tga  
g -3’), that generate a 152 BP PCR product. The thermo cycling protocol used was as follows: 
94˚C for 3min; 37x[94˚C for 10 sec, 55˚C for 20sec]; 72˚C for 40sec.  PCR products were 
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separated on a 1% agrose gel made with TBE and 5µl of PCR product was loaded with 2µl 
trypan blue (New England Biolabs, Ipswich, UK).  
The Atm-/-, Atm+/- and Atm+/+ mice could be distinguished as shown in Figure 2.1 
2.2.3 Morbidity assessment  
Mice were monitored daily for signs of morbidity. All animal procedures were performed 
according to protocol.  
 
Figure 2.1 Atm knockout identification  
This agrose gel shows the result of an Atm genotyping PCR. Rows 1-9 mice, row 10 is a water control 
and row 11 is a known genotype control.  The top band is the KO (knockout) allele and the bottom 
band is the wild type allele. A sample with two bands was heterozygote (Atm+/-) (Lanes 1, 4, 9). 
Lanes 2, 5, 6 and 8 were Atm-/- and lanes 3 and 7 were Atm+/+. 
bp =base pair 
M =marker 
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2.3 Analysis of cellular phenotype 
2.3.1 Total protein extraction for subsequent Atm analysis 
Tissues were isolated from the mouse and snap frozen in liquid nitrogen immediately after 
culling.  All procedures were performed at 4°C or on ice where possible. Tissue was disrupted 
using a 1ml syringe plunger in 50µl RIPA buffer (Pierce, Illinois, USA) with added Halt 
protease inhibitor and 0.5M EDTA solution according to manufacturer’s instructions (Thermo 
Scientific), then incubated at 4°C for 5 minutes. Samples were sonicated for 30 seconds and 
incubated again on ice for 10 minutes. Samples were then vortexed briefly, and centrifuged at 
7°C for 20-30 minutes at a speed of 1400rpm. Finally, the supernatant was removed and 
protein determination was undertaken using Bio-Rad protein determination solution, before 
being snap frozen in liquid nitrogen and stored at -80°C until needed.  
2.3.2 Total protein determination assay 
Protein extracts were prepared as above (section 2.3.1). A standard curve was made using 
BSA diluted in distilled water to 0, 100, 200, 300, 400 and 500µg/ml and an example standard 
curve is shown in Figure 2.2. The standards were aliquoted in triplicate into a Falcon 96-well 
plate (Fisher Scientific).  Protein samples were diluted 1 in 10 in distilled water and aliquoted 
in triplicate onto the 96-well plate. Bio-Rad protein determination solution was diluted 1 in 5 
in distilled water and 200µl of this diluted solution was added all the samples in the 96-well 
plate. The reaction was incubated for 5 minutes at room temperature before the absorbance 
was measured at 595nm.  A standard curve was plotted, from which the protein concentration 
of the samples were determined.   
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Figure 2.2 Representative BSA standard curve  
 
Total protein concentration was calculated using a standard curve like the one shown above.   
 
2.3.3 SDS PAGE  
Total protein from thymus, spleen, and brain was separated on a 6% acrylamide gel consisting 
of 4ml of 1M Tris/1M Biscine, 8 ml 30% acrylamide, 200µL 20% SDS, 80µL TEMED, 
27.6ml of distilled water, and 200µL of 10% APS added last to initiate polymerisation. The 
mixture was poured into the gel apparatus and a well forming gel comb was inserted, ensuring 
all air bubbles were removed. Once the gel was set, the combs were removed and the wells 
were washed with running buffer (0.1M Tris/0.1M Biscine, 0.1% SDS).  25µg of human 
protein and 50µg of mouse protein was diluted 3:1 in 4X sample buffer (0.125 M Tris/HCl pH 
6.8, 4% (w/v) SDS, 20% Glycerol, 0.2 M DTT, 0.02% bromophenol blue). Samples were 
denatured at 100°C for 5 minutes and loaded on to the gel alongside a molecular weight 
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marker (Thermo Fisher Fermentas). The gel apparatus were filled with running buffer and 
samples were electrophoresed for 4.5 hours at 30mA per gel.  
2.3.4 Electrophoretic transfer of proteins 
The gel was carefully removed from the plates and a piece of nitrocellulose membrane, that 
had been pre-soaked in transfer buffer (0.02 M Tris, 0.19 M glycine and 20% v/v methanol), 
was overlaid on to it ensuring all air bubbles were removed. The gel and membrane were 
sandwiched between 2 pieces of Whatman filter paper that were also pre-soaked in transfer 
buffer, and enclosed in a blotting cassette with two sponges. The whole cassette was placed in 
a transfer tank filled with transfer buffer and proteins were immunoblotted at 200mA 
overnight.  
2.3.5 Immunodetection of proteins  
Once transferred, the membrane was removed from the cassette and incubated with Ponceau 
stain (Sigma-Aldrich) for 5 minutes to visualise the proteins and check the success of the 
transfer. The stain was removed and the membrane was rinsed twice in distilled water. Using 
the molecular weight markers and the Ponceau stained lanes as a guide, the membrane was 
cut into sections that contained the proteins of interest (Atm is approximately 350kDa and 
SMC1 is approximately 150kDa). The membranes were then incubated in distilled water, with 
constant agitation, until there was no stain left on the membranes. To prevent non-specific 
background binding, the membranes were incubated in 5% Marvel dried milk powder made 
up in TBS-T, for 2 hours at room temperature with constant agitation. The membranes were 
then washed 3 times for 5 minutes in TBS-T at room temperature with constant agitation. The 
membranes were probed with anti-ATM (MAT3) (Sigma-Aldrich) or anti-ATM (2C1) 
(Abcam, Cambridge, UK) or anti-SCMC1 (Bethyl, Montgomery, Texas, USA) diluted in 5% 
milk in T-BST, in a sealed bag overnight at 4°C with constant rocking. The following day, 
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after removing primary antibody and washing thoroughly in TBS-T, the membranes were 
incubated with either anti-rabbit (1 in 3000) or anti-mouse (1 in 1000) HRP conjugated 
secondary antibodies (both from Dako, Cambridge, UK) for 1 hour at room temperature. The 
secondary antibody was removed, and the membrane was washed thoroughly for 3 x 10 
minutes in TBS-T with constant agitation to remove any remaining secondary antibody.   
For visualisation, the membranes were incubated with Amersham ECL solution (GE 
healthcare life sciences, Little Chalfont, UK) for 1 minute. Excess solution was removed and 
the membrane was placed in an X-Ray cassette. The luminescence generated from the HRP 
catalysed oxidation reaction was detected using X-Ray film (Amersham, GE healthcare) that 
was developed with a Xograph Imaging Systems Compact X4. 
2.3.6 Splenocyte radiosensitivity analysis 
A single cell suspension was generated from whole mouse spleen by forcing it through a 
70µm strainer (Falcon). Cells were treated with Ammonium-Chloride-Potassium (ACK) 
lysing solution (Gibco, Life Technologies) to remove red blood cells. Splenocytes were 
cultured for 3 days in media containing 1% penicillin-streptomycin (Gibco, Life 
Technologies), 10% FCS (Sigma-Aldrich), 50µM β-mercaptoethanol (Gibco, Life 
Technologies,) and 150µg/ml E. coli lipopolysaccharide (LPS) (Sigma-Aldrich) at a cell 
density of 5x10 6  per ml. After 3 days in culture the sample was divided into two: half was 
exposed to 1 Gray of radiation and the other was not exposed and used as a control. After 
irradiation the samples were incubated again at 37°C for 3 hours after which, a couple of 
drops of colcemid (Gibco, Life Technologies) were added using a 1ml Pasteur pipette. After 1 
hour the media was removed and replaced with 2mls of 0.75M KCl solution (BDH, VWR, 
Pennsylvania, USA), incubated at 37°C for 15-20 minutes, and then fixed in 3:1 methanol: 
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acetic acid added drop-wise in the first instance. Fixation was repeated twice and after the 
final fix cells were left in approximately 10mls of fixative at room temperature, overnight.  
Metaphase spreads were made by dropping a concentrated cell solution onto a slide that was 
air-dried and then stained with Geimsa diluted in buffer, pH 6.8 (Gurr®, VWR, Pennsylvania, 
USA) for 10 minutes. After which the slides were rinsed in pH 6.8 buffer and air-dried before 
a large cover slip was applied using DPX (VWR, Pennsylvania, USA). 
For each mouse 25 metaphases were analysed for the control and irradiated sample, using a 
Leitz microscope. The quality of a metaphase was assessed to be sufficient for analysis at low 
power, before the metaphase was assessed for damage at high power (x100). Chromatid 
breaks, chromosome breaks tri-radial or quadri-radial chromosomes (three or four 
chromosomes attached together respectively) were quantified and as well as any abnormality 
that did not fit these standard descriptions, but was clearly abnormal and therefore was 
described as ‘other’. The total number of abnormalities in 25 cells in the control sample was 
subtracted from the total amount of damage in 25 cells in the irradiated sample; to give the 
total amount of irradiation induced damage. Two Atm-/- and two Atm+/+ mice were analysed, 
and one of each Atm-/-nu-/-, Atm+/+nu-/-, and Atm-/- were also analysed.  
2.4 Analysis of haematopoietic system in Atm-/- and Atm-/-nu-/- mice 
2.4.1 Mouse tissue preparation  
Mice were culled by cervical dislocation and a post mortem was undertaken where organs 
were checked for abnormality and lymph node size was assessed. 
Both hind legs were removed, tissue was removed from the bone and then the bone was 
flushed with PBS or DMEM with 10% FCS to remove the marrow. Both the spleen, 
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approximately 0.5cm3 of liver and tumour (when present), were also removed and a single 
cell suspension was made from these tissues by forcing them through a 70µm cell strainer 
(Falcon) that was then washed with PBS or DMEM with 10% FCS, collecting the cells in a 
50ml falcon tube. The cells were treated with Ammonium-Chloride-Potassium (ACK) buffer 
(Gibco, Life Technologies) to remove red blood cells, except for erythrocyte analysis in the 
bone marrow cells were removed prior to ACK treatment. At this point cells were either 
stained for FACS analysis or frozen viably in FCS containing 10% DMSO (Sigma-Aldrich) 
for analysis at a later point. Comparison was always undertaken between fresh, or frozen 
samples only.  
2.4.2 Cell staining with fluorophore conjugated antibodies 
At least 1x106 cells were used for each panel of antibodies that was used. If using frozen cells, 
these were revived by thawing the cells at 37°C and diluting in 10ml of cold PBS or DMEM 
with 10% FCS, followed by spinning the cells at 1,100 RPM for 5 minutes. The cells were 
washed once more and finally re-suspended in 1ml of PBS or DMEM with 10% FCS in a 
1.5ml eppendorf tube, and stored on ice ready to begin staining.  
Staining was done on ice in a volume of 100µl in a V- bottom 96-well plate. Non-specific 
antibody binding was prevented by blocking the cells with 5µg/ml of anti- mouse CD16/32, 
except when CD16/32 expression was being analysed. Cocktails of antibodies were made for 
analysis of each cell type. Cells were incubated with the antibodies for 1 hour on ice in the 
dark (see Table 2.2). To stop the staining 100µl of PBS or DMEM with 10% FCS was added 
to the cells to dilute the antibody, before the plate was spun and then all the media was 
removed. Cells were resuspended in 300µl PBS or DMEM with 10% FCS and transferred into 
FACS tubes for analysis.  
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2.4.3 FACS analysis 
Cells were analysed using a CyAn ADP analyser. All flow cytometry data was analysed using 
Summit software (Version 4.3). 20,000 (50,00 for stem cells) events were analysed for each 
sample. Control cells stained with a single antibody was used to compensate for spectral 
overlap.  Gates were set on live cells for all analysis, which was determined by known size 
and density of live cells.  
Cell populations were identified based on surface marker expression. The most pluripotent 
progenitor cells, the KSL (Lin-Sca-1+c-Kit+) population was subdivided into; (in order of 
decreasing pluripotency) long- term progenitors (LTP) (Flt3- CD34-), short-term progenitors 
(STP) (Flt3- CD34+) and multipotent progenitors (MPP) (Flt3+ CD43+). The Lin- Sca-1- c-
Kit+ population was subdivided into common myeloid progenitors (CMP) 
(CD16/32+CD34med), GMP (CD16/32- CD34-) and MEP (CD16/32+CD34+).  
T cell populations were identified as follows; immature double positive (DP) T cells 
(CD4+CD8+) and more mature single positive T cells; T- helper cells (CD4+ CD8-) and T-
cytotoxic cells (CD4-CD8+).  
B cell populations were identified as follows; Pro-B cells (CD43+B220+), Pre B cell (CD43-
B220+) and immature B cells (CD43-B220med IgM+), transitional B cells (CD43-B220high 
IgM+) and follicular B cells (CD43-B220high IgM-) were also analysed. For measurement of 
IgM expression, B220 positivity was measured as medium and high to distinguish between 
immature and re-circulating B cells in the bone marrow and transitional and follicular B cells 
in the spleen.  
For the myeloid cell populations, macrophage (CD11b+ Gr-1-) and granulocytes (CD11b+Gr-
1+) were measured.  The following erythrocyte populations were measured; pro erythroblast 
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(CD71+ TER-119-), erythroblast (CD71+ TER-119+) and mature erythrocyte (CD71- 
TER119+). Platelets and mature megakaryocytes (c-Kit-CD41+) megakaryocyte progenitors 
(c-Kit+CD41+) and all progenitors (c-Kit+CD41-). All populations except where stated, were 
expressed as a proportion of the total bone marrow cells or total spleen cells. A list of the all 
cell types and surface marker expression can be found in Table 2.2. 
2.4.4 Antibodies  
The antibodies used for FACS analysis are listed here and summarised in Table 2.3; CD4-PE 
(12-0041; clone GK1.5), CD8a-APC (17-0081; clone 53-6.7), B220-APC (17-0452; clone 
RA3-6B2), Gr-1-APC (17-5931; clone PB6-8C5), CD11b-APC (17-0112; clone M1/70), 
CD5-APC (17-0051; clone 53-7.3), TER119-APC (17-5921; clone TER-119), CD71-PE 
(12-0711; clone R17217), c-Kit- Pe-Cy5 (15-1171; clone 2B8), B220-E450 (48-0452; clone 
RA3-6B2), CD11b-Pe-Cy7 (25-0112; clone M1/70), Gr-1-FITC (11-5931; clone RB6-8C5), 
CD41-PE (12-0411: clone eBioMWReg30), CD34- FITC (11-0341; clone RAM34), Flt3-
PE (12-1351; clone A2F10), Sca-1 -PeCy7 (25-5981; clone D7), CD16/32-PE (12-0161; 
clone 93), CD43-PE (12-0431; clone ebioR2/60), CD16/32 (purified)(14-0161; clone 93), 
CD5-APC (17-0051; clone 53-7.3) and CD19-PE (eBio-D3, 12-0193). Lin+ cells were 
identified using lineage cocktail of the following APC conjugated antibodies B220, CD8a, 
Gr-1, CD11b, CD5 and TER-119. LSK cells were identified as Lin- Sca1+ c-Kit+. 
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Table 2.2 Categorisation of cell type by surface marker expression for FACS analysis 
Cell Type  Cell markers 
Progenitors:  
LSK  Lin-Sca-1+c-Kit+ 
Long term progenitor Lin-Sca-1+c-Kit+Flt3- CD34- 
Short term progenitor  Lin-Sca-1+c-Kit+Flt3- CD34+ 
Multipotent progenitor  Lin-Sca-1+c-Kit+Flt3+CD34+ 
Common myeloid progenitor Lin-Sca-1-c-Kit+ CD16/32+CDCD34med 
Granulocyte monocyte progenitor Lin-Sca-1-c-Kit+ CD16/32-CDCD34- 
Megakaryocyte erythrocyte progenitor Lin-Sca-1-c-Kit+ CD16/32+CDCD34+ 
T cells:  
Double positive T cells CD4+CD8+ 
Helper T cell CD4+CD8- 
Cytotoxic T cell CD4-CD8+ 
B cells:  
Pro B cell CD43+B220+ 
Pre B cell CD43-B220+ 
Immature B cell CD43-B220mediumIgM+ 
Transitional B cell CD43-B220+IgM+ 
Follicular B cell CD43-B220+IgM- 
IgM+IgD+  B cells B220+IgM+IgD+ 
IgD+ B cell B220+IgM-IgD+ 
Myeloid Cells:  
Monocyte  CD11b+ Gr-1- 
Granulocyte CD11b+ Gr-1+ 
Pro-erythroblast CD71+ TER-119- 
Erythroblast CD71+ TER-119+ 
Erythrocyte CD71- TER-119+ 
All progenitors c-Kit-CD41- 
Megakaryocyte progenitors c-Kit+CD41+ 
Mature megakaryocytes and platelets c-Kit-CD41+ 
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Table 2.3 Antibodies used for FACS analysis 
Antibody Cell Type Conjugate  Lot number Clone 
Flt3 Progenitor PE 12-1351 A2F10 
CD16/32 Progenitor PE 12-0161 93 
c-Kit Progenitor PE-Cy5 15-1171 2B8, 
Sca-1 Progenitor PE-CY7 25-5981 2 D7 
CD34 Progenitor PE-CY7 11-0341 RAM34 
CD43 B cell PE 12-0431 ebioR2/60 
CD19 B cell PE 12-0193 eBio1D3 
B220 B cell E450 48-0452 RA3-6B2 
B220 B cell* APC 17-0452 RA3-6B2 
CD4 T cell PE 12-0041 GK1.5 
CD5 T cell*  APC 17-0051 53-7.3 
CD8a T cell* APC 17-0081 53-6.7 
CD71 Erythrocyte PE 12-0711 R17217 
TER119 Erythrocyte* APC 17-5921 TER-119 
CD41 Megakaryocyte PE 12-0411 eBioMWReg30 
Gr-1 Myeloid* APC 17-5931 PB6-8C5 
CD11b Myeloid PE-Cy7 25-0112 M1/70 
CD11b Myeloid* APC 17-0112 M1/70 
CD16/32  Block Purified 14-0161 93 
 
All antibodies were purchased from eBioscience, San Diego, California, USA 
* these antibodies were used in the lineage cocktail to identify Lin+ cells.  
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2.4.5 Side population analysis 
Higher levels of multi-drug resistance (mdr) protein on the surface of haematopoietic stem 
cells (HSC) compared to other cell lineages, causes a faster rate of Hoechst 33342 dye efflux 
from HSC. This difference has been utilised as an alternative method of isolating HSC from 
mouse bone marrow. Bone marrow was removed from the mouse and prepared as described 
for FACS analysis. Cells were resuspended at a concentration of 1x 106/ml in pre-warmed 
DMEM. Hoechst 33342 dye was added to a final concentration of 5µg/ml, the sample was 
mixed well and incubated at 37°C for 90 minutes mixing regularly. To ensure that the correct 
population of cells was analysed the cells were co-stained with lineage cocktail, c-Kit and 
Sca-1 antibodies as previously done for FACS analysis. Analysis was done on a BD flow 
cytometer with UV a channel.  
2.4.6 Colony forming assay  
The ability of haematopoietic stem cells (HSCs) in the spleen and bone marrow to 
differentiate into different myeloid cell lineages was measured using a colony forming unit 
(CFU) assay. Myeloid differentiation is outlined in Figure 2.3. Single HSCs can differentiate 
and grow to form a colony of mature myeloid cells, termed a CFU, that can be identified 
morphologically.  The colony forming assay was carried out in order to detect a range of 
different colony types. 2x 104 bone marrow cells or 2x 105 splenic cells were added to 1 ml of 
semi-solid methylcellulose (M3434, Stem cell technologies, Manchester, UK), in duplicate. 
M3434 contains recombinant mouse-stem cell factor, recombinant human- IL-3, recombinant 
human- IL-6 and recombinant human- erythropoietin along with added thrombopoietin (TPO) 
to a concentration of 6.25ng/ml (Peprotech, London, UK) to stimulate megakaryocyte growth. 
After incubation at 37°C for 10-14 days, colonies were counted. Colonies were visualised on 
an inverted microscope and given one of the following colony descriptions; CFU-G, CFU-
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GM, CFU-M, CFU-MK, CFU-M/MK, BFU-E and CFU-GEMM based on the criteria defined 
by Stem Cell Technologies and is outlined in Figure 2.4 and Table 2.4. After the colony type 
was determined, cells were removed from the plate by diluting in cold DMEM, washed by 
spinning down and resuspending in DMEM, and the total number of cells was counted.   
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Figure 2.3 Haematopoietic differentiation  
 
Haematopoietic stem cells (HSC) have the potential to differentiate into all haematopoietic 
cell types. Differentiation occurs in a stepwise manner, as outlined above, and is guided by a 
series of signals, such as growth factors. The colony forming unit (CFU) assay can be used to 
analyse the functional ability of HSCs and multipotent progenitors to differentiate into the 
different myeloid lineages in vitro. Growth and differentiation was supported by a cocktail of 
growth factors specific to myeloid cell lineages.  
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Figure 2.4 Representative colony types 
 
      
 
Pictures were taken from ‘Stem Cell Technologies Technical Manual’. For CFU analysis, colonies 
were identified using these pictures, along with the written descriptions given Table 2.4 for guidance. 
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Table 2.4 Colony forming unit (CFU) descriptions 
Colony type (Cell type) Description  
CFU-G (Granulocyte) Bright small cells, uniform in size, form dense clusters 
of cells 
CFU-GM (Granulocyte, macrophage) Mixture of GM and M cells. A dense core of cells 
surrounded by larger brighter cells 
CFU-M (Macrophage) Large oval/ round cells, bright with a grainy centre.  
CFU-MK (Megakaryocyte) Large cells with visible budding or surrounded by very 
small cells, form small colonies of 5-10 cells.  
CFU-M/MK (Macrophage, 
Megakaryocyte) 
Mixture of CFU-M and CFU-MK. Medium-large 
colonies of M interspersed with MK cells.  
CFU-GEMM (Granulocyte, erythroid, 
macrophage, megakaryocyte) 
Mixture of all cell lineages. Have a dense core. 
Erythrocyte clusters and MK cells are easily 
distinguished around the periphery.  
BFU-E (Burst forming unit-erythroid) Very small cells, irregular in shape, can appear red/pink 
in colour 
CFU-Undifferentiated (Undetermined) Large colony of small- medium cells with no 
distinguishable characteristics.  
 
Descriptions are adapted from the ‘Stem Cell Technologies Technical Manual’. 
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2.4.7 Peripheral blood counts 
60-90µl of blood was taken from the tail vein of mice prior to being sacrificed. 30µl of acid 
citrate dextrose (ACD) (citric acid 6.8 mM, trisodium citrate 11.2 mM, glucose 24 mM, Atm-
/- bleeding) or heparin (Sigma-Aldrich) (Atm-/-nu-/- comparison at 6, 24 and 48+ weeks) was 
used to prevent coagulation. Total volume was measured and then the blood was analysed 
using an ABX Pentra 60 haematology analyser. The dilution factor was accounted for to give 
the actual blood cell count.  
2.5 Atm-/-nu-/- tumour phenotyping  
2.5.1 Tissue preservation  
At post mortem, tissues removed from the mice for histological analysis were fixed 
immediately in neutral buffered formaldehyde, 10% v/v (Surgipath, Leica Microsystems, 
Milton Keynes, UK). After a minimum of 24 hours, the tissues were embedded in paraffin 
wax using an automated system either at the Biobank, University of Birmingham or the 
histopathology department at the Queen Elizabeth Hospital Birmingham (QEHB). Tissue 
sections were cut at 4µm for H&E staining and immunohistochemistry.  
H&E staining was done according to standard protocols by the Biobank at the University of 
Birmingham, or the histopathology department at the QEHB. H&E section analysis was 
undertaken by histopathologists Dr Zbigniew Rudzki, at Birmingham Heartlands hospital and 
Dr Maha Ibrahim, University of Birmingham, as outlined in the results section, with guidance 
from the WHO classification of tumours of haematopoietic and lymphoid tissue, 4th edition 
(Swerdlow, 2008).  
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2.5.2 Sectioning tissues 
For immunohistochemical analysis slides were prepared as follows. FFPE blocks were chilled 
for approximately 20 minutes on ice. Blocks were cut 4µm in thickness and placed on X-tra 
Adhesive micro-slides (Surgipath, Leica Microsystems, Milton Keynes, UK). Slides were 
heated to 60°C for 60 minutes to completely dry the section.  
2.5.3 Preparation of tissue sections  
For analysis of antigen expression analysis heat induced antigen retrieval was used prior to 
visualisation using the HRP-DAB technique and sections were counterstained with 
haematoxylin as follows. Firstly, to remove paraffin wax, tissue sections were incubated in 
histoclear (National Diagnostics, UK), for a minimum of 20 minutes and until all wax was 
removed. To rehydrate the sections, they were immersed in IMS for 2x 5 minutes, followed 
by rinsing under tap water for 5 minutes. Slides were then blocked with 3% H2O2 (Sigma-
Aldrich) for 15 minutes to inactivate any endogenous peroxidase, followed by rinsing under 
running tap water again.  
2.5.4 Antigen retrieval  
Antigen retrieval was done by heating the slides in a beaker containing pre-heated sodium 
citrate buffer (1.26g of sodium citrate (VWR, Pennsylvania, USA) 0.25g citric acid (VWR, 
Pennsylvania, USA) in 1L, pH 6.0) in the microwave for 10 minutes on medium power, 
followed by 10 minutes on low power. The slides were left to cool before they were removed 
and then rinsed under running tap water for 5 minutes.  
2.5.5 Detection of antigen by immunohistochemistry 
Prior to staining, tissue sections were outlined with a wax pen (Sigma-Aldrich) and 
conditioned with Tris-buffered saline with 0.1% Tween-20 (TBS-T) for 5 minutes. Tissue 
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sections were blocked with 1X casein (Vector Labs, Peterborough, UK) diluted in TBS-T for 
10 minutes to prevent non-specific background staining. Tissue sections were incubated 
overnight at 4°C, with an adequate volume of primary antibody to cover the sections. The 
primary antibodies were used as follows; anti-B220 (RA3, BD Biosciences, Oxford, UK) 
(dilution 1:400, 1:800 and 1:1600), anti CD3 (A0452, Dako, Cambridge, UK) (dilution: 1:250. 
1:500 and 1:1000) and anti MAC-1 (CL8941AP, Cederlane, Gateshead, UK) (dilution: 1:50). 
In certain cases a sample was tested with 3 different antibody concentrations to account for 
variation in fixation and paraffin block preparation. 
The following day, the slides were washed 3 times in TBS-T before incubation with anti- 
rabbit (K4010, Dako, Cambridge, UK) or anti- rat secondary antibody (P0450, Dako, 
Cambridge, UK) both used at a 1:100 dilution, at room temperature for 30 minutes. After 
which the slides were washed 3 times in TBS-T. For visualisation Dako, (Cambridge, UK) 
DAB+ liquid (K3467) was used, and the staining development was observed using an 
inverted microscope. When the staining was saturated, the reaction was stopped by dilution 
with TBS-T, and the slides were rinsed in tap water for 5 minutes. Counterstaining was done 
using Meyers haematoxylin incubated for 1- 5 minutes, then immersed in warm running water 
until the colour turned blue.  Finally, the slides were dehydrated in two changes of IMS and 
then incubated in histoclear for 10 minutes. Immediately prior to mounting the slides were 
immersed in xylene (Sigma-Aldrich) and air-dried before the cover slip was applied with 
DPX (VWR, Pennsylvania, USA). All staining was repeated twice on separate occasions.  
Staining of FOXP1, IRF4/MUM1 and CD10 along with B220 and CD3 was done in the lab of 
Dr Teresa Marafiott, at the University College London hospitals according to local procedures.  
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2.6 V(D)J recombination analysis 
2.6.1 V(D)J recombination PCR 
V(D)J rearrangements were amplified by polymerase chain reaction (PCR) from normal and 
tumour genomic DNA extracted using a Qiagen (Manchester, UK) DNA easy blood and 
tissue kit, according to manufacturers instructions for cells in culture. The PCR reaction mix 
contained 200ng of DNA, 5µL of 10X PCR buffer, 0.2mM dNTP’s, 10pM each of forward 
and reverse primer, 2.5mM magnesium chloride and 2.5units hot-start Taq polymerase 
(Promega, Southampton, UK) in a total volume of 50µl.  The JH-4 (5’ CTC CAC CAG ACC 
TCT CTA GAC AGC 3’) reverse primer was used along with one of the following forward 
primers VH7183 (5’ GAA SAM CCT GTW CCT GCA AAT GAS C 3’) (where S = C and G 
and M= A and C), VHQ52 (5’CAG GTG CAG CTG AAR CAG TCA 3’), or J558 (5’CAG 
CCT GAC ATC TGA GGA CTC TGC 3’).  The three forward primers correspond to the 3 
most common V gene families and JH-4 being the most distal J gene. Thermocycling was 
done at 95°C for 3 minutes, 35x(95°C for 30 seconds, 61/63°C for 30 seconds, 72°C for 2 
minutes), and 72°C for 7 minutes.  The annealing temperature was 63°C for J558 and 61°C 
for VH7183 and VH52Q. PCR products were separated on a 1.5% agrose gel. A single PCR 
product was determined to be indicative of a monoclonal rearrangement in the V(D)J gene in 
the sample. A smear, or 4 fuzzy bands was present in polyclonal sample that correspond to 
multiple different rearrangements involving the same J genes.  
2.6.2 Sequencing of V(D)J 
To confirm a single PCR product was indeed a monoclonal rearrangement it was sequenced. 
dNTP’s were removed from the PCR reaction using Exosap (1µL PCR product, 1µL Exosap 
(Affymetrix, High Wycombe, UK)) and 8µl water). After which the entire 10µL of reaction 
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mix was added to a sequencing reaction mix containing 1µ 2.5X Big Dye, 3.5µ Buffer, 10pM 
primer, made up to 20µL with water. The forward primer used in the PCR reaction was used 
with one of each JH-4, JH-3 (5’ GTC ACT GAC CCT GAA ATT GTC 3’) and JH-2 (5’ AGA 
TGG AGG CCA GTG AGG GAC 3’), depending on the re-arrangement at least one of these 
reverse primers would enable amplification. The DNA produced in this reaction was 
precipitated from the mix using sodium acetate; then it was cleaned with EtOH and air-dried. 
The pellet was re-suspended in Hi-Di (BD Biosciences, Oxford UK) for sequencing using an 
Applied Biosystems 3500XL sequencer. 
The sequence obtained was analysed using the NCBI Ig Blast software to confirm a 
rearrangement and to identify what V, D and J genes were used in the rearrangement.  
2.7 Sub-cutaneous transplant of tumour cells in to immunocompromised 
mice.  
5x106 cells were injected sub-cutaneously into the right flank of a NOG (NOD/Shi-scid/IL-
2Rγ null) immunocompromised mouse. The NOG mice used here were obtained from a 
colony bred and maintained in house. The strain was originally derived at the Central Institute 
for Experimental Animals, CIEA, Japan by cross breeding three mouse strains: 1) non-obese 
diabetic - NOD/Shi; 2) severe combined immune deficiency – SCID; 3) interleukin 2 
receptor-gamma-null - IL-2Rγnull. As a consequence of this genetic background, NOG mice 
have defective macrophage, T and B lymphocyte and natural killer cell function. The 
experiment was done in triplicate. Mice were monitored daily for tumour growth and once 
tumour was detected, the size of the tumour was measured twice weekly using calipers, until 
the tumour neared the maximum size permissible by the project license. At this point the mice 
were culled, and a post mortem was undertaken. The tumour was removed, along with the 
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spleen and liver if tumour was visible in these organs also. For each sample cells were frozen 
viably, fixed in formalin and DNA was extracted. The fixed tissue was processed into paraffin 
blocks from which sections were cut and stained with H&E and immunohistochemically 
stained as described in section 2.5.2 to2.5.5 with anti-CD3 and anti-B220. V(D)J 
recombination was also analysed by PCR as described in section 2.6.   
2.8 Chromosome analysis 
2.8.1 T cell culture 
Frozen viable thymoma cells were revived and cultured at a density of 2x 107 cells/ml in 
media containing 20% FCS, 100units/ml IL-2, penicillin / streptomycin (1 in 100) (Gibco, 
Life Technologies) for 24 to 48 hours. The cells were harvested as described in section 2.3.6 
for splenocyte radiosensitivity analysis.  
2.8.2 B cell culture 
Tumour cells and normal B cells were cultured in media containing 15µg/ml LPS, penicillin-
streptomycin (1 in 100), 50µM β-mercaptoethanol and 10% FCS for up to 72 hours. Cells 
were harvested as described for splenocyte radiosensitivity analysis in section 2.3.6.  
2.8.3 Multicolor fluorescence in situ hybridisation  
Slides were aged overnight before hybridisation. 7µl of mouse 21X Metasystems (Bicester, 
UK) M-FISH probe was applied to the slide and covered with an 18x18mm coverslip and 
sealed. Hybridisation was done on a Vysis HyBright (Abbot Molecular, Illinois, USA) at a 
melting temperature of 73°C for 2 minutes followed by hybridisation at 37°C for 16 hours. 
After removing the coverslip, the slide was washed in pre-warmed 0.4x SSC at 73°C for 2 
minutes followed by 2X SSCT at room temperature for 30 seconds.  Slides were 
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counterstained with 7.5µl of DAPI and a cover slip was applied. Images of metaphases were 
automatically captured using a Zeiss Axio imager Z.1, with Metasystems Metafer slide 
scanning software. Analysis of karyotype was done using ISIS software for multicolour FISH.  
All suitable metaphases, up to a maximum of 40 metaphases, were analysed. Chromosome 
gains, losses, duplications and translocations were counted and an aberration was determined 
to be clonal if it was present in two or more cells.   
2.8.4 Targeted fluorescence in situ hybridisation   
FISH probes were custom made using the following BACS; IgH alpha- 5-ROX dUTP (RP23-
455J10), IgH V1 5-Fluorescein dUTP (RP23-303N6), c-Myc 5-ROX dUTP (RP23-307D14) 
(Empire Genomics, Buffalo, New York, USA). 
Slides were prepared as described in section 2.8.3 for M-FISH. For IgH analysis 0.5µL of IgH 
alpha and 0.5µL IgH V1 were added to 5µL of buffer. For c-Myc 0.5µL of probe was added 
to 4.5µL of buffer. For IgH or c-Myc analysis, the probe mixture was added to the slide and a 
cover slip placed on top and sealed. Hybridisation was undertaken using a Vysis HyBright 
(Abbot Molecular, Illinois, USA) with a melting temperature of 75°C for 2 minutes followed 
by hybridisation at 37°C for 16 hours. 
After hybridisation was complete the coverslip was removed and the slide was washed in pre 
warmed 0.4 SSC/ 0.3%NP-40 at 73°C for 2 minutes followed by 2xSSC/0.1% NP-40 for 1 
minute. Slides were counterstained with 7.5µl of DAPI before cover slipping. Analysis was 
done on a Zeiss fluorescence microscope using ISIS software.  
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3 THE SUITABILITY OF THE ATM-/-NU-/- MOUSE AS A MODEL 
FOR ATAXIA TELANGIECTASIA  
3.1 Generation of the Atm-/-nu-/- mouse 
Nude Atm heterozygous (Atm+/-nu-/-) males were mated with Atm+/-nu+/- double 
heterozygote females to generate Atm-/-nu-/- mice. An eighth of the offspring of this mating 
would be expected to be nude Atm-/- mice (Atm-/-nu-/-) another quarter expected to be Atm-
/- and half expected to be nude.  The genotypes of animals expected from this mating are 
given in Table 3.1. Since 2012, a record of each mouse born from these pairings and its 
genotype was recorded on an ARMIS database and a summary of these records can be found 
in Table 3.1. In total 490 offspring were born to these matings between 15/05/2012 and 
07/03/2013.  The number of Atm-/-nu-/- mice that survived until genotyping at 2-3 weeks of 
age was roughly a quarter of the predicted Mendelian frequency (15 compared to 61, Table 
3.1).  The frequency of Atm-/-nu+/- mice was also roughly half and Atm+/+nu-/- mice were 
two thirds of the expected number also.  
Pups were genotyped at weaning which clearly excluded those that did not survive until this 
point. Pre-wean losses calculated for 20 litters in Table 3.2 was 11%. If this value is 
extrapolated to all of the colonies of this mating type, 11% of pups born in this mating were 
likely to have died before weaning. It therefore can be estimated that for the 490 mice 
recorded in Table 3.1 there would have been an additional 60 that died before weaning. This 
pre-weaning loss could be one of the reasons for reduced number of Atm-/-nu-/- and Atm-/-
nu+/- mice than predicted. Another explanation for this reduced number is that these mice 
died in utero; this however has not been investigated. 
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3.2 Survival of the Atm-/-nu-/- mouse  
In total, 103 mice (in both matings to produce double knockouts and also in the Atm 
heterozygote colony) in this study were culled because of morbidity. Of these 16/103 were 
Atm-/-nu+/- or Atm-/-  (from the heterozygote colony), 18/103 were nude Atm+/+nu-/- and 
69/103 were double knockouts Atm-/-nu-/- Figure 3.1. Atm+/+nu+/- are not included in this 
group because no Atm+/+nu+/- mice developed morbidity, they were mostly culled when 
healthy and used as controls during the analysis of Atm-/-nu-/- mice. Nevertheless, 2 
Atm+/+nu+/- and 1 Atm+/-nu+/- mice were allowed to age and reached over 90 weeks old 
before they were culled, and post mortem revealed no abnormalities. Similarly, only 18 
Atm+/+nu-/- mice are included in the survival analysis because they were also used alongside 
Atm+/+nu+/- mice as controls and therefore few remained that could be included.  
Atm-/-nu-/- mice lived longer than Atm-/- mice. Atm-/-nu-/- mice had a mean age of 25 ±16 
weeks (range = 6-90 weeks), compared to single knockout Atm-/- mice, from the 
heterozygote colony, which had a mean age of 13 ±1 weeks (range = 11-15 weeks). The mean 
age of Atm+/+nu-/- mice was 32 ±15 weeks (range = 12-72 weeks). The age of death for 
Atm+/+nu+/- and Atm+/+ mice could not be calculated as these mice were only culled when 
healthy as controls.  
3.3 Morbidity in the Atm-/-nu-/- mouse  
All 16/16 Atm-/-nu+/- and Atm-/- mice developed laboured, rapid breathing and a starry coat, 
which indicated a mouse in pain and these were immediately culled (Table 3.3). In 
Atm+/+nu-/- mice, 10/18 were culled as a consequence of showing symptoms indicating poor 
body condition, 4/18 an eye abscess and 2/18 a prolapsed bowel (Table 3.3). In Atm-/-nu-/- 
mice 31/69 had poor body condition, 17/69 had an eye abscess, 3/69 had a prolapsed bowel, 
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8/69 had a swollen abdomen, 1/69 had a growth on its front right limb and 1/69 had hind leg 
paralysis and were culled as a consequence of these morbidities but for 8/69 the cause of 
death was unknown (Table 3.3). 
For the mice with declining body condition, H&E sections from tissues from 6 mice (4 Atm-/-
nu-/- and 2 Atm+/+nu-/-) were analysed by a consultant histopathogist Zbigniew Rudski, to 
try and elucidate the cause of death. Pictures of these sections are found in Figure 3.2. Briefly, 
2/4 Atm-/-nu-/- mice had evidence of pneumonia with pneumocystis in the lungs. 1/4 Atm-/-
nu-/- mouse had granulocytes present in the portal tract of the liver, which is indicative of 
hepatitis and 1/4 had reactive bone marrow, which could indicate infection. 1/2 Am+/-nu-/- 
mice had pneumocystis in the lungs and the remaining one had focal pneumonia. 
3.4 Cellular Atm protein expression  
Atm-/-nu-/- mice would not be expected to have any ATM protein in their cells. The 
expression of Atm protein in extracts from Atm-/- single knockout and Atm-/-nu-/- tissue was 
measured using western blotting with two anti-Atm antibodies. Figure 3.3a (lane 1) and 
Figure 3.3b (lane 1) shows the recognition of ATM in a normal human lymphoblastoid cell 
line by antibodies MAT3 and 2CI but not in a lymphoblastoid cell line from a classical ataxia 
telangiectasia patient without any ATM protein (Figure 3.3a& b, lane 2). Figure3.3a also 
shows that these same antibodies recognised murine Atm in all tissues tested from Atm+/+ 
mice (Figure 3.3a, lanes, 3, 5, 7) but not in Atm-/- single knockout mice (lanes 4, 6 & 8). 
Figure 3.3a shows expression of Atm in Atm+/+nu+/- mice (lanes 3 & 6) and in Atm+/+nu-/- 
mice (lanes 4 & 7).  For both antibodies, no Atm protein was detected in the spleen and brain 
of the Atm-/-nu-/ - mouse (Figure 3.3b lanes 5 & 8).  
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3.5 Cellular radiosensitivity of the Atm-/-nu-/- mouse  
Cells from ataxia telangiectasia patients and Atm-/- single knockout mice are unusually 
radiosensitive. Splenocytes from Atm-/-nu-/- and Atm-/- mice were assessed for their 
chromosomal sensitivity to ionising radiation. After exposure to ionising radiation the cells 
were arrested in metaphase and spread on slides and stained. Metaphases were examined on 
high power, by light microscopy, for the presence of induced damage (see Figure 3.4 for 
representative examples). Cells from 2 Atm+/+ and 2 Atm-/- mice were tested. Atm-/- 
splenocytes had more than three times the amount of damage as Atm+/+ cells (124.5 ± 29 bits 
of damage and 37.5 ± 9 bits of damage respectively (Figure 3.4). In both Atm-/- and Atm+/+ 
cells the damage was mostly chromatid breaks, and chromatid gaps were the second most 
frequent type of damage to be present (Table 3.4).  
Using the same method, the radiosensitivity of cells from a single Atm-/-nu-/- mouse spleen 
was tested. Atm-/-nu-/- and Atm-/- cells had more damage than Atm+/+nu-/- cells  (78 and 82 
compared to 31 bits of damage). Again, like Atm-/- cells, Atm-/-nu-/- cells the most common 
type of damage to be present was chromatid breaks and the second most common being 
chromatid gaps (Table 3.5 and Figure 3.4).   
3.6 Discussion 
The number of Atm-/-nu-/- mice born was lower than expected using Mendelian ratios. 
Whether Atm-/-nu-/- mice died in utero, or shortly after birth but prior to weaning cannot be 
known for certain. However, there was a significant pre-wean loss in litters from Atm+/+nu-/-, 
Atm+/-nu+/- pairings that could account for the mice dying shortly after birth. To generate 
Atm+/-nu-/- males that are required to generate Atm-/-nu-/- mice, a nude (nu-/-) BALBc male 
was mated with Atm+/- females. The Mendelian ratio was most reduced in the mice that were 
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homozygous for Atm loss. Atm-/- 129S6/SvEvTac were born at the expected frequency but a 
lower than the expected birth rate has been observed for Atm-/- BALBc mice, although this 
reduction was not significant (χ2 =5.886, P=0.0527, df= 2) (Genik et al., 2014). Therefore the 
lower than expected numbers of Atm-/-nu-/- mice could be in part a consequence of the 
BALBc phenotype inherited from the nude male founder of the colony. 
The Atm-/- mice used in this study survived between 11 and 15 weeks of age. These mice had 
the same mutation in the Atm gene as those used by Barlow and colleagues that survived 
between 8 and 20 weeks of age (Barlow et al., 1996). The age range of Atm-/- mice in the 
Barlow study was larger than that was observed here. Differences in the survival between 
Atm null mouse models have been observed previously and were attributed to differing 
husbandry conditions or strain background.  Like the mice in the Barlow study, the Atm-/- 
mice used in this study were housed in specific pathogen free (SPF) conditions but variation 
could occur between housing facilities and local environmental factors could account for the 
small difference in survival between the two studies (Reliene and Schiestl, 2006). The mice 
used in this study were the same strain background as those used by Barlow and colleagues in 
1996 and therefore the age of survival should be similar.  
The median age of survival for Atm-/-nu-/- was 25 weeks, which was almost double that of 
my Atm-/- mice that had a median survival of 13 weeks. Therefore the Atm-/-nu-/- model has 
achieved the objective of increasing the survival of A-T mice. Schubert and colleagues noted 
a median survival of the Atm-/- Barlow mouse of 30 weeks (Schubert et al., 2004). Petiniot 
and colleagues reported a similar median survival of 30 weeks for a mouse containing the 
same mutation in Atm as the Wynshaw-Boris mice, but had a C57BL/6 genetic background as 
a consequence of being heterozygote for a Rag knock-out gene (Petiniot et al., 2002). The 
C57BL/6 Atm-/- mouse has been shown to have an increased survival compared to the 
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129S6/SvEvTac Atm-/- mouse and therefore genetic background could cause the increased 
longevity of the mice in the Petiniot study (Genik et al., 2014). 
The most common reason for having to cull the Atm-/-nu-/- mice in my study was a declining 
body condition. This was also the most common cause of death for the Atm+/+nu-/- mice and 
therefore this morbidity is may be associated with the nude phenotype. Analysis of 
histological sections from a selection of mice that had declining body condition by a 
histopathologist revealed evidence of pneumonia, pneumocystis and hepatitis. These diseases 
are all cause by infection.  Bone marrow from one mouse analysed was reactive, which is also 
indicative of an infection (Swerdlow, 2008). Nude mice are prone to hepatitis virus and 
Sendai virus infections further suggesting that the declining body condition could be cause by 
an infection (Sharkey, 1978). Nude mice are immunocompromised and the immune system of 
Atm-/-nu-/- mice is further compromised by the loss of Atm causing reduced T and B 
lymphocytes (Barlow et al., 1996). It is therefore plausible that declining body condition 
observed in Atm-/-nu-/- and Atm+/+nu-/- mice was the consequence of an infection. None of 
hairy mice (nu+/-) developed an eye abscess or prolapsed bowel so it is possible that these 
conditions are a consequence of the nude (nu-/-) phenotype. These conditions developed in 
20/69 nude mice and therefore made over one quarter of the Atm-/-nu-/- mice unsuitable to be 
used for investigation into the A-T phenotype.   
The mutation in the Barlow Atm-/- mice is predicted to lead to truncation of the Atm protein, 
which in humans causes instability and loss of Atm protein from the cell (Reiman et al., 2011). 
In 1996, due to not having a suitable antibody available, Barlow and colleagues confirmed 
knock out of the Atm gene in the Barlow Atm-/- mice using functional assays, such as testing 
cell cycle checkpoint analysis. Since then, several human ATM antibodies have been found to 
cross-react with murine Atm. Using two of these, no Atm protein was observed in the spleen 
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or brain of my Atm-/- and Atm-/-nu-/- mice by western blotting. However, these findings are 
contrary to a report by Li and colleagues that detected mutant Atm protein in the brains of the 
Atm-/- Barlow mice (Li et al., 2011). The same anti-Atm antibody (2C1A1) that was used to 
detect Atm in the brain of Atm-/- Barlow mice in the study by Li and colleagues was unable 
to detect Atm protein in the brains of my Atm-/- and Atm-/-nu-/- mice. In this report Li and 
colleagues used two antibodies, 5C2 and Y170, in addition to 2C1A1 and Atm protein could 
be also detected in the brain of Barlow Atm-/- mice using 5C2 but not Y170.  
Cells from my Atm-/-nu-/- mice lacked Atm protein expression and were chromosomally 
radiosensitive like the Atm-/- single knockout animals. For these two crucial reasons the Atm-
/-nu-/- mice can be regarded as A-T mice. The Atm-/-nu-/- mice survived longer than Atm-/- 
mice, but they also developed morbidities possibly associated with the nude phenotype.    
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Table 3.1 Expected and observed genotypes of offspring from mating Atm+/-nu-/- males 
with Atm+/-nu+/- females 
Genotype Atm+/+ 
nu+/- 
Atm+/- 
nu+/- 
Atm-/- 
nu+/- 
Atm+/+ 
nu-/- 
Atm+/- 
nu-/- 
Atm-/- 
nu-/- 
Expected genotype frequencies  1/8  2/8  1/8  1/8  2/8  1/8 
Expected number of each genotype 
(n=490) 
  61 123   61   61 123   61 
Actual number   71 181   34   43 146  15 
 
Based on a total of 490 offspring in 103 litters from matings between 15/05/2012 and 07/03/13.  The 
numbers of observed genotypes differ from the number expected (χ2 =85.2, with 5 degrees of freedom, 
P> 0.001). 
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Table 3.2 Pre-wean losses in 20 litters from mating Atm+/-nu-/- males with Atm+/-nu+/- 
females 
Litter number  Litter size Pre-wean loss 
 121 1 0 
 120 5 3 
 119 7 0 
 118 8 0 
 117 6 1 
 116 6 2 
 115 8 0 
 114 6 0 
 113 9 1 
 111 4 0 
 110 13 0 
 109 10 3 
 107 7 2 
 106 6 2 
 105 10 0 
 104 10 1 
 103 7 0 
 102 10 0 
 101 13 0 
 100 1 1 
 Total  147 16 
 Average 7.35 0.8 
 
In 20 litters, 147 mice were born and 16 died before weaning (loss of 11%).  
Extrapolating the 11% pre wean loss to the population of 490 mice genotyped between 15/05/2012 
and 07/03/13, 60 mice would have died after birth and before genotyping was done at weaning. 
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Figure 3.1 Survival of the Atm-/-nu-/- mouse 
  
Atm-/-nu-/- mice lived longer than Atm-/- or Atm-/-nu+/- mice  
Mean age of Atm-/-nu-/- = 25 ± 16 weeks 
Mean age of Atm-/-nu+/- and Atm-/- (from Atm heterozygote colony) single knockout mice =13± 1 
weeks.  
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Table 3.3 Morbidity associated with Atm-/-nu-/- mouse 
Genotype 
Number 
of mice 
Mean 
age of 
death 
(Weeks) 
Morbidity 
D
iff
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O
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er
  
 Atm-/-nu+/-, 
Atm-/- 
16 13 16 0 0 0 0 0 0 
 Atm+/+nu-/- 18 33 0 10 4 2 1 1 0 
 Atm-/-nu-/- 69 25 0 31 17 3 8 8 2 
 
Atm-/-nu-/- mice lived longer than Atm-/-nu+/- and Atm-/- mice.  
Death associated morbidity was recorded for 105 mice.  
Mean age of death:  
Atm-/- nu+/- and Atm-/- mice =13±1 weeks 
Atm-/-nu-/- = 25 ±16 weeks 
Atm+/+nu-/- = 18 ±15 weeks 
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Figure 3.2 Pathological analysis of mice that were culled because of poor body condition  
Mouse: H&E analysis:   
39M1 
Atm-/- 
nu-/- 
   
 Brain: inflammation around 
vessel in 20x 
Lung: Massive pneumonia, 
looks like pneumocystis 20X 
Lung: massive pneumonia, 
looks like pneumocystis 63X 
46M2 
Atm-/- 
nu-/- 
 
  
 Reactive bone marrow   
40F3 
Atm-/- 
nu-/- 
 
  
 Liver: Mild acute hepatitis 
granulocytes in the portal 
tract 20X 
  
40M2 
Atm-/- 
nu-/- 
  
 
 Lung: Acute 
bronchopneumonia with 
pneumocystis 20X 
Lung: Acute 
bronchopneumonia with 
pneumocystis 63X 
 
46F1 
Atm+/- 
nu-/- 
  
 
 Lung: Pneumocystis 20X Lung: Pneumocystis 63X  
40F2 
Atm+/+ 
nu-/- 
   
 Lung: Focal pneumonia 20X Lung: Focal pneumonia 20X Lung: Increased neutrophils 
20X 
Atm-/-nu-/- and Atm+/+nu-/- mice, which had a poor body condition, were investigated for cause of 
death. Sections from spleen, liver, lung, brain, bone marrow, kidney, gut, and lung were H&E stained 
and analysed by histopathologist Dr Zbigniew Rudski to identify possible abnormalities associated 
with the declining health of the mouse. The mice analysed had evidence of hepatitis pneumonia or 
pneumocystis.  It is possible that infections were the cause of morbidity in these mice.   
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Figure 3.3 Cellular Atm protein expression in the Atm-/- and Atm-/-nu-/- mouse  
 
 
Western blot analysis of Atm protein expression in;  
a. Atm+/+ and Atm-/-  (from the Atm +/- heterozygote colony) spleen, brain and thymus.  
b. Atm-/-nu-/-, Atm+/+nu-/-, Atm+/+nu+/- spleen and brain.  
Human and mouse Atm was identified using two monoclonal antibodies (MAT3 and 2CI) which 
recognise human ATM.  
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Table 3.4 Radiosensitivity of Atm+/+ and Atm-/- splenocytes 
Mouse  Chromatid 
break 
Chromosome 
breaks 
Tri-
radial 
Quadri-
radial 
Other Total 
Damage 
Atm+/+ 1 12 31 0 1 2 46 
Atm+/+ 2 12 12 3 0 2 29 
 Mean   12 22 2 1 2 37.5 
 s.d 0 10 2 1 0 9 
 Atm-/- 1 18 74 6 2 4 104 
 Atm-/- 2 37 104 3 0 1 145 
 Mean 28 89 5 1 3 124.5 
 s.d 13 21 2 1 2 29 
 
25 metaphases were analysed for each mouse. The experiment was carried out twice. 
s.d= standard deviation 
Table 3.5 Radiosensitivity of Atm-/-nu-/- splenocytes 
Mouse Chromatid 
break 
Chromosome 
breaks 
Tri-
radial 
Quadri-
radial 
Other Total 
Damage 
Atm+/+nu-/-  14 16 0 0 1 31 
Atm-/-  36 43 0 0 3 82 
Atm-/-nu-/-  25 40 10 0 3 78 
 
25 metaphases were analysed for each mouse.  
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Figure 3.4 Graphical representation of radiosensitivity analysis 
a. b. 
  
c.  
     
 
a. Atm-/- splenocytes described in table 3.4 and b. Atm-/-nu-/- splenocytes described in table 3.5. 
c. Representative metaphases showing normal chromosomes, chromatid gap (tg), chromosome breaks 
(cb), triradial (tr) and quadriradial (quad). 
Mouse splenocytes were stimulated in culture with LPS. After 3 days, splenocytes were irradiated, 
incubated for 3 hours and colcemid was added for 1-2 hrs. Cells were spread on slides and stained 
with Giemsa. 25 cells were analysed for each mouse (except Atm+/+ 1 =10)  
0	  
50	  
100	  
150	  
200	  
Mouse	  Splenocytes	  
To
ta
l	  D
am
ag
e/
	  c
el
l	  
Atm	  +/+	  (2)	  	  Atm-­‐/-­‐	  (2)	  
0	  10	  
20	  30	  
40	  50	  
60	  70	  
80	  90	  
Mouse	  Splenocytes	  
To
ta
l	  D
am
ag
e/
	  C
el
l	   Atm+/+nu-­‐/-­‐	  (1)	  Atm-­‐/-­‐	  (1)	  Atm-­‐/-­‐nu-­‐/-­‐	  (1)	  
 92 
 
 
 
 
 
CHAPTER 4 
THE HAEMATOPOIETIC SYSTEM IN 
ATM-/-, ATM-/-NU-/- AND ATM+/+NU-/- 
MICE 
  
 93 
4 THE HAEMATOPOIETIC SYSTEM IN ATM-/-, ATM-/-NU-/- AND 
ATM+/+NU-/- MOUSE  
4.1 Immunological phenotyping of Atm-/- bone marrow and spleen by 
FACS.  
Atm-/- mice have been shown to have altered lymphocyte populations (see section 1.6.1). To 
determine if we could replicate these findings and determine if there were any additional 
changes in the immune system as a consequence of Atm loss, immunological phenotyping of 
Atm-/- and Atm+/+ bone marrow and spleen was undertaken at age six weeks of age, before 
thymoma development occurred. Details are given in ‘Materials and Methods’ (section 2.4), 
but briefly, the proportions of progenitor cells, lymphocyte and myeloid cell populations, 
were measured based on expression of the following cell surface markers, Progenitors; LSK 
(Lin-Sca-1+c-Kit+), long- term progenitors (LTP) (Flt3- CD34-), short-term progenitors 
(STP) (Flt3- CD43med), multipotent progenitors (MPP) (Flt3+ CD43+), common myeloid 
progenitors (CMP) (CD16/32+CDCD34med), granulocyte macrophage progenitors (GMP) 
(CD16/32- CD34-) and megakaryocyte erythrocyte progenitors (MEP) (CD16/32+CD34+). T 
cells; double positive T cell (CD4+CD8+), helper T cell (CD4+CD8-), cytotoxic T cells 
(CD4-CD8+). B cells; pro B cell (B220+CD43+), pre B cell (B220+CD43-), immature B cell 
(CD43-B220medium IgM+), transitional B cell (CD43- B220high IgM+) and follicular B cell 
(CD43- B220high IgM-), plus B220+ IgM+IgD-) and (B220+IgM+IgD+) also. Myeloid cells; 
monocytes/ macrophages (CD11b+ Gr-1-) and granulocytes (CD11b+ Gr-1+). Erythrocytes; 
pro-erythroblast (CD71+TER-119-), erythroblast (CD71+ TER-119+) and mature erythrocyte 
(CD71- TER119+). Megakaryocytes; all progenitors (c-Kit+ CD41-), megakaryocyte 
progenitor (c-Kit+ CD41+) and mature megakaryocyte and platelets ( c-Kit- CD41+) . The 
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gating strategies used for the different populations for the bone marrow and spleen, are shown 
in Figure 4.1 and Figure 4.3. 
Atm-/- bone marrow was compared to Atm+/+ bone marrow and the results are shown in 
Figure 4.2. No difference was seen in early progenitor (LSK, LT, ST progenitors) and late 
progenitor (MPP, GMP, MEP) cell populations in these two genotypes. 
Lymphoid cell populations were altered in the bone marrow of Atm-/- mouse.  The numbers 
of single positive (SP) T cells, both cytotoxic-T cells (CD4- CD8+) and helper-T cells  (CD4+ 
CD8-), were significantly reduced in the Atm-/- mice although the more immature double 
positive (DP) (CD4+CD8+) T cells were normal (Figure 4.2 d, e &f).  
The progenitor B cells; pro B (B220+ CD43+), pre-B (B220+ CD43-)  and immature B cells 
(B220med IgM+) cells, were also altered in Atm-/- mice. The pro B cell population was 
increased and pre B and immature B cells were significantly reduced but the most mature B 
cell population analysed here, the transitional B cells (B220high IgM-), were not significantly 
different (Figure 4.2 g, h, i & j).  
Comparison of myeloid cell populations in the bone marrow showed that the proportion of 
macrophages (CD11b+ Gr-1 -) was normal in Atm-/- mice bone marrow but the proportion of 
granulocytes (CD11b+ Gr-1+) was significantly increased. Considering the erythrocyte 
populations, pro erythroblast (CD71+ TER-119-), erythroblast (CD71+ TER-119+) and 
mature erythrocyte (CD71- TER119+) cells were normal in Atm-/- mice (Figure 4.2 m, n, o). 
Finally, megakaryocyte cell populations were analysed. All progenitors (c-Kit+ CD41-), 
megakaryocyte progenitor (c-Kit+ CD41+) and mature megakaryocyte and platelets (c-Kit- 
CD41+) cell populations were normal in Atm-/- bone marrow (Figure 4.2 p, q, r).  
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Overall, only lymphocyte and granulocyte cell populations were altered in Atm-/- bone 
marrow. Atm-/- bone marrow lymphocyte population differed from normal Atm+/+ bone 
marrow in that mature single positive T cells were reduced in these mice. B cell populations 
were also changed; the more immature pro B cells were increased whereas the proportion pre 
B cells, which differentiate from pro B cells, were reduced. 
FACS analysis of splenic T cells showed that the proportion of both DP and SP T cells were 
reduced in the Atm-/- spleen compared to Atm+/+ spleen.  Unlike the bone marrow, there was 
no significant change in the B cell population in the Atm-/- mouse spleen. In the Atm-/- 
spleen, the immature B cell population was normal, and the more differentiated transitional 
and follicular B cell populations were also unchanged. The proportion of macrophage and 
granulocyte populations in the spleen of Atm-/- mice were increased at 6 weeks compared to 
Atm+/+. Finally, there was no statistical difference observed in erythrocyte or megakaryocyte 
populations in the spleen (Figure 4.4) 
Analysis of both Atm-/- bone marrow and spleen showed that the proportion of single 
positive T cells was reduced. In the spleen only, early B cell populations (Pro, Pre and 
immature B cell) were altered but the more differentiated B cells (transitional and follicular) 
were normal. Changes were observed in the myeloid cells also, granulocytes cells were 
increased both in the bone marrow and spleen, and macrophages were increased in the spleen 
only.  
4.2 Analysis of Atm-/- peripheral blood 
After changes were observed in the spleen and bone marrow of Atm-/- mice, peripheral blood 
was analysed to see if loss of Atm altered this haematological compartment. Comparison of 
Atm-/- and Atm+/+ peripheral blood cells was undertaken using a blood counter (ABX  Pentra 
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60 haematology analyser, see section 2.4.7). The results are shown in Figure 4.5.  The platelet 
count was not significantly different in Atm-/- mice compared to Atm+/+ mice. The mean 
white blood cell (WBC) count was lower in Atm-/- blood compared to Atm+/+ blood, 
however this was not a significant change. 
When considering sub-types of WBC independently, differences were seen between Atm-/- 
and Atm+/+ control mice.  Both the total lymphocyte count and proportion of lymphocytes 
were reduced in Atm-/- mice.  Conversely myeloid cell populations were increased in Atm-/- 
mice compared to Atm+/+ mice. The mean monocyte count and proportion of monocytes was 
increased in Atm-/- mice, although only the increase in the proportion was significant. Of the 
granulocyte population, the proportion of neutrophils was significantly increased; the mean 
proportion of eosinophils and basophils was also increased (but not significantly). In 
summary, like the spleen and bone marrow, Atm-/- peripheral blood had a reduced proportion 
of lymphocytes, and an increased proportion of monocytes and granulocytes.  Overall, these 
abnormalities were the most marked in the spleen. 
4.3 Determination of normal Atm-/- stem cell function using side 
population analysis 
Side population analysis refers to a method of identifying the most primitive haematopoietic 
stem cells population. These cells efflux Hoechst dye faster than other cell in the bone 
marrow and therefore can be sorted by FACS due to their low fluorescence level (see 
materials and methods). Co-staining for LSK markers was done to confirm that the side 
population was in fact within the stem cell compartment.  
After observing the changes in the bone morrow, spleen and peripheral blood cell populations, 
side population analysis was used to determine if a change in the character of stem cells was 
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responsible for an increase in myeloid cells in the spleen of Atm-/- mice. FACS analysis of 
stem cell populations LSK, LT and ST progenitors using cell surface markers; Lin-, Sca-1, c-
Kit, CD34, Flt3 and CD16/32, showed no difference in the proportions of these cells, so side 
population analysis was used in addition to cell surface marker expression, as another 
measurement of stem cell populations. The proportion of cells in the side population was 
comparable between Atm-/- and Atm+/+ mice showing no difference stem cell phenotype by 
this test and therefore the change in Atm-/- myeloid cell population is unlikely to be the result 
of abnormal stem cell function (Figure 4.6).  
4.4 Measuring Atm-/- bone marrow and spleen cell proliferation and 
differentiation using an in vitro colony forming unit (CFU) assay.  
Side population analysis indicated it was unlikely that there was a defect in stem cell function 
causing a change in the myeloid population in Atm-/- mice. Therefore, the differentiation 
potential of myeloid cell progenitors was tested using a colony forming unit assay. Atm-/- and 
Atm+/+ bone marrow cells were grown in methylcellulose with added cytokines that 
stimulate myeloid growth and differentiation, and the number and type of colonies were 
quantified. Examples of the different types of colony morphology expected are shown in 
Figure 4.7. 
In Atm-/- bone marrow the total number of colonies per plate were significantly reduced 
compared to Atm+/+ bone marrow and the total number of cells per plate were also reduced, 
however this was not significant ( Figure 4.8a). This suggests that fewer cells in Atm-/- bone 
marrow had the potential to form colonies than in Atm+/+ bone marrow, but the colonies that 
were formed were possibly larger and had more cells than Atm+/+ bone marrow colonies. 
The number of different types of colony was expressed as a proportion of the total number of 
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colonies counted per plate. CFU-GM and CFU-M were both decreased in Atm-/- bone 
marrow compared to Atm+/+ bone marrow and no difference was seen in the proportion of 
the remaining colony types ( Figure 4.8). The most striking difference between Atm-/- and 
Atm+/+ bone marrow was that Atm-/- bone marrow formed more colonies which were unable 
to be identified morphologically and were therefore categorised as ‘CFU-undetermined’. This 
could be a result of reduced differentiation in these colonies as a consequence of a slower 
growth rate, which would also cause a reduced total colony number.  
In Atm-/- spleen the number of colonies per plate was decreased and Atm-/- spleen had a 
reduced proportion of CFU-M colonies along with increased BFU-E and CFU-GEMM 
colonies. Undetermined colonies were more frequent in Atm-/- spleen, although this was not 
statistically significant (Figure 4.9).  
In summary, the CFU potential of Atm-/- bone marrow and spleen was similar in that both 
Atm-/- bone marrow and spleen had reduced potential to form colonies, formed more 
unidentifiable colonies, and CFU-M colonies were less frequent. However unlike the Atm-/- 
bone marrow, no difference was seen in the proportion of CFU-GM colonies in spleen and 
conversely no change in BFU-E and CFU-GEMM colony formation was seen in bone marrow 
that was present in the spleen. These results highlight an altered myeloid proliferation 
potential in vitro in Atm-/- bone marrow and spleen cells but is not consistent with the 
observation of the increased proportion of monocytes and or granulocytes detected in the 
bone marrow, spleen and peripheral blood of Atm-/- mice.  
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4.5 FACS analysis of Atm-/-nu-/- bone marrow, spleen and liver, at 6, 24 
and 48 weeks of age  
Comparison of Atm-/- mice with Atm+/+ mice suggested changes in lymphocytes and 
myeloid cell populations in the bone marrow and spleen of these mice.  A limitation of the 
Atm-/- single knock out model meant that changes in these populations could not be studied 
beyond the age of 8 weeks. In order to determine if Atm loss affects these cell populations 
with age, the Atm-/-nu-/- model was utilised. Atm-/-nu-/- mice were compared to Atm+/+nu-
/- and Atm+/+nu+/- mice to determine the effect of Atm loss on the haematopoietic cell 
populations. The same gating strategy was used for the Atm-/-nu-/- analysis as the Atm-/- 
analysis and can been seen in Figure 4.1 (bone marrow) and Figure 4.3 (spleen).  
Like the Atm-/- mouse no difference was seen in Atm-/-nu-/- early progenitor cells at 6-8 
weeks (Figure 4.10a). This did not change significantly with age, although the proportion of 
MPP cells decreased between 6 and 48+ weeks (not significant).  
Comparison of the lymphocyte populations showed similar changes in Atm-/-nu-/- bone 
marrow cells as Atm-/- mice (Figure 4.10b). The immature, DP T cell population was normal 
at 6, 24 and 48+ weeks and did not vary with age. With regards to the more mature single 
positive T cells, CD4+ CD8- T cell proportions were normal until 48+ weeks, where they 
were reduced in Atm-/-nu-/- compared to Atm+/+nu+/- bone marrow. The CD4- CD8+ Atm-
/-nu-/- T cell population was reduced compared to Atm+/+nu+/- at 6 weeks but was 
comparable to Atm+/+nu-/- and Atm+/+nu+/- at 24 and 48+ weeks. In addition both 
CD4+CD8- and CD4-CD8+ populations in Atm+/+nu-/- bone marrow were also reduced 
compared to Atm+/+nu+/-, which is expected of the nude phenotype (Figure 4.10b.i). 
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Therefore, apparently, loss of Atm does not significantly reduce the proportion of T cells 
further in the nude mice.  
Pro-B cells were comparable to Atm+/+nu-/- and Atm+/+nu+/- mice at 6 and 24 weeks, but in 
the eldest mice analysed (48+ weeks), there was a significant reduction in the proportion of 
Atm-/-nu-/- pro-B cells compared to Atm+/+nu+/- pro-B cells. Atm+/+nu-/- pro B cells were 
also reduced. 
Pre-B cells were reduced in Atm-/-nu-/- bone marrow compared to Atm+/+nu+/- bone 
marrow at 6 weeks and at 48+ weeks. At 24 weeks Atm-/-nu-/- pre-B cells were also reduced 
in the bone marrow compared to Atm+/+nu-/- and Atm+/+nu+/- but this was not statistically 
significant. Immature B cells were significantly reduced in Atm-/-nu-/- compared to 
Atm+/+nu-/- mice, but no differences were seen at older ages. Similarly, transitional-B cells 
were significantly reduced in Atm-/-nu-/- bone marrow at all ages compared to Atm+/+nu-/- 
and Atm+/+nu+/-, but this reduction was not statistically significant at 24 and 48 weeks 
(Figure 4.10b.ii). 
With regard to the myeloid cells, the monocyte population in Atm-/-nu-/- bone marrow was 
normal at all ages. On the other hand granulocytes were increased in Atm-/-nu-/- mice 
compared to Atm+/+nu+/- mice at 6 and 48+ weeks, but no difference was seen between 
Atm-/-nu-/- bone marrow and Atm+/+nu-/- at any age. Therefore both the Atm+/+nu-/- mice 
and Atm-/-nu-/- mice had increased granulocytes compared to Atm+/+nu+/- mice (Figure 
4.10c).  
The erythroid populations were unchanged in Atm-/-nu-/- bone marrow compared to 
Atm+/+nu-/- and Atm+/+nu+/- bone marrow.  All three populations measured, CD71+ TER-
119-, CD71+ TER-119+ and CD71- TER-119+, were comparable in Atm-/-nu-/-, Atm+/+nu-
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/- and Atm+/+nu+/- bone marrow at 6, 24 and 48 weeks of age.  The erythroid population was 
also unchanged in Atm-/- bone marrow compared to Atm+/+ (Figure 4.10d). 
At 6, 24 and 48+ weeks the proportion of megakaryocytes and their progenitors were 
comparable between Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- bone marrow. A noteworthy 
observation is that mature megakaryocytes (c-Kit- CD41+) from all genotypes were lower at 
48 weeks compared to 6 and 24 (Figure 4.10e).  
In Atm-/-nu-/- spleen, unlike Atm-/-nu-/- bone marrow where the DP T cell population is 
normal, DP- T cells are reduced compared to Atm+/+nu+/- at 48 weeks. In contrast, Atm-/-
nu-/- and Atm+/+nu-/- spleen single positive CD4+ and CD8+ T cell populations were 
reduced at 6 and 48 weeks, which was consistent with what was found in Atm-/-nu-/- bone 
marrow (Figure 4.11a.i).   
For the most part, B cell populations in Atm-/-nu-/- spleen were comparable to Atm+/+nu-/- 
and Atm+/+nu+/- spleen. Although there was one exception, Atm-/-nu-/- transitional B cells 
(B220high IgM+) were reduced in 6-week-old Atm-/-nu-/- mice compared to Atm+/+nu+/- 
mice (Figure 4.11a.ii). Mature follicular IgM and IgD expressing B cells were also reduced in 
the Atm-/-nu-/- mouse compared to both the Atm+/+nu-/- and Atm+/+nu+/- mouse at 6 weeks. 
This is unlike the Atm-/- mouse in which the pre B (B220+CD43+), pro B (B220+CD43-) 
cells and immature B (B220medIgM+) but not the transitional (B220high IgM+) and 
follicular cell (B220high IgM-) population are changed (Figure 4.2 and Figure 4.4). 
Myeloid cell pupations were altered in Atm-/-nu-/- spleen. At 6 weeks monocytes were 
increased in Atm-/-nu-/- and Atm+/+nu-/- spleen compared to Atm+/+nu+/-. Granulocytes 
were increased in the Atm-/-nu-/- and Atm+/+nu-/- spleen compared to Atm+/+nu+/- at 6 and 
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48 weeks. Importantly, there was no difference in myeloid cells between the Atm-/-nu-/- and 
Atm+/+nu-/- (nude) mouse spleen (Figure 4.11b). 
Megakaryocyte populations were unchanged in Atm-/-nu-/- spleen compared to Atm+/+nu-/- 
and Atm+/+nu+/- at 6, 24 and 48+ weeks of age. This reflects the normal population of 
megakaryocytes that was found in the Atm-/- spleen, Atm-/- bone marrow and Atm-/-nu-/- 
bone marrow (Figure 4.11c).  
Haematopoietic populations in the liver were analysed and the results are shown in Figure 
4.12.  As the liver is not associated with haematopoiesis in adulthood, any change in the 
populations of this tissue is likely to suggest an abnormality in the haematopoietic system in 
Atm-/-nu-/- mice.  
T cell populations in the liver were normal apart from Atm-/-nu-/- and Atm+/+nu-/- CD4+ T 
cells in 6-week-old mice, which were reduced. There was no significant change in any other T 
cell populations in the liver (Figure 4.12a).  
 Analysis of immature, transitional and follicular B cell populations in the liver of 6, 24 and 
48+ week old Atm-/-nu-/- mice showed these B cell populations were comparable to 
Atm+/+nu-/- and Atm+/+nu+/- mice (Figure 4.12a).  
Finally in the liver of Atm-/-nu-/- mice, monocytes and granulocytes were increased 
compared to Atm+/+nu+/- mice. In 24 and 48+ week old mouse liver these cell populations 
were also increased but these differences were not statistically significant. An increase in 
Atm-/-nu-/- and Atm+/+nu-/- monocytes and granulocytes in the liver, along with the 
observed increase in monocytes and granulocytes in the bone marrow and spleen shown 
above, suggests that there could be an abnormality in these cell populations in these mice 
(Figure 4.12b). 
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Finally, megakaryocytes were comparable between Atm-/-nu-/-, Atm+/+nu-/- and 
Atm+/+nu+/- liver cell population in 6, 24 and 48+ week old mice. In addition, no difference 
was seen in megakaryocyte cell populations in the bone marrow and spleen of Atm-/-nu-/- 
mice and therefore it is likely that megakaryocyte cells are normal in Atm-/-nu-/- mice 
(Figure 4.12c).  
4.6 Atm-/-nu-/- peripheral blood analysis with age 
Peripheral blood counts were taken to determine if Atm loss caused any changes in the blood 
cell population and are shown in Figure 4.13. The red blood cell count was comparable 
between Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- mice. There was also no difference in 
platelet and total white blood cell count (WBC). 
At 6 weeks both the lymphocyte count and proportion of lymphocytes was significantly 
reduced in Atm-/-nu-/- peripheral blood compared to both Atm+/+nu+/-, and Atm+/+nu-/- 
mice. At 24 and 48 weeks there was no significant difference in lymphocyte populations.   
The proportion of monocytes in the peripheral blood of Atm-/-nu-/- mice was increased at 6 
weeks, although there was no significant difference in the monocyte count in the peripheral 
blood. Considering granulocyte cell populations, the proportion of neutrophils was 
significantly increased in the peripheral blood of Atm-/-nu-/- mice compared to Atm+/+nu+/- 
mice. There was also an increase in the proportion of neutrophils compared to Atm+/+nu-/- 
mouse peripheral blood, but this was not significant. In older mice, the proportion of 
neutrophils is comparable to Atm+/+nu-/- and Atm+/+nu+/- peripheral blood and is therefore 
likely to be normal in these mice.  
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In summary the proportions of both lymphocytes and granulocytes were altered in 6-week-old 
Atm-/-nu-/- mice in a similar way to the Atm-/- mouse but no differences in these populations 
were seen in the peripheral blood of older Atm-/-nu-/- mice. 
4.7 Measuring Atm-/-nu-/- bone marrow and spleen cell proliferation and 
differentiation using an in vitro CFU assay  
The growth and differentiation of Atm-/-nu-/- bone marrow was assessed by CFU assay 
analysis. Due to the limited number of mice available, the analysis was carried out on three 6-
week-old mice, two mice at 24 weeks old and 2 mice at 48+ weeks old. Therefore the results 
here give an indication of the potential of Atm-/-nu-/- bone marrow cells, but the statistical 
significance of these results cannot be determined for the 24 and 48 week old mice. The 
results of the Atm-/-nu-/- CFU analyses are presented in Figure 4.14. The total number of 
colonies was slightly reduced in 6 and 24 week Atm-/-nu-/- mouse bone marrow; the number 
of colonies formed from 48+ week old mice bone marrow was comparable to controls. The 
total number of cells per plate derived from Atm-/-nu-/- bone marrow was reduced in 6-week 
mice, but at 24 and 48 week old the number of cells was normal.  The proportion of CFU-G 
cells derived from Atm-/-nu-/- bone marrow was also normal, along with the proportion of 
CFU-M and CFU-E colonies. Atm+/+nu+/- CFU-GM colony frequency increased with age, 
whereas Atm-/-nu-/- was stable. Conversely CFU-MK cell proportions decreased in Atm-/-
nu-/- bone marrow with age, while the frequency of CFU-MK colonies produced by 
Atm+/+nu+/- bone marrow was stable (Figure 4.14). 
CFU analysis of Atm-/-nu-/- spleen showed similar results to Atm-/-nu-/- bone marrow. The 
number of colonies formed and number of cells per plate were normal in Atm-/-nu-/- spleen. 
All colonies types were normal in Atm-/-nu-/- spleen apart from the proportion of CFU-
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M/MK which was higher in Atm-/-nu-/- and Atm+/+nu-/- spleen produced a than 
Atm+/+nu+/- spleen (Figure 4.15.  
In summary, CFU analysis of Atm-/-nu-/- bone marrow and spleen suggests that Atm-/-nu-/- 
bone marrow and spleen differentiation in vitro is comparable to Atm+/+nu-/- and 
Atm+/+nu+/- at 6, 24 and 48 weeks of age. It is worth noting here that there were differences 
observed between Atm-/- and Atm+/+ bone narrow and spleen at 6 weeks of age although 
these differences were not consistent with the abnormalities found in the bone marrow and 
spleen of the Atm-/- mouse ( Figure 4.8 and Figure 4.9).  
The Atm-/-nu-/- mouse was made with the intention of overcoming the limitations of the 
existing single knock out models that only develop a single type of cancer and die before 4 
month of age. In abrogating the thymus in the A-T mouse, by crossing the Atm-/- with the 
athymic nude mouse, thymoma development was prevented, and thus this early death due to 
thymoma development the Atm-/- mouse was overcome allowing any other phenotypes 
associated with Atm loss to develop. Despite this clear benefit, the consequence of the 
addition of nu-/- mutation to the Atm-/- A-T mouse was evaluated to determine the validity of 
the Atm-/-nu-/- mouse as a model of A-T. A summary of the evaluation of the haematopoietic 
system in the Atm-/-nu-/- mouse is shown in Table 4.1. 
4.8 Discussion 
The haematopoietic system of the Atm-/-nu-/- mouse is phenotypically similar to the 
Atm-/- mouse and both are distinguishable from the nude mouse. 
An important objective was to compare the components of the haematopoietic system, 
particularly B and T cell development, in the Atm-/-nu-/- mouse, the single knockout (Atm-/-) 
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but also with the nude mouse (Atm+/+nu-/-). In the Atm-/- single knockout and nude mouse, 
thymic development is severely curtailed for different underlying reasons (see Introduction, 
Section 0). At age 6 weeks in BM and spleen in Atm-/- and Atm-/-nu-/- mice there is a large 
reduction in CD8+ T cells. A similar reduction in CD4+ T cells was seen in spleen cells in all 
three genotypes. This is in agreement with previously published work on this Atm-/- mouse 
that had reduced CD4+ and CD8+ T cells in the spleen (Barlow et al, 1996) and another A-T 
mouse generated by Elson et al., that had reduced CD4+ and CD8+ cells in the spleen also 
(Elson et al., 1996).  CD4+ and CD8+T cells were also reduced in the Atm+/+nu-/- spleen. 
This is consistent with observations that T cell development is perturbed in the nude mouse 
due to the absence of a thymus, the main organ where T cell development and maturation 
takes place (Ikehara et al., 1984).  Thus the A-T mice and nude mice had similar defects in T 
cells.  
B cells are produced in the bone marrow and they mature in peripheral lymph nodes such as 
the spleen (Lebien and Tedder, 2008). Pre, pro and immature B cell development occurs in 
the bone marrow. At age 6 weeks there was a similar level of Pro B (B220+ CD43+) but a 
reduction in pre B (B220+ CD43-) and immature (B220med IgM+), B cells in both Atm-/- 
and Atm-/-nu-/- mice.  This observation in the Atm-/- and Atm-/-nu-/- mouse is consistent 
with the analysis of the Atm-/- mouse by Loizou and colleagues (Loizou et al., 2011) who 
noted a reduction in pre and immature B cells. No reduction was seen in the nude mouse of 
any B cell population in the spleen or bone marrow at age 6 weeks. Antigen dependent 
differentiation occurs in the peripheral compartments such as the spleen (Allen et al., 2007b). 
In the spleen of Atm-/- mice the more mature B cell populations, transitional (B220high 
IgM+) and follicular (B220high IgM-) B cells were normal but the transitional B cells were 
reduced in the Atm-/-nu-/- spleen. The Atm-/-nu-/- have a reduced ability to undergo class 
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switch recombination as a consequence of the loss of Atm protein and nude mice have 
reduced functional T cells, which combined could perturb B cell differentiation in the spleen 
greater than in the Atm-/- mouse (Lumsden et al., 2004, Ikehara et al., 1984).  
The reduction in both T and B lymphocytes in the A-T mice but not the nude was also 
reflected in the reduced lymphocyte count in the peripheral blood of the Atm-/- and Atm-/-nu-
/- mouse but not the Atm+/+nu-/- mouse.  The absence of B cell defect in the nude mouse 
bone marrow at 6 weeks of age highlighted a crucial difference between the A-T mice (Atm-/- 
and Atm-/-nu-/-) and nude (Atm+/+nu-/-). 
Altered B cell development in the A-T mice but not the nude is likely to be due to the 
involvement of Atm in B cell development. Pro B cells differentiate into pre B cells and 
undergo V(D)J recombination which requires Atm, and therefore the changes in the cell 
population observed in the A-T mice could be a consequence of perturbed development due to 
Atm loss (Petiniot et al., 2000). 
In the spleen and bone marrow of A-T mice (Atm-/- and Atm-/-nu-/-) the proportion of T and 
B cells did not change significantly between age 6 weeks and at age 48 weeks. In the bone 
marrow the pre and pro B cell populations are decreased in the Atm+/+nu-/- mice at age 48 
weeks. This age related decline in early B cells in the nude mouse could be a consequence of 
decreased expression of RAG-1 and RAG-2 proteins with age. These proteins are involved in 
V(D)J recombination in developing B cells. Aging and thymic involution are both associated 
with reduced levels of RAG-1 and RAG-2 and therefore could be a contributing factor in the 
reduction in pre and pro B cells in age 48 week nude mice (Szabo et al., 1998, Szabo et al., 
1999).  
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With regard to myeloid defects, an increase in granulocytes and monocytes was found in the 
Atm-/- and Atm-/-nu-/- mouse at 6 week of age suggesting that in addition to lymphocyte 
defects, A-T mice were susceptible to myeloid defects. Monocytes and granulocytes are part 
of the innate immune system. They are produced in the bone marrow and released into the 
blood system and from here they migrate to sites of inflammation and infection (Summers et 
al., 2010).  
The proportion of monocytes and granulocytes were increased in the bone morrow of the both 
the Atm-/- and Atm-/-nu-/- mouse at 6 weeks of age. This suggests either there was an 
increase in the production of monocytes and granulocytes in the bone marrow or a decrease in 
loss, either though reduced release from the bone marrow compartment or reduced cell death. 
Monocyte and granulocytes differentiate from granulocyte monocyte progenitor (GMP) cells. 
FACS analysis showed that the proportion of GMP cells, along with other stem cells 
populations in the Atm-/- and Atm-/-nu-/- bone marrow were normal, so it is unlikely that 
increased production of granulocytes and monocytes is caused by an abnormality in the 
progenitor cells. In addition, in vitro culture of bone marrow cells showed no abnormality in 
the differentiation into myeloid colonies, and reduced proliferation of the bone marrow cells, 
suggesting that it is unlikely that increased cell production by progenitors is causing increased 
granulocytes and monocytes in the A-T mice. As in vitro development was normal, the 
increased proportion of monocytes and granulocytes could be the result of stimulation from 
the bone marrow environment to promote the survival of the monocytes and granulocytes or 
to increase the production of new cells from progenitors.  Monocytes and granulocytes were 
also increased in the peripheral blood and spleen suggesting that the migration of monocytes 
and granulocytes from the bone marrow is not impaired and thus not producing an increase in 
cells in the bone marrow. It is worth noting here that the granulocyte cell population increased 
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in the peripheral blood was the neutrophils. The markers used for FACS analysis of the spleen 
and bone marrow could did not distinguish between granulocytic subpopulations, but the 
increased neutrophils in the peripheral blood may suggest that it could have been the 
neutrophil population that were increased in the bone marrow and spleen.  
The increase of monocytes and granulocytes in the spleen suggest that more monocytes and 
granulocytes were homing to the spleen more than normal. This could be due to abnormal 
cytokine signalling or infection/inflammation. Abnormal cytokine signalling was not 
investigated here so this possibility cannot be excluded, but A-T mice are 
immunocompromised due to the reduced lymphocytes, and therefore it is possible that  
infection was resulting in increased monocytes and granulocytes in these mice. An increase in 
granulocytes and monocytes was also seen in the liver. As the increase was seen in multiple 
organs, the cause of increased monocyte and granulocyte numbers could be due to systemic 
infection or inflammation.  
Myeloid abnormalities were less marked in the nude mouse. At age 6 weeks monocytes were 
increased in the spleen only but they also developed increased granulocytes at age 48 weeks. 
Nude mice are mice are also immunocompromised, plus as the immune system declines with 
age, both increase the likelihood of susceptibility to infection and could be a possible cause 
for increased granulocytes and monocytes in these older nude mice. All mice were in good 
health when analysed, therefore if an infection was present and causing an increase in 
monocyte and granulocyte levels, it could only have been underlying and did not affect the 
overall health of the animal.  In addition the mice were kept in a pathogen-controlled 
environment, and so risk to infection was minimised but not fully eliminated.  
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Overall, both the Atm-/- and Atm-/-nu-/- mouse have myeloid abnormalities but in 
comparison, the Atm+/+nu-/- mouse does not share this phenotype at 6 weeks of age. In all 
three genotypes there was a reduction in the lymphocyte population, which are part of 
adaptive immunity, and therefore it is possibly that the innate immunity (macrophage and 
granulocytes) is stepped up to control pathogens in these mice when the effectiveness of the 
adaptive immune system is reduced. This isn’t the first report of myeloid defects in A-T mice, 
Gr-1+ cells were also increased in the A-T mouse made by Xu and Baltimore but no further 
investigation was made into this defect (Xu et al., 1996).   
Comparison of the Atm-/-nu-/- mouse at a 24 and 48 weeks of age were undertaken to 
determine any change in the haematopoietic system with age.  Only two mice were available 
at 24 weeks of age for analysis, as the limited numbers of Atm-/-nu-/- mice available were 
also required for observation for tumour development. Nevertheless, the comparison of 
haematopoietic cells in the bone marrow, spleen and peripheral blood followed the same 
pattern as seen at 6 weeks and/ or 48 weeks of age in most instances and therefore, along with 
the data compiled from 48 week old mice, is included to give an indication of any 
haematopoietic abnormalities that may develop with age in the Atm-/-nu-/- mouse. In the 
Atm-/-nu-/- and Atm+/+nu-/- mouse peripheral blood cell populations did not change 
significantly with age.  Some changes were seen in the Atm-/-nu-/- mouse bone marrow; both 
pro B cell and CD4+ T cells were reduced at age 48 weeks. Similarly in the Atm+/+nu-/- 
mouse bone marrow CD4+ T cells and both pro and pre B cells were reduced, along with an 
increase in granulocytes in the bone marrow and spleen at age 48 weeks.  
Immunodeficiency in patients with A-T is mostly stable; it does not worsen with age. Defects 
are primarily seen in T and B cells and include reduced immunoglobulin levels, particularly 
IgA and IgG subtypes. Patients have increased respiratory tract infections but do not generally 
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succumb to opportunist viral infections because of residual functioning lymphocytes (Nowak-
Wegrzyn et al., 2004, Micol et al., 2011). To my knowledge there are no reports of defects in 
myeloid cells in A-T patients. Therefore the increased monocytes and granulocytes in the 
Atm-/- and Atm-/-nu-/- mice could be unique to A-T mice.  
To summarise, the reduced B and T cell defects associated with A-T and that are recapitulated 
in the Atm-/- mouse model are also present in the Atm-/-nu-/- mouse. Atm+/+nu-/- mice also 
have reduced T lymphocytes, but no defect was detected in B cells. Also, the Atm+/+nu-/- 
mouse did not have any of the myeloid defects that were associated with the Atm-/- and Atm-
/-nu-/- mice. Taking the B and T lymphocyte and myeloid abnormalities all into consideration, 
the Atm-/-nu-/- phenotype is most similar to the Atm-/- mouse and is therefore a suitable 
model of A-T.  
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Figure 4.1 Representative FACS chromatograms of Atm-/- and Atm+/+ bone marrow 
cells at 6 weeks of age  
a.     b. 
          
c.     d.i 
         
e.     d.ii 
       
f.        g. 
        
Representative chromatograms for FACS analysis in Figure 4.2. Boxes represent gates used to 
measure a particular cell population.  
a. Early progenitors 
b. Late progenitors  
c. T cells  
d. (i). Pre and pro B cells, (ii). Immature 
B cells 
e. Monocytes and granulocytes 
f. Erythrocytes 
g. Megakaryocytes 
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Figure 4.2 FACS comparison of Atm-/- and Atm+/+ bone marrow cells at 6 weeks of age   
a. 
 
b.      c. 
      
d.           e.          f. 
 
Grey =Atm-/- (n=14), black =Atm+/+ (n=15)  
Error bar =S.E.M, *=p< 0.05, ** =p<0.01, *** =p<0.001 
a. Haematopoietic stem cells: Lin-kit+ Sca-1+ cells (LSK) 
b. Early progenitors: long-term progenitors (LTP) short-term progenitors (STP), multipotent 
progenitors  (MPP) 
c. Late progenitors: common myeloid progenitor (CMP), megakaryocyte and erythrocyte progenitor 
(MEP), granulocyte and monocyte progenitor (GMP)  
d. Double positive (DP) T cells, e. single positive CD4 T cells, f. single positive CD8 T cells  
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Figure 4.2 continued FACS comparison of Atm-/- and Atm+/+ bone marrow cells at 6 
weeks of age  
g.     h. 
     
i.     j. 
     
Grey =Atm-/- (n=14), black = Atm+/+ (n=15)  
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** =p<0.001  
g, h, i and j. Pro B, Pre B, immature and transitional B cells respectively  
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Figure 4.2 continued FACS comparison of Atm-/- and Atm+/+ bone marrow cells at 6 
weeks of age  
k.    l. 
 
m.    n.   o. 
 
p.    q   r. 
 
Grey =Atm-/- (n=14), black = Atm+/+ (n=15)  
error bar = S.E.M. *=p< 0.05, ** = p<0.01, *** = p<0.001  
k & l. myeloid cells: macrophages and granulocytes respectively 
m, n & o. Pro-erythroblasts, erythroblasts and mature erythrocytes respectively 
p, q & r. c-Kit+ progenitor cells, megakaryocyte (meg.) progenitor and mature megakaryocytes and 
platelets cell populations respectively   
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Figure 4.3 Representative FACS chromatograms of Atm-/- and Atm+/+ spleen at 6 
weeks of age  
a. 
 
b. 
 
c. 
 
d. 
 
Representative chromatograms for FACS analysis in figure 3.3 Boxes represent gates used to measure 
a population.  
e. T cells  
f. Immature, transitional and follicular B 
cells 
g. Monocytes and granulocytes 
h. Megakaryocytes
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Figure 4.4 FACS comparison of Atm-/- and Atm+/+ spleen cells at 6 weeks of age 
a.        b.          c. 
 
d.       e.          f. 
 
Grey =Atm-/- (n=14), black = Atm+/+ (n=15) 
Error bar = S.E.M. *=p< 0.05, ** = p<0.01, *** =p<0.001  
a, b & c. double positive  (DP) T cells, single positive CD4 T cells, single positive CD8 cells 
respectively 
d, e & f. immature B cells, Transitional B cells and Follicular B cells respectively  
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Figure 4.4 continued FACS comparison of Atm-/- and Atm+/+ spleen cells at 6 weeks of 
age 
 g.           h. 
 
i.            j.                k. 
 
Grey =Atm-/- (n=14), black = Atm+/+ (n=15)  
error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** =p<0.001.  
g &h. myeloid cells: macrophage and granulocytes respectively 
i, j & k. c-Kit+ progenitor cells, megakaryocyte (meg.) progenitors and mature megakaryocytes and 
platelets cell populations  
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Figure 4.5 Atm-/- peripheral blood counts at 6 weeks of age 
a.    b.        c. 
  
d.                 e.          f.            g. 
 
Grey =Atm-/- (n=9), black = Atm+/+ (n=8) 
Error bar = S.E.M. *=p< 0.05, ** = p<0.01, *** =p<0.001  
a. Platelet count 
b. Red blood cell count  
c. White blood cell count  
d and e. Lymphocyte proportion and count respectively 
f and g. Monocyte proportion and count respectively 
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Figure 4.5 continued Atm-/- peripheral blood counts at 6 weeks of age 
h.          i.            j. 
 
k.           l.          m. 
 
Grey =Atm-/- (n=9), black = Atm+/+ (n=8)  
Error bar = S.E.M. *=p< 0.05, ** = p<0.01, *** =p<0.001  
h, i & j. neutrophils, eosinophil and basophil proportion   
k, l & m. neutrophils, eosinophil and basophil count  
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Figure 4.6 Atm-/- side population analysis 
a.      b. 
 
c. 
  
Black bar = Atm+/+ (n=4), grey bar= Atm-/- (n=4), Error bars = S.E.M 
a. Gating of LSK cells  
b. Gating of side population  
c. Proportion of side population   
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Figure 4.7 Colony forming unit (CFU) morphology 
a.     b. 
  
c.     d. 
  
Representative pictures of different colony types that grow on M3434 media. 
a. Diamond is CFU-E, circle is CFU-M, triangle is CFU-GM, square is CFU-G (x20) 
b. CFU-GEMM (x40) 
c. CFU-E (x100) 
d. CFU-MK (x40)  
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 Figure 4.8 Atm-/- bone marrow CFU potential at six weeks of age 
a. 
  
b. 
 
 
Black= Atm+/+ (n=4), grey= Atm-/- (n=4), error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001 
a. Total number of colonies per plate and total cells per plate  
b. Differentiation potential expressed as a proportion of the total number of colonies formed per plate 
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Figure 4.9 Atm-/- spleen CFU potential at six weeks of age  
a. 
 
b. 
 
 
Black= Atm+/+ (n=4), grey= Atm-/- (n=4), error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = 
p<0.001 
a. Total number of colonies per plate and total cells per plate  
b. Differentiation potential expressed as a proportion of the total number of colonies formed per plate  
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Figure 4.10 FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- bone 
marrow at 6, 24 and 48+ weeks of age 
a.  
 
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001. 
At 6 weeks, 4 mice of each genotype were analysed, at 24 weeks 2 mice of each genotype were 
analysed and at 48+ weeks 3 mice of each genotype were analysed.  
a. Progenitor cells;  LSK (lin-, Sca-1-, c-Kit-), long term (Flt3-CD34-) (LTP), short term (Flt3- CD34 
med)(STP) and multipotent progenitors (Flt3+, CD34+) (MPP). 
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Figure 4.10 continued FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- 
bone marrow at 6, 24 and 48+ weeks of age 
b.i   
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/-, error bar = S.E.M, *=p< 0.05, ** = 
p<0.01, *** = p<0.001 
At 6 weeks 4 mice of each genotype were analysed, at 24 weeks 2 mice of each genotype were 
analysed and at 48+ weeks 3 mice of each genotype were analysed.  
b.i T and B lymphocytes: Double positive (DP) T cell (CD4+CD8+), Helper T cell (CD4+Cd8-), 
Cytotoxic T cells (CD4-CD8+).  
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Figure 4.10 continued FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- 
bone marrow at 6, 24 and 48+ weeks of age 
b.ii 
 
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/-, error bar = S.E.M, *=p< 0.05, ** = 
p<0.01, *** = p<0.001 
At 6 weeks 4 mice of each genotype were analysed, at 24 weeks 2 mice of each genotype were 
analysed and at 48+ weeks 3 mice of each genotype were analysed.  
b.ii Pro B cell (B220+CD43+), pre B cell (B220+CD43-), Immature B cell (B220medium IgM+), 
transitional B cell (B220medium IgM+).   
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 Figure 4.10 continued FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- 
bone marrow at 6, 24 and 48+ weeks of age  
c.   
 
d.   
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001 
At 6 weeks 4 mice of each genotype were analysed, at 24 weeks 2 mice of each genotype were 
analysed and at 48+ weeks 3 mice of each genotype were analysed.  
c. Myeloid cells: monocytes (CD11b+ Gr-1-) and granulocytes (CD11b+ Gr-1+) 
d. Erythrocyte populations: pro-erythroblast (CD71+ TER-119-), erythroblast (CD71+ TER-119+) and 
mature erythrocytes (CD71- TER119+)  
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Figure 4.10 continued FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- 
bone marrow at 6, 24 and 48+ weeks of age 
e.  
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001 
At 6 weeks 4 mice of each genotype were analysed, at 24 weeks 2 mice of each genotype were 
analysed and at 48+ weeks 3 mice of each genotype were analysed.  
e. Megakaryocyte population: all progenitors (c-Kit+ CD41-), megakaryocyte progenitor (c-Kit+ 
CD41+) and mature megakaryocyte and platelets (c-Kit- CD41+)  
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Figure 4.11 FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- spleen at 6, 
24 and 48+ weeks of age 
a.i. 
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/-, error bar = S.E.M, *=p< 0.05, ** = 
p<0.01, *** = p<0.001  
At 6 weeks 4 mice each genotype were analysed, at 24 weeks 2 mice of each genotype were analysed 
and at 48+ weeks 3 mice of each genotype were analysed.  
a.i. T lymphocytes: Double positive (DP) T cell (CD4+CD8+), helper T cell (CD4+Cd8-) and 
cytotoxic T cells (CD4-CD8+)  
  
0	  
0.1	  
0.2	  
0.3	  
0.4	  
0.5	  
0.6	  
0.7	  
0.8	  
0.9	  
6	  Wks	   24	  Wks	   48+	  Wks	  
CD
4+
	  C
D8
+	  
ce
lls
	  (%
)	  
DP	  T	  cells	  
*	  
0	  
5	  
10	  
15	  
20	  
25	  
6	  Wks	   24	  Wks	   48+	  Wks	  
CD
4+
	  C
D8
-­‐	  c
el
ls
	  (%
)	  
Helper	  T	  Cell	  
*	  
*	  ***	  
0	  
2	  
4	  
6	  
8	  
10	  
12	  
14	  
6	  Wks	   24	  Wks	   48+	  Wks	  
CD
4-­‐
	  C
D8
+	  
ce
lls
	  (%
)	  
Cytotoxic	  T	  cell	  **	   *	  
 131 
Figure 4.11 continued FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- 
spleen at 6, 24 and 48+ weeks of age 
a.ii. 
 
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/-, error bar = S.E.M, *=p< 0.05, ** = 
p<0.01, *** = p<0.001  
At 6 weeks 4 mice each genotype were analysed, at 24 weeks 2 mice of each genotype were analysed 
and at 48+ weeks 3 mice of each genotype were analysed.  
a.ii. B lymphocytes: immature B cell (B220medium IgM+), transitional B cell (B220high IgM+), 
follicular B cells (B220high IgM-) and mature B cells (IgM+ IgD+ and IgM-IgD+)  
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Figure 4.11 continued FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- 
spleen at 6, 24 and 48+ weeks of age 
b.    
 
c.  
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/-, error bar = S.E.M, *=p< 0.05, ** = 
p<0.01, *** = p<0.001  
At 6 weeks 4 mice each genotype were analysed, at 24 weeks 2 mice of each genotype were analysed 
and at 48+ weeks 3 mice of each genotype were analysed.  
b. Myeloid cells: monocytes (CD11b+ Gr-1-) and granulocytes (CD11b+ Gr-1+) 
c. Megakaryocyte population: all progenitors (c-Kit+ CD41-), megakaryocyte progenitor (c-Kit+ 
CD41+) and mature megakaryocyte and platelets ( c-Kit- CD41+)  
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Figure 4.12 FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- liver at 6, 
24 and 48+ weeks of age 
a.      
 
 
Black= Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001  
At 6 weeks 4 mice each genotype were analysed, at 24 weeks 2 mice of each genotype were analysed, 
and at 48+ weeks 3 mice of each genotype were analysed.  
a. T and B lymphocytes: Double positive (DP) T cell (CD4+CD8+), helper T cell (CD4+Cd8-), 
cytotoxic T cells (CD4-CD8+), immature B cell (B220medium IgM+), transitional B cell (B220high 
IgM+), follicular B cells (B220high IgM-)   
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Figure 4.12 continued FACS comparison of Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/- 
liver at 6, 24 and 48+ weeks of age 
b. 
 
c.  
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/-, error bar = S.E.M, *=p< 0.05, ** = 
p<0.01, *** = p<0.001  
At 6 weeks 4 mice each genotype were analysed, at 24 weeks 2 mice of each genotype were analysed, 
and at 48+ weeks 3 mice of each genotype were analysed.  
b. Myeloid cells: monocytes (CD11b+ Gr-1-) and granulocytes (CD11b+ Gr-1+) 
c. Megakaryocyte population: all progenitors (c-Kit+ CD41-), megakaryocyte progenitor (c-Kit+ 
CD41+) and mature megakaryocyte and platelets (c-Kit- CD41+)  
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Figure 4.13 Atm-/-nu-/- peripheral blood analysis at 6, 24 and 48 weeks of age  
a.        b.    c. 
  
d.   e.       f.      g. 
 
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/-, error bar = S.E.M, *=p< 0.05, ** = 
p<0.01, *** = p<0.001  
Four mice each of genotype were analysed at 6 weeks of age, 2 mice of each genotype were analysed 
at 24 weeks and at 48+ weeks 3 mice of each genotype were analysed.  
a. Platelet count 
b. Red blood cell count  
c. White blood cell count  
d and e. Lymphocyte proportion and count respectively 
f and g. Monocyte proportion and count respectively  
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Figure 4.13 continued Atm-/-nu-/- peripheral blood analysis at 6, 24 and 48 weeks of age   
h.        i.    j. 
 
k.        l.    m. 
  
Black = Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001  
Four mice each of genotype were analysed at 6 weeks of age, 2 mice of each genotype were analysed 
at 24 weeks and at 48+ weeks 3 mice of each genotype were analysed.  
h, I and j. neutrophils, eosinophil and basophil proportion 
k, l and m. neutrophils, eosinophil and basophil count   
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Figure 4.14 Atm-/-nu-/- bone marrow CFU potential at 6, 24 and 48 weeks of age   
a. 
 
Black= Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001   
Four mice each of genotype were analysed at 6 weeks of age, 2 mice of each genotype were analysed 
at 24 weeks and at 48+ weeks 3 mice of each genotype were analysed. 
a. Total number of colonies per plate and total cells per plate  
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Figure 4.14 continued Atm-/-nu-/- bone marrow CFU potential at 6, 24 and 48 weeks of 
age 
b. 
 
Black= Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001  
Four mice each of genotype were analysed at 6 weeks of age, 2 mice of each genotype were analysed 
at 24 weeks and at 48+ weeks 3 mice of each genotype were analysed. 
b. Differentiation potential expressed as a proportion of the total number of colonies formed per plate  
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Figure 4.15 Atm-/-nu-/- spleen CFU potential at 6, 24 and 48 weeks of age 
a. 
 
Black= Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001  
Four mice each of genotype were analysed at 6 weeks of age, 2 mice of each genotype were analysed 
at 24 weeks and at 48+ weeks 3 mice of each genotype were analysed. 
a. Total number of colonies per plate and total cells per plate  
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Figure 4.15 continued Atm-/-nu-/- spleen CFU potential at 6, 24 and 48 weeks of age 
b. 
 
Black= Atm+/+nu+/-, grey=Atm+/+nu-/- and white = Atm-/-nu-/- 
Error bar = S.E.M, *=p< 0.05, ** = p<0.01, *** = p<0.001   
Four mice each of genotype were analysed at 6 weeks of age, 2 mice of each genotype were analysed 
at 24 weeks and at 48+ weeks 3 mice of each genotype were analysed.  
b. Differentiation potential expressed as a proportion of the total number of colonies formed per plate  
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Table 4.1 Summary of hematopoietic comparison of Atm-/-, Atm-/-nu-/- and Atm+/+nu-
/- mice 
 Atm-/- Atm-/-nu-/- Atm+/+nu-/- 
FACS: Bone  Normal stem cells Normal stem cells Normal stem cells 
Marrow ê CD4+ T 
ê CD8+ T 
ê CD4+ at 48 weeks 
êCD8+ at 6 weeks 
ê CD4+ at 48 weeks 
ê CD8+ at 6 weeks 
 é Pro B 
êPre B 
ê Immature B 
 
ê Pro B at 48 weeks 
ê Pre B at 6 and 48 weeks 
ê Immature B 
ê Transitional B at 6 weeks 
ê Pro B at 48 weeks 
ê Pre B at 48 weeks 
 égranulocytes é Granulocytes at 6 and 48 
weeks 
égranulocytes at 48 weeks 
 
FACS: 
Spleen  
ê DP 
ê CD4+ T 
ê CD8+ T 
ê DP at 6 and 48 weeks 
ê CD4+ T at 6 and 48 weeks 
ê CD8+ T at 6 and 48 weeks 
ê DP at 6 and 48 weeks 
ê CD4+ T at 6 and 48 weeks 
ê CD8+ T at 6 and 48 weeks 
 B cells normal ê Transitional B cell 
ê IgM+ IgD+ B cells 
B cells normal 
 é Macrophages 
é Granulocytes 
é Macrophages at 6 weeks 
é Granulocytes at 6 and 48 
weeks 
é Macrophages at 6 weeks 
é Granulocytes at 48 weeks 
 Megakaryocytes normal é mature meg/ platelets at 48 
weeks 
Megakaryocytes normal 
Peripheral 
blood 
analysis 
ê Lymphocytes 
é Monocytes 
é Neutrophils 
ê Lymphocytes 
é Monocytes 6 weeks 
é Neutrophils 6 weeks 
ê Basophils 48 weeks 
 
Normal 
CFU: 
Bone marrow 
ê Number colonies 
ê CFU-GM 
ê CFU-M 
 
Normal Normal  
CFU: Spleen ê Colony number 
ê CFU-M 
é CFU- E 
é CFU-GEMM 
Normal Normal 
Levels relative to Atm+/+ and Atm+/+nu+/- mice  
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5 TUMOUR DEVELOPMENT IN THE ATM-/-NU-/- MOUSE 
5.1 Type of tumour development in the Atm-/-nu-/- mouse  
5.1.1 Post mortem analysis of Atm-/-nu-/- mice. 
The longevity of Atm-/-nu-/- mice was examined in a cohort of 71 mice and 17/71 Atm-/-nu-
/- mice found to have a tumour at post mortem. These mice died aged between 7 and 69 
weeks, with a median age of 25 weeks compared with a median age of 13.5 weeks for the 
Atm-/- and 13 weeks for the Atm-/-nu+/- mice (Figure 5.1).  
Figure 5.2 details the occurrence of tumours in 17 Atm-/-nu-/ mice, with a summary of 
locations of each tumour given in Table 5.1. 15/17 mice had a tumour in the spleen. Five of 
these 17 mice had tumour at one site only (4 in the spleen and 1 axillary). The remaining 12 
mice had tumours in multiple locations, 6 in the spleen and liver, 2 mice had tumour in the 
spleen, liver and abdomen, 2 mice had tumour in spleen, liver, abdomen and thorax, 1 mouse 
had tumour in the abdomen and thorax and 1 mouse had a tumour in the liver and abdomen. 
Two mice did not have detectable tumour in the spleen. 
5.1.2 H&E analysis of Atm-/-nu-/- tumours  
H&E stained sections were made from all 17 Atm-/-nu-/- tumours. Ten were analysed by 
consultant histopathologist, Dr Zbigniew Rudski (ZR), Birmingham Heartlands Hospital, who 
made a diagnosis of lymphoma in all 10 cases. Histopathologist Dr Maha Abd El Kalek Hafez, 
School of Cancer Sciences, University of Birmingham, confirmed the diagnosis in these 10 
and also diagnosed lymphoma in a further 7 lymphomas. The WHO classification of human 
haematopoietic malignancies considers the morphology, immunophenotype, genetic features 
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and clinical features of the disease and the Atm-/-nu-/- lymphomas were assessed according to 
these criteria.  
Firstly, H&E stained sections of all 17 Atm-/-nu-/- tumours were evaluated and given a 
preliminary classification based solely on morphological appearance. Details of this analysis 
are given in Table 5.2 and summarised in Table 5.3. 17/17 tumours were Non-Hodgkin’s 
lymphomas (NHL). Of these 17, one tumour (68F2) was a low-grade lymphoma and 16/17 
were high grade lymphomas. The low-grade lymphoma was a small cell lymphoma, possibly 
of either mantle cell or marginal zone type. Of the 16 high-grade lymphomas one (656) was 
an anaplastic large–cell lymphoma (ALCL), one (519) was NHL (unclassifiable), with 
features intermediate between diffuse large B cell lymphoma (DLBCL) and Burkitt 
lymphoma, 11 were DLBCL (NOS) and 3 were follicle centre cell lymphomas, predominantly 
diffuse, grade 3A. Another noteworthy observation was that, one of the DLBCLs contained 
tingible body macrophages and had a ‘starry sky’ appearance, which suggested an aggressive 
nature and is also characteristic of Burkitt lymphoma. 
In summary, analysis of H&E sections indicated that 16/17 Atm-/-nu-/- lymphoma were high 
grade NHL with most (11/16), being diffuse large cell lymphoma that have morphological 
features consistent with DLBCL and therefore were assigned this classification pending 
immunophenotypic analysis. Also, one of these high grade NHL (case 656), an ALCL, could 
be a T cell tumour because >70% of ALCL tumours are of this origin.  
5.1.3 Discussion 
Secondary lymphoid tissue consists of follicles, the most obvious of which is the germinal 
centre (GC) follicle. Within these follicles B cells respond to antigen stimulation and undergo 
maturation, which involves a process of immune receptor gene editing called somatic 
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hypermutation, to enhance antigen specificity. The outer portion of the follicle, the mantle, 
contains re-circulating B cells. The dark inner section is composed of densely packed large B 
cells (centroblasts), and a lighter inner section is composed of smaller B cells (centrocytes 
derived from centroblasts) interspersed by dendritic cells (Maclennan, 1994) (Summarised in 
Figure 1.2). 
Tumour cell morphology is considered when classifying lymphoid tumours. DLBCL is 
composed of large centroblasts cells only. Follicular lymphoma (FL) contains mostly smaller 
centrocytes and a variable number of large centroblasts. The proportion of centroblasts in the 
lymphoma determines the grade of FL.  Grade 1: 0-5 centroblasts per high power field (hpf), 
grade 2: 5-15 centroblasts per hpf, grade 3A: some centrocytes still present and 3B: sheets of 
centroblasts with no centrocytes present per hpf. (High power field of 0.159mm2 40x 
objective lens, 18mm field of view ocular) (Maclennan, 1994, Swerdlow, 2008, Kogan et al., 
2002). 
Morphological analysis suggested that 1 Atm-/-nu-/- tumour could be of T cell origin and the 
remaining 16/17 were all of B peripheral cell origin, albeit not all the same classification of B 
cell lymphoma. Typically, FL develops from a germinal centre cell, and DLBCL can develop 
from a GC or post-GC B cell. Therefore, the Atm-/-nu-/- lymphomas described here are likely 
to have a GC or post-GC origin. In contrast, the small cell lymphoma is likely to be derived 
from marginal zone or mantle zone B cells, outside the germinal centre.  
For both Burkitt and DLBCL the normal cellular origin is GC or post-GC and consequently 
this may be the cellular origin of tumour 519, (B Cell lymphoma, unclassifiable, with features 
intermediate between DLBCL and Burkitt lymphoma). In humans it has been seen that FL 
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can progress to this type of B cell lymphoma, and therefore tumour 519 could have a common 
origin as FL, and have therefore have developed from a GC B cell. 
5.2 Phenotyping of the Atm-/-nu-/- tumours as B cell tumours 
5.2.1 Immunohistochemical staining of Atm-/-nu-/- tumours 
Immunohistochemical (IHC) staining of the Atm-/-nu-/- tumours was undertaken to further 
define the cell type of these tumours. Tumour sections were stained with antibodies against B 
cell marker B220, T cell marker CD3 and monocyte marker CD11b (Figure 5.3). 
Control tissues from Atm+/+nu+/- and Atm+/+nu-/- mice were stained alongside the 17 Atm-
/-nu-/- tumours. Because, B220 was a rat antibody, control tissues were stained with a rat 
isotype control and no staining was detected; similarly as anti-CD3 was a rabbit antibody, 
tissues were stained with no primary plus anti-rabbit secondary and again no staining was 
detected indicating that both secondary antibodies (anti-Rat and anti-Rabbit) did not cross 
react with mouse tissue. As an additional negative control, Atm-/- T cell lymphoma stained 
with B220 antibody also showed no positive staining, indicating that the anti-B220 did not 
bind to mouse thymocytes.  
Figure 5.3 shows the results of IHC staining and a summary of staining is given in Table 5.4. 
With regard to B220 staining of Atm-/-nu-/- tumours, 10/17 were B220+ and 6/17 were 
B220-. B220 staining in tumour 36F1 was positive, however it was weaker than normal B 
cells within the same histological section. 
11/11 Atm-/-nu-/- tumours tested were CD11b- (Figure 5.3).   
Further immunophenotypic analysis undertaken for one Atm-/-nu-/- tumour (519) is shown in 
Figure 5.4. Expression of B cell associated transcription factor PAX5 is often used to confirm 
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B cell origin of lymphoid neoplasms. No PAX5 expression could be detected in tumour 519, 
despite positive staining for B220.  
Large B cell lymphomas can be classified further depending on the expression of CD10, 
BCL6 and IRF4/MUM1. Foxp1 can also be a prognostic indicator in patients. It is expressed 
in activated B cells, prior to the germinal centre (GC) reaction and is commonly 
overexpressed in DLBCL. Cells in tumour 519 stained positively for Foxp1. These Atm-/-nu-
/- tumour cells also stained negatively for CD10 and IFR4/MUM1. In DLBCL negative 
staining of CD10 and IRF4/MUM1 along with BCL6 positivity normally indicates a germinal 
centre cell origin. No BCL6 staining was undertaken with tumour 519 and, therefore, without 
this confirmation a germinal centre cell origin for tumour 519 cannot be confirmed.  
14 /17 tumours with suitable material were also analysed for surface marker expression by 
flow cytometry (Figure 5.5 with results summarised in Table 5.4). Five of the six tumours that 
had no detectable B220 expression by IHC were tested using FACS; 1/5 (5F1) also had no 
detectable B220 expression by FACS; for another 2/5 tumours (55F1 and 319M1), the bulk of 
the total cell population were B220- and only a subpopulation were positive and the 
remaining 2/5 (107F2 and 656) were B220+ despite no B220 expression being detected by 
IHC. B220 positivity by FACS and not detected IHC could be the result of normal B cell in 
the cell population or could be the result of technical limitations. 
All 10 tumours tested expressed B cell marker CD19, 4 of these 10 were B220 negative by 
IHC including 1 that had no B220 expression by FACS either. For one tumour, 37F3, staining 
of tumour cells could not be distinguished from normal spleen. 
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One Atm-/-nu-/- tumour (656) was CD3+ and the remaining were CD3-. Expression of 
another T cell surface marker, CD5 was measured using FACS for 10/17 tumours, of which 
1/10 was CD5+, 1/10 was CD5normal and 8/10 were CD5- (Figure 5.5 and Table 5.4). 
5.2.2 Identifying the developmental origin of Atm-/-nu-/- B cell lymphoma - FACS 
profiling of tumours 
The 14 /17 tumours with suitable material were analysed for surface marker expression by 
flow cytometry, to further elucidate the developmental origin of the Atm-/-nu-/- tumours 
(Figure 5.5 and summarised in Table 5.4). In addition to CD5 and CD19 discussed above, 
CD43, IgM, IgD, CD4 and CD8 surface marker expression was also measured. 11/14 Atm-/-
nu-/- tumours expressed CD43. In seven of these 11 Atm-/-nu-/- tumours CD43 was only 
expressed by a small proportion of the total cell population, but for the other 4 Atm-/-nu-/- 
tumours (656, 593, 69F5 and 107F2), CD43 expression was detected on the majority of the 
total cell population. Interestingly, ALCL lymphomas express CD43, which further supported 
the diagnosis of tumour 656 as an ALCL.  
11/14 Atm-/-nu-/- tumours expressed IgM; including 2/14 that expressed both IgM and IgD. 
Surface immunoglobulin expression is expected on DLBCL and FL. Atm-/-nu-/- lymphoma 
surface IgM or IgD expression could not be distinguished from normal cells in 1/14  (37F3) 
and the remaining two (5F1 and 107F2) tumours had no detectable expression. These two 
tumours may not express surface immunoglobulin or have undergone class switch and 
therefore expression would not be detected with the antibodies used here. Two tumours of 13 
tested had a population of CD8+ cells, likely to be associated with tumour infiltrating CD8 T 
cells. Overall, most Atm-/-nu-/ lymphomas are IgM expressing B cell lymphoma.  
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5.2.3 Discussion 
In summary, 16/17 tumours were either B220 or CD19 expressing and therefore of B cell 
origin. 11/17 these were also diffuse large cell lymphomas and because these are now 
identified as B cells they can be confirmed as diffuse large B cell lymphoma (DLBCL) (Table 
5.4 Summary of morphological and immunophenotypic analysis of Atm+/+ nu-/- lymphoma 
Table 5.5). 
Interpretation of this staining to determine the cellular origin of Atm-/-nu-/- lymphoma 519 
was difficult. FOXP1 expression suggested a non-GC origin whereas CD10 and IRF4/MUM1 
negativity suggested a GC origin. The WHO classification system does not consider FOXP1 
to be a marker of a non-GC B cell and rather uses it as a prognostic factor in patients. Taking 
these considerations into account, the additional staining undertaken of Atm-/-nu-/- tumour 
519 suggested that it is likely to have an activated B cell origin and may be of GC origin. 
In addition one Atm-/-nu-/- tumour, 55F1, expressed CD5, a marker of normal T cells but also 
can be aberrantly expressed on DLBCL, where it is associated with an aggressive phenotype. 
As 55F1 expressed B cell associated antigens CD19, IgM and IgD, the classification of 
DLBCL (NOS) was still applicable to this tumour.  
The only non B cell tumour, therefore, was an anaplastic large cell lymphoma (656), that had 
no B220 expression by IHC and had only a sub population of B220+ staining cells by FACS; 
it also stained positively for T cell marker, CD3. Positive expression for a T cell marker in 
this tumour further suggested that this tumour was a T cell ALCL.  
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5.3 IgH V(D)J rearrangements in Atm-/-nu-/- lymphomas - their clonal 
nature 
5.3.1 Results 
To detect V(D)J rearrangement and ascertain clonal status in the Atm-/-nu-/- lymphomas, 
PCR amplification of IgH V(D)J was undertaken. Three forward primers corresponding to the 
three most commonly used V gene families were used along with a single reverse primer 
downstream of the most proximal J gene, JH-4.  Normal Atm-/-nu-/-, Atm+/+nu-/- and 
Atm+/+nu+/- spleen was used as a positive control. Figure 5.6 shows the PCR reaction 
products of a representative selection of control and tumour DNA samples. Amplification of 
V(D)J from normal spleen produced four major bands, relating to the mixed population of B 
cells with V(D)J rearrangements within the spleen. DNA extracted from mouse ear clipping 
was used as a germline control. No V(D)J rearrangements could be amplified from this DNA 
(Figure 5.6, lane 11).  
16/17 Atm-/-nu-/- tumours, for which DNA was available, were analysed for IgH V(D)J 
rearrangements. Table 5.6 shows that 11/16 tumours had detectable monoclonal V(D)J 
rearrangements determined by the amplification and sequencing of a single product with 
primers that span the V, D, and J genes. Conversely, PCR amplification of this region in 5/16 
Atm-/-nu-/- lymphomas produced products of multiple sizes, similar to that of normal spleen, 
and were provisionally termed ‘polyclonal’ tumours. Tumours with a monoclonal 
rearrangement were sequenced and the V, D and J gene to which there was the highest 
sequence similarity was identified.  The IgBlast alignments are shown in Figure 5.7. Sequence 
analysis of one of the 11 Atm-/-nu-/- tumours (40F1) with a monoclonal rearrangement 
showed that the rearrangement contained a V and J gene, but between these two gene 
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sequences there were 6 nucleotides which could not be assigned to a D gene family.  Also, 
1/16 Atm-/-nu-/- tumour (319M1) had two different detectable V(D)J rearrangements within 
the same tumour.  
In 4/16 tumours (36F2, 69F5, 319M1 and 61M3) with a monoclonal rearrangement, and 
where there was DNA available from multiple tumour sites, the V(D)J rearrangement was the 
same at all tumour sites.  
The V, D, and J families used in V(D)J recombination in the Atm-/-nu-/- tumours were varied. 
4 different V gene families were used in the rearrangements found in the 16 tumours tested; 
V1, V2, V3, and V5, 3 different D gene families were used; D1, D2, and D3. Equally varied, 
J1, J2, J3, and J4 were used in the Atm-/-nu-/- tumour rearrangements. Therefore no single 
gene rearrangement is associated with Atm-/-nu-/- tumour development.  
5.3.2 Discussion 
In summary, 11/16 Atm-/-nu-/-tumours had a single detectable rearrangement by sequencing 
suggesting that each of these lymphomas was clonal. During B cell development, pre-B cells 
undergo V(D)J gene rearrangement in the bone marrow, therefore the tumours with a 
detectable V(D)J rearrangement are likely to originate from a cell which has reached this 
stage of development. The Atm-/-nu-/- mice which had tumours at more than one site and that 
had the same V(D)J rearrangement are likely to have developed from a primary tumour that 
has spread to multiple sites as a result of metastasis.  
For the 5/11 tumours from this analysis, for which a monoclonal rearrangement could not be 
detected, and were therefore termed ‘polyclonal’ there could be one of several explanations; 
(1) they may not have undergone V(D)J rearrangement and their origin was from a B cell that 
had not reached this stage of development, (2) the tumour cell population was contaminated 
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with normal B cells and therefore a monoclonal rearrangement could not be distinguished in 
this mixed population, (3) the B cell had undergone V(D)J recombination but the 
rearrangement was not amplifiable with the primer combinations used here. These five 
tumours are DLBCL, which are peripheral mature B cell origin, and therefore are expected to 
have undergone V(D)J rearrangement. Therefore, it is likely that these tumours are 
monoclonal, but with clonality undetected by this method.  
5.4 Validating the malignant character of Atm-/-nu-/- B cell lymphoma by 
subcutaneous transplant into immunocompromised mice 
5.4.1 Results 
Cells from Atm-/-nu-/- DLBCL case 593, were injected subcutaneously into the right flank of 
3 immunocompromised NOG mice. Normal Atm+/+nu-/- splenic cells were also injected 
subcutaneously in the right flank of a NOG mouse. Subcutaneous tumour growth was 
detected 48 days post injection, at the site of injection, in all 3 mice injected with Atm-/-nu-/- 
DLBCL cells (Figure 5.8a). Ten days post detection, the average tumour volume had tripled, 
almost reaching maximum permissible by the licence, so the experiment was ended (Figure 
5.8c). No tumour growth was detected in the mouse injected with normal spleen cells. At post 
mortem, 2/3 mice injected with Atm-/-nu-/- DLBCL, also had tumour growth in the liver and 
spleen, visible as white patches. A photograph of the spleen from one mouse is shown in 
Figure 5.8b.  The pathologist’s analysis of H&E stained tissue sections from each of the three 
recipient mice showed the subcutaneous tumour to be a large cell lymphoma (the same as the 
injected tumour) and confirmed the presence of lymphoma cells in the spleen and liver in two 
of these animals (Figure 5.8d). In addition, the cells from the subcutaneous tumour could be 
seen to be infiltrating nearby skeletal muscle. IHC staining of these sections showed that the 
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subcutaneous tumour had low expression of B220 and no expression of CD3. The clusters of 
infiltrating lymphoid cells in the liver had expression of both B220 and CD3 (Figure 5.8e). 
PCR amplification and sequencing of IgH V(D)J using DNA extracted from the primary 
tumour, Atm-/-nu-/-  DLBCL 593, and from the tumour growth in the donor mouse showed 
these two samples had the same rearrangement (Figure 5.8f). 
5.4.2 Discussion 
In summary, the ability to propagate the tumour in an immune compromised host confirmed 
the malignant character of Atm-/-nu-/- tumour 593. Metastasis to the host organs suggested 
that the lymphoma was aggressive.  IgH V(D)J rearrangement in the primary tumour and the 
subcutaneous secondary tumour was the same and therefore the subcutaneous tumour was 
derived from the Atm-/-nu-/- tumour cells injected into the mouse.  
5.5 Investigating the mechanism of tumour development using 
multicolour-fluorescence in situ hybridisation (M-FISH) 
5.5.1 Results 
Development of B cell lymphomas is frequently associated with chromosomal translocation. 
In order to establish if chromosomal abnormalities were involved in Atm-/-nu-/- B cell 
lymphoma development, tumours were karyotyped using multicolour florescence in situ 
hybridisation (M-FISH). 
A normal Atm+/+ spleen was analysed and no clonal chromosomal abnormalities were 
detected (Figure 5.9).  
Before examining the B cell lymphomas in the Atm-/-nu-/- mice, thymomas from Atm-/- 
single knockout animals were examined, as these have been shown, previously to have clonal 
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chromosomal rearrangements.  Three Atm-/- T cell lymphomas (F1, F2 and 58M4) were 
karyotyped. Each tumour had multiple chromosomal translocations; the most frequent 
rearrangements involved chromosomes 12, 14 and 15 (Figure 5.10 and summarised in Table 
5.7). Other chromosomes that were involved in clonal rearrangements included 1, 4, X, and Y. 
Two of the three Atm-/- T cell lymphomas (F1 and 58M4) had a clonal translocation that was 
present in all cells; the remaining tumour (F2) had two clones with different chromosome 
abnormalities exclusive to each clone (Table 5.7).  
Like Atm-/- T cell lymphomas, M-FISH analysis of Atm-/-nu-/- B cell lymphomas revealed 
several types of chromosome abnormalities, including chromosomal duplications, balanced 
and unbalanced translocations, whole chromosome loss and also whole chromosome gain. 2/6 
tumours (cases 5F3 and 593) (Table 5.8) each had an abnormality that was present in most 
cells and in both tumours the abnormality involved a derivative chromosome 17, although 
involving a different second chromosome (Figure 5.11 and Figure 5.12). Both tumours had 
additional aberrations that were detected at a lower frequency than the chromosome 17 
translocations and in varied combinations.  The predominance of the chromosome 17 
translocations within the tumour cell population, suggested that the chromosome 17 
translocations may have arisen earlier on in tumour development and may have conferred a 
selective advantage to the tumour, over other abnormalities, which appeared at a lower 
frequency i.e. these additional changes represent a subclone as a consequence of selection. It 
is also worth noting that in tumour 5F3, apparently two different chromosome 18 
translocations, der(18)t(15;12;18) and der(18)t(15;18) were detected in 10/20 and 8/20 cells 
respectively. The part of chromosome 12 involved in the first translocation is relatively small, 
and therefore due to the limitations of M–FISH analysis, it is possible, even likely that all 
18/20 cell could have either der(18)t(15;12;18) or der(18)t(12;18). Therefore, tumour 5F3 
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could also have both a chromosome 17 and also a chromosome 18 abnormality present at a 
high frequency. 
 On the other hand, 3/6 tumours (37F3, 50F2 and 703) had multiple clonal aberrations, with 
none being present in the majority of cells (Figure 5.13, Figure 5.14 and Figure 5.15). These 
tumours may be in an earlier state of maturity, when a single clone, representing cells with a 
clear growth advantage, had not arisen. In each of these tumours, the most common aberration 
involved an unbalanced translocation of chromosome 18. However, the translocation involved 
a different partner chromosome in each tumour (3, 7, 13 and X). Each tumour also had a 
mixture of additional abnormalities and no two cells in these tumours contained the same 
combination of abnormalities. Also, there was no evidence to suggest that the abnormalities 
were acquired as a result of successive clonal selection. Interestingly, one Atm-/-nu-/- 
lymphoma (case 37F3) had chromosome 18 translocations in 35/40 cells analysed, but in 
many of these cells the recipient chromosomes were different. The most common 
translocation, der(18)t(3;18) was present in 10/40 cells and the second most common, 
der(18)t(12;18) was found in 6/40 cells, the remaining clonal chromosome 18 translocations 
were detected in three or fewer cells. 
Finally, 1/6 tumour (case 68F2) had der(12)t(12;15) present in 8/12 cells, the remaining 4/12 
cells were normal. In addition to this der(12)t(12;15), the abnormal cells had either an 
abnormal chromosome 12 or der(19)t(12;19) (Figure 5.16) consistent with the notion that, 
since all the tumour cells had a der(12)t(12;15), this translocation could be associated with 
tumour initiation.  
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5.5.2 Discussion  
Chromosome 17 translocations were present at a high frequency in 2/6 tumours and 
Chromosome 18 abnormalities are present in 4/6 Atm-/-nu-/- tumours. One explanation for 
the recurring involvement of chromosome 18 suggests that the abnormalities confer an 
advantage to the tumour, possibly by an up regulation of an oncogene gene or a down 
regulation of a tumour suppressor. However the presence of a multiple different chromosome 
18 aberrations in one Atm-/-nu-/- tumour suggests that the chromosome 18 translocations are 
due to genetic instability, and this area of the genome may be easily prone to translocation. 
Translocations of one chromosome with multiple recipients in a single tumour are termed 
jumping translocations. These are rare genetic events where part of a donor chromosome is 
fused to two or more different recipient chromosomes within the cell line. Jumping 
translocations are thought to not be causative in the development of the tumour, but a by-
product of the genetic instability.  In human patients they are thought to indicate a poor 
prognosis.  Evidence suggests that they may be caused by the shortening of telomeres in the 
tumour (Mills et al., 2003, Manola et al., 2008). 
5.6 Confirming the absence of IgH and Myc involvement in Atm-/-nu-/- B 
cell lymphoma using targeted FISH 
5.6.1 Results 
Using targeted FISH analysis, normal Atm+/+ spleen cells were shown to have 2 copies of 
Myc. 4/6 Atm-/-nu-/- tumours tested (703, 593, 50F2, 37F3) had a normal copy number of 
Myc, and 2/6 had 3 copies of Myc (5F3 & 68F2). In the tumour cells with 3 copies of Myc, 
the Myc directed probe was found on 3 different chromosomes (Figure 5.17to Figure 5.22). 
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Targeted FISH of the IgH locus in normal Atm+/+ spleen cells showed two intact IgH genes, 
represented by a ‘fusion’ or close localisation of the red IgH constant alpha and green IgH v1 
probe, in all cells. Splitting of the red and green probes would indicate an IgH translocation. 
This was demonstrated using Atm Δ/Δ B cells, which undergo IgH translocation at a rate of 1 
in 4 cells (personal communication, Monica Gostissa). I found an IgH translocation in 2/11 
Atm Δ/Δ B cells (Figure 5.23). 
5/6 of the Atm-/-nu-/-B cell lymphomas (703, 5F3, 593, 50F2, 37F3) did not have a 
translocation involving breakage within IgH. However, 2/5 (5F3, 593) of these had loss of 
IgH v1 or loss of both IgH constant alpha (IgHa) and IgH v1 in one allele. 1/6 tumour (68F2) 
had an IgH translocation shown by splitting of the IgH constant alpha and IgH v1 probes 
along with amplification of IgH constant alpha (Figure 5.24 to Figure 5.29) (Summarised in 
Table 5.8).  
5.6.2 Discussion 
Previous studies have found that Atm-/- T cell lymphomas are associated with abnormalities 
in chromosome 12, 14, and 15.  In mice chromosome 12 contains IgH, chromosome 14, TCR 
alpha and delta, and chromosome 15 carries Myc. T cell lymphoma has been associated with 
aberrant immune gene rearrangement and Myc amplification (Liyanage et al., 2000, Barlow et 
al., 1996). The analysis of Atm-/- T cell lymphoma undertaken here replicated previous 
findings that showed that Atm-/- T cell lymphoma development was associated with 
abnormalities involving the chromosome that contain TCR and Myc genes. Specificity of T 
cells to antigen is established by rearrangement of the T cell receptor and aberrant 
rearrangement can lead to translocations. 
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In B cells antigen specificity is established by the rearrangement of the immunoglobulin 
genes IgH and IgL. IgH has also been shown to be involved in translocations in B cell 
lymphoma (Nussenzweig and Nussenzweig, 2010). 
In addition, IgH, Myc translocations have been found in B cell lymphoma from DNA repair 
protein XRCC4 deficient mice (Wang et al., 2008b). However, in Atm-/-nu-/- lymphoma 
chromosome 12 translocations were only detected here in 2/6 cases using M-FISH. To 
determine if an IgH translocation or Myc amplification had taken place targeted FISH was 
performed, which has a greater sensitivity than M-FISH. Only 1/6 B cell lymphoma was 
found to contain an IgH translocation using FISH probes that span the IgH locus. This 
suggested that IgH translocations were not essential for Atm-/-nu-/- tumour development and 
that there may be more than one mechanism of development associated with Atm-/-nu-/- B 
cell lymphoma. In two tumours either part or all of IgH could not be detected, which may 
indicate instability in this region.  
The targeted FISH results can be related to the M-FISH analysis. The 2/6 cells with 3 copies 
of Myc had additional chromosome 15 material; the consequence of an unbalanced 
translocation involving chromosome 15. As only 2/6 tumours analysed had an increase Myc it 
is unlikely that Myc amplification is essential for Atm-/-nu-/- B cell lymphoma development.  
In Atm-/-nu-/- B cell lymphoma case 5F3, M-FISH detected an aberration involving 
chromosome 18, 12 and 15. However, the IgH gene is not likely to be translocated, as IgH v 
was completely lost from the cell. The chromosome 12 translocation in this tumour could 
have been caused by fusion of the vulnerable distal end of chromosome 12, generated by the 
loss of the region of chromosome 12 containing IgH v, to another double strand break in 
chromosome 18 or 15.  
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Loss of both IgH a and IgH v in Atm-/-nu-/- B cell lymphoma 593 suggested that this tumour 
lost a single copy of IgH. M-FISH analysis of this tumour suggested that this loss of IgH 
could be caused by an unbalanced translocation involving chromosome 12. M-FISH analysis 
of chromosome 12 detected a translocation involving a small part of chromosome 12 in 2/20 
cells. This low frequency translocation suggested that it could be possible that this loss of 1 
copy of IgH is associated with this chromosome 12 translocation.  
In summary, IgH translocation and Myc amplification was only detected in 1 Atm-/-nu-/- B 
cell lymphoma (68F2) so development of the other 5/6 Atm-/-nu-/- lymphoma is likely to be 
associated with another mechanism, possibly involving chromosome 17 and or 18. 
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Figure 5.1 Tumour free survival in Atm-/-nu-/- mice 
 
Survival of Atm-/-nu-/-, Atm-/-nu+/- and Atm-/- mice that developed tumours only; analysis excludes 
mice that died of non-tumour related cause. Age of tumour free survival is longer in Atm-/-nu-/- mice 
compared to Atm-/- and Atm-/-nu+/- mice (Median survival Atm-/- = 13.5 weeks, Atm-/-nu+/- = 13 
weeks and Atm-/-nu-/- =25 weeks). 
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Figure 5.2 Post mortem analysis of 17 Atm-/-nu-/- tumours 
Mouse Age (weeks) Tumour sites Tumour 
519 13 Spleen, liver  
 
703 7 Spleen   
656 27 Spleen, liver, 
abdomen, thorax  
 
5f3 25 Spleen, liver   
593 53 Spleen, liver, 
abdomen, thorax 
 
5F1 31 Spleen, abdomen, 
thorax 
 
37M 3 22 Spleen, liver  
 
 
Atm-/-nu-/- mice were culled when moribund. At post mortem, all organs were examined for signs of 
abnormality. The table details the age of death, location of tumours found and photograph of tumours 
in the 17 Atm-/-nu-/- mice.  
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Figure 5.2 continued post mortem analysis of 17 Atm-/-nu-/- tumours 
Mouse Age (weeks) Tumour sites Tumour 
50F2 14 Spleen, liver, 
abdomen x2 (near 
gut & spine) 
 
40F 1 20 Liver, abdomen, 
   
53M 7 14 Axillary tumour  
 
36F1 41 Spleen, liver       
69F5 23 Spleen, liver 
  
 
Atm-/-nu-/- mice were culled when moribund. At post mortem, all organs were examined for signs of 
abnormality. The table details the age of death, location of tumours found and photograph of tumours 
in the 17 Atm-/-nu-/- mice.  
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Figure 5.2 continued Post mortem analysis of 17 Atm-/-nu-/- tumours 
Mouse Age (weeks) Tumour sites Tumour 
68F2 30 Spleen  
 
319M1 69 Spleen, liver, 
abdomen 
 
61M3 38 Spleen, liver  
  
55F1 47 Spleen 
 
107F2 14 Spleen  
 
 
Atm-/-nu-/- mice were culled when moribund. At post mortem, all organs were examined for signs of 
abnormality. The table details the age of death, location of tumours found and photograph of tumours 
in the 17 Atm-/-nu-/- mice. 
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Table 5.1 Summary of 17 Atm-/-nu-/- tumour locations 
Mouse  
Location 
Spleen Liver Abdomen Thorax Axillary 
703 X	   	   	   	   	  
68F2 X	   	   	   	   	  
55F1 X	   	   	   	   	  
107F2 X	   	   	   	   	  
519 X	   X	   	   	   	  
5F3 X	   X	   	   	   	  
37F3 X	   X	   	   	   	  
36F1 X	   X	   	   	   	  
69F5 X	   X	   	   	   	  
61M3 X	   X	   	   	   	  
319M1 X	   X	   X	   	   	  
50F2 X	   X	   X	   	   	  
656 X	   X	   X	   X	   	  
593 X	   X	   X	   X	   	  
5F1 X	   	   X	   X	   	  
40F 1 	   X	   X	   	   	  
53M 7 	   	   	   	   X	  
 
Tumours were most commonly found in the spleen. 
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Table 5.2 Detailed cellular morphological examination of 17 Atm-/-nu-/- tumours   
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Table 5.3 Summary of Atm-/-nu-/- tumour classification 
Mouse Classification  
High Grade: 
703 DLBCL, NOS 
5F3 DLBCL, NOS 
593 DLBCL, NOS 
37M 3 DLBCL, NOS 
40F 1 DLBCL, NOS 
53M 7 DLBCL, NOS 
36F1 DLBCL, NOS 
69F5 DLBCL, NOS 
61M3 DLBCL, NOS 
55F1 DLBCL, NOS 
107F2 DLBCL, NOS 
5F1 Follicle centre cell lymphoma, predominantly diffuse, Grade 3A 
50F2 Follicle centre cell lymphoma, predominantly diffuse, Grade 3A 
319M1 Follicle centre cell lymphoma, predominantly diffuse, Grade 3A 
519 B cell lymphoma, unclassifiable, with features intermediate between DLBCL 
and Burkitt lymphoma  
656 ALCL 
Low Grade: 
68F2 Small cell lymphoma 
 
Summary of Table 5.2. Atm-/-nu-/- tumours were assigned a preliminary lymphoma classification 
based on the criteria assessed by the histopathologist during morphological examination of H&E 
stained sections. 
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Figure 5.3 Histological analysis of Atm-/-nu-/- tumours 
Mouse H&E B220 CD3 CD11b 
Atm+/+ 
nu+/- 
    
Atm+/+ 
nu-/- 
   
ND 
519 
    
703 
    
656 
    
5f3 
(Liver) 
    
593 
    
 
Sections of 17 Atm-/-nu-/-lymphoma, along with normal Atm+/+nu-/- and Atm+/+nu+/- spleen, were 
H&E stained and immunohistochemically stained for B220, CD3 and CD11b. The antigen stained 
brown and images of stained sections were taken at x40 magnification 
ND = not done  
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Figure 5.3 continued Histological analysis of Atm-/-nu-/- tumours 
Mouse H&E B220 CD3 CD11b 
5F1 
    
37M 3 
    
50F2 
    
40F 1 
   
ND 
53M7 
    
36F1 
    
 
Sections of 17 Atm-/-nu-/-lymphoma, along with normal Atm+/+nu-/- and Atm+/+nu+/- spleen, were 
H&E stained and immunohistochemically stained for B220, CD3 and CD11b. The antigen stained 
brown and images of stained sections were taken at x40 magnification. 
ND= not done  
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Figure 5.3 continued Histological analysis of Atm-/-nu-/- tumours 
Mouse H&E B220 CD3 CD11b 
69F5 
    
68F2 
   
ND 
319M1 
   
ND 
61M3 
   
ND 
55F1 
   
ND 
107F2 
   
ND 
 
Sections of 17 Atm-/-nu-/-lymphoma, along with normal Atm+/+nu-/- and Atm+/+nu+/- spleen, were 
H&E stained and immunohistochemically stained for B220, CD3 and CD11b. The antigen stained 
brown and images of stained sections were taken at x40 magnification. 
ND= not done 
 Figure 5.4 Additional immunophenotyping of Atm-/-nu-/- lymphoma 519 and normal 
spleen from Atm-/-nu-/-, Atm+/+nu-/- and Atm+/+nu+/-  mice  
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Figure 5.5 FACS 
profiling of 
Atm-/-nu-
/- 
lymphoma 
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Table 5.4 Summary of morphological and immunophenotypic analysis of Atm+/+ nu-/- 
lymphoma 
Table 5.5 Atm-/nu-/- lymphoma developmental origin 
Mouse Histology Developmental Type 
703 DLBCL, NOS Mature B Cell: GC/ Non- GC 
5F3 DLBCL, NOS Mature B Cell: GC/ post GC 
593 DLBCL, NOS Mature B Cell: GC/ post GC 
61M3 DLBCL, NOS Mature B Cell: GC/ post GC 
36F1 DLBCL, NOS Mature B Cell: GC/ post GC 
69F5 DLBCL, NOS Mature B Cell: GC/ post GC 
37M 3 DLBCL, NOS Mature B Cell: GC/ post GC 
55F1 DLBCL, NOS Mature B Cell: GC/ post GC 
40F 1 DLBCL, NOS Mature B Cell: GC/ post GC 
107F2 DLBCL, NOS Mature B Cell: GC/ post GC 
53M 7 DLBCL, NOS Mature B Cell: GC/ post GC 
50F2 FL* Mature B Cell: GC 
5F1 FL* Mature B Cell: GC 
319M1  FL* Mature B Cell: GC 
519 B cell lymphoma, unclassifiable+ Mature B Cell: GC 
656 ALCL B/T cell** 
68F2 Small cell lymphoma Peripheral B cell: Marginal Zone or Mantle cell 
 
Atm-/-nu-/- lymphomas were assigned to a developmental group based on human morphology and 
immunophenotype. The postulated normal counterpart cell types are as follows:  
DLBCL, NOS = mature B cell, germinal centre (GC) or post-GC B cell 
Follicular lymphoma = mature B cell, GC;  
Small cell lymphoma = Mantle cell or Marginal zone cell origin.  
** Further Immunophenotyping is needed to confirm the origin of this tumour. 
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Figure 5.6 PCR analysis of IgH V(D)J rearrangements in Atm-/-nu-/- lymphomas 
 
 
Agrose gel with representative tumours 703, 656, 593, 5F1 and 37M3 showing a single gene product 
from PCR amplification of IgH V(D)J, which indicates monoclonality. Forward primers J558, VHQ52 
and VH7183 were used with reverse primer JH4.  DNA from normal spleen of Atm-/-nu-/- and 
Atm+/+nu-/- and Atm+/+nu+/- spleen cells were used as positive control. Multiple bands present in 
these lanes correspond to the presence of multiple B cells in spleen each having a different 
rearrangement. DNA extracted from ear clippings was used as a negative control; no band was present 
in genomic ear DNA.  
Lane:	  	  	  	  	  1	  	  	  2	  	  	  3	  	  	  4	  	  	  5	  	  	  6	  	  	  7	  	  	  8	  	  	  9	  	  10	  11	  12	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Table 5.6 Sequence analysis of IgH V(D)J rearrangement of Atm-/-nu-/- lymphoma 
Mouse Tissue V(D)J rearrangement Sequencing 
  J558 VHQ52 VH7183 V Gene 
D 
Gene 
J 
Gene 
519 - ND ND ND ND ND ND 
703 Tumour Monoclonal Monoclonal  V1 D2 J3 
656 Spleen Monoclonal Monoclonal  V1 D2 J4 
5F3 Tumour Monoclonal   V1 D1 J2 
593 Spleen Monoclonal   V1 D3 J4 
5F1 Spleen  Monoclonal Monoclonal V5 D2 J2 
37M 3 Spleen Monoclonal  Monoclonal V5 D2 J2 
50F2 Spleen Monoclonal Monoclonal  V1 D1 J4 
40F1 Liver  Monoclonal  V3 None J1 
53M 7 Tumour Polyclonal Polyclonal Polyclonal - - - 
36F1 Spleen & Liver Polyclonal Polyclonal Polyclonal - - - 
69F5 Spleen & Liver Polyclonal Monoclonal Polyclonal V2 D2 J3 
68F2 Spleen Polyclonal Polyclonal Polyclonal - - - 
319M1 Spleen, Liver, Monoclonal Polyclonal Monoclonal V1, 
V2 
D1, 
D1 
J4, 
J2 
61M3 Spleen, Liver  Monoclonal  V5 D2 J3 
55F1 Spleen Polyclonal Polyclonal Polyclonal - - - 
107F2 Spleen Polyclonal Polyclonal Polyclonal - - - 
 
Summary of PCR amplification and sequencing of IgH V(D)J for 16 Atm-/-nu-/- lymphomas with 
DNA available. Tumours with a monoclonal rearrangement were sequenced. The NCBI IgBlast tool 
was used to align each sequence to the closest matching V, D and J gene family. Tumour 319M1 had 
two different rearrangements.  
For mice with tumours at multiple locations and that there was DNA was available, all tumours were 
tested and found to have the same IgH V(D)J rearrangement.  
ND=Not done. 
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Figure 5.7 IgH V(D)J sequence analysis 
Mouse: 703 
 
Mouse: 656 
 
Mouse: 5F3 
 
Mouse: 593 
 
Mouse: 69F5 
 
Mouse: 50F2 
 
DNA from 11 Atm-/-nu-/- lymphoma with monoclonal V(D)J PCR products were sequenced and the 
sequence was aligned to most similar V,D,J genes using IgBlast tool from NCBI.  
                                               <------------------------------FR1-IMGT------------------------------><-------CDR1-IMGT--- 1	  
                            703 reversed  17   CCAGCTGAAGCAGTCAGGACCTGAGCTGGTGAAACCTGGGGCCTCAGTGAAGATATCCTGCAAGGCTTCTGGATACACATTCACTGACTA  106 2	  
V  96.9% (281/290)  IGHV1S29*02           6    CCAGCTTCAGCAGTCAGGACCTGAGCTGGTGAAACCTGGGGCCTCAGTGAAGATATCCTGCAAGGCTTCTGGATACACATTCACTGACTA  95 3	  
 4	  
                                               ---><---------------------FR2-IMGT---------------------><-------CDR2-IMGT------><--------- 5	  
                            703 reversed  107  CAACATGCACTGGGTGAAGCAGAGCCATGGAAAGAGCCTCGACCCCCATTGGATATATTTATCCTTACAATGGTGGTACTGGCTACAACC  196 6	  
V  96.9% (281/290)  IGHV1S29*02           96   CAACATGCACTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGG-ATTGGATATATTTATCCTTACAATGGTGGTACTGGCTACAACC  184 7	  
 8	  
                                               -------------------------------------------FR3-IMGT--------------------------------------- 9	  
                            703 reversed  197  AGAAGTTCAAGAGCAAGGCCACATTGACTGTAGACAATTCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTG  286 10	  
V  96.9% (281/290)  IGHV1S29*02           185  AGAAGTTCAAGAGCAAGGCCACATTGACTGTAGACAATTCCTCCAGCACAGCCTACATGGAGCTCAGCAGCCTGACATCTGAGGACTCTG  274 11	  
 12	  
                                               ------------->                                                                    13	  
                            703 reversed  287  CAGTCTATTACTGTGCAAGAAGGGGGGATGGTTACGGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG  367 14	  
V  96.9% (281/290)  IGHV1S29*02           275  CAGTCTATTACTGTGCAAGA-------------------------------------------------------------  294 15	  
D  100.0% (9/9)     IGHD2-9*01            7    ---------------------------ATGGTTACG---------------------------------------------  15 16	  
J  100.0% (45/45)   IGHJ3*01              4    ------------------------------------GGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG  48 17	  
                                              <------------FR3-IMGT------------>                                                         1"
                           656 reversed  6    CCCGACATCTGAGGACTCTGCAGTCTATTATTGTGGAAAGGGCTATGGTAACTACGCTATGGACTACTGGGGTCAAGGAACCTCAGTCAC  95 2"
V  94.7% (36/38)   IGHV1-20*01           255  CCTGACATCTGAGGACTCTGCAGTCTATTATTGTGCAA----------------------------------------------------  292 3"
D  100.0% (13/13)  IGHD2-1*01            5    ------------------------------------------CTATGGTAACTAC-----------------------------------  17 4"
J  98.0% (50/51)   IGHJ4*01              4    --------------------------------------------------ACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCAC  43 5"
 6"
                                                          7"
                               reversed  96   CGTCTCCTCAG  106 8"
J  98.0% (50/51)   IGHJ4*01              44   CGTCTCCTCAG  54 9"
                                              <------------FR3-IMGT------------->                                                        1	  
                           5F3 reversed  4    GCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGAAGGGAAATTACTACGGTAGTATCTGACTACTGGGGCCAAGGCACCACTC  93 2	  
V  100.0% (41/41)  IGHV1S126*01          254  GCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGA-------------------------------------------------  294 3	  
D  100.0% (15/15)  IGHD1-1*01            4    -----------------------------------------------ATTACTACGGTAGTA----------------------------  18 4	  
J  100.0% (41/41)  IGHJ2*01              8    ----------------------------------------------------------------TGACTACTGGGGCCAAGGCACCACTC  33 5	  
 6	  
                                                              7	  
                           5F3 reversed  94   TCACAGTCTCCTCAG  108 8	  
J  100.0% (41/41)  IGHJ2*01              34   TCACAGTCTCCTCAG  48 9	  
                                              <-----------FR3-IMGT----------->                                                           
                           593 reversed  7    TGACATCTGAGGACTCTGCGGTCTATTTCTGTGCAAGACACGAAGAGACGAGGGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCG  96 
V  97.8% (45/46)   IGHV1-62-2*01         257  TGACATCTGAAGACTCTGCGGTCTATTTCTGTGCAAGACACGAAGA--------------------------------------------  302 
D  100.0% (6/6)    IGHD3-3*01            10   --------------------------------------------------AGGGCT----------------------------------  15 
J  100.0% (46/46)  IGHJ4*01              9    -----------------------------------------------------GCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCG  45 
 
                                                        
                           593 reversed  97   TCTCCTCAG  105 
J  100.0% (46/46)  IGHJ4*01              46   TCTCCTCAG  54 
                                       <---------FR1-IMGT---------><-------CDR1-IMGT------><--------------------FR2-IMGT--------- 
                        69F5      37   GAGCCTGTCCATAACCTGCACAGTCTCTGGTTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCCAGTCTCCAGGAAAGGGTCTGGA  126 
V  100.0% (246/246)  IGHV2-5*01   48   GAGCCTGTCCATAACCTGCACAGTCTCTGGTTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCCAGTCTCCAGGAAAGGGTCTGGA  137 
 
                                       ------------><-----CDR2-IMGT-----><----------------------------------------------------FR3 
                        69F5      127  GTGGCTGGGAGTGATATGGAGAGGTGGAAGCACAGACTACAATGCAGCTTTCATGTCCAGACTGAGCATCACCAAGGACAACTCCAAGAG  216 
V  100.0% (246/246)  IGHV2-5*01   138  GTGGCTGGGAGTGATATGGAGAGGTGGAAGCACAGACTACAATGCAGCTTTCATGTCCAGACTGAGCATCACCAAGGACAACTCCAAGAG  227 
 
                                       -IMGT---------------------------------------------------->                                 
                        69F5      217  CCAAGTTTTCTTTAAAATGAACAGTCTGCAAGCTGATGACACTGCCATATACTACTGTGCCAAAAAAAACTATAGGTACGCCTGGTTTGC  306 
V  100.0% (246/246)  IGHV2-5*01   228  CCAAGTTTTCTTTAAAATGAACAGTCTGCAAGCTGATGACACTGCCATATACTACTGTGCCAAAAA------------------------  293 
D  100.0% (12/12)    IGHD2-14*01  4    --------------------------------------------------------------------ACTATAGGTACG----------  15 
J  100.0% (48/48)    IGHJ3*01     1    --------------------------------------------------------------------------------CCTGGTTTGC  10 
 
                                                                              
                        69F5      307  TTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG  344 
J  100.0% (48/48)    IGHJ3*01     11   TTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG  48 
                                              <--------FR3-IMGT-------->                                                                 1	  
                          50F2 reversed  19   CTGAGGACTCTGCGGTCTATTACTGTACAAAGCTATTACTACGGTAGTAGCTACTGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTC  108 2	  
V  100.0% (30/30)  IGHV1S36*01           263  CTGAGGACTCTGCGGTCTATTACTGTACAA------------------------------------------------------------  292 3	  
D  100.0% (21/21)  IGHD1-1*01            3    ---------------------------------TATTACTACGGTAGTAGCTAC------------------------------------  23 4	  
J  100.0% (53/53)  IGHJ1*01              1    --------------------------------------------------CTACTGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTC  40 5	  
 6	  
                                                            7	  
                          50F2 reversed  109  ACCGTCTCCTCAG  121 8	  
J  100.0% (53/53)  IGHJ1*01              41   ACCGTCTCCTCAG  53 9	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Figure 5.7 continued IgH V(D)J sequence analysis 
Mouse: 319M1 (1) 
 
  (2) 
 
Mouse: 61M3 
 
Mouse: 5F1 
 
Mouse: 37F3 
 
Mouse: 40F1 
 
 
DNA from 11 Atm-/-nu-/- lymphoma with monoclonal V(D)J PCR products were sequenced and the 
sequence was aligned to most similar V,D,J genes using IgBlast tool from NCBI.  
                                     <----------FR1-IMGT-----------><-------CDR1-IMGT------><--------------------FR2-IMGT------ 
                        319M1   30   ACCGAGCCTGTCCATAACCTGCACAGTCTCTGGTTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCCAGTCTCCAGGAAAGGGTCT  119 
V  99.6% (245/246)  IGHV2-5*01  45   ACAGAGCCTGTCCATAACCTGCACAGTCTCTGGTTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCCAGTCTCCAGGAAAGGGTCT  134 
 
                                     ---------------><-----CDR2-IMGT-----><---------------------------------------------------- 
                        319M1   120  GGAGTGGCTGGGAGTGATATGGAGAGGTGGAAGCACAGACTACAATGCAGCTTTCATGTCCAGACTGAGCATCACCAAGGACAACTCCAA  209 
V  99.6% (245/246)  IGHV2-5*01  135  GGAGTGGCTGGGAGTGATATGGAGAGGTGGAAGCACAGACTACAATGCAGCTTTCATGTCCAGACTGAGCATCACCAAGGACAACTCCAA  224 
 
                                     FR3-IMGT---------------------------------------------------->                              
                          319   210  GAGCCAAGTTTTCTTTAAAATGAACAGTCTGCAAGCTGATGACACTGCCATATACTACTGTGCCAATTACTACGGTAGTAGTACTACTTT  299 
V  99.6% (245/246)  IGHV2-5*01  225  GAGCCAAGTTTTCTTTAAAATGAACAGTCTGCAAGCTGATGACACTGCCATATACTACTGTGCCAA------------------------  290 
D  100.0% (16/16)   IGHD1-1*01  4    -----------------------------------------------------------------ATTACTACGGTAGTAG---------  19 
J  100.0% (48/48)   IGHJ2*01    1    ----------------------------------------------------------------------------------ACTACTTT  8 
 
                                                                              
                          319   300  GACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAG  339 
J  100.0% (48/48)   IGHJ2*01    9    GACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAG  48 
 
                                              <------------FR3-IMGT------------->                                                        
                         319M1 reversed  3    GCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGTTACTACGGTAGTAGCTATGCTATGGACTACTGGGGTCAAGGAACCTCAG  92 
V  100.0% (40/40)  IGHV1-39*01           254  GCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAG--------------------------------------------------  293 
D  100.0% (18/18)  IGHD1-1*01            5    ----------------------------------------TTACTACGGTAGTAGCTA--------------------------------  22 
J  100.0% (50/50)  IGHJ4*01              5    -------------------------------------------------------CTATGCTATGGACTACTGGGGTCAAGGAACCTCAG  39 
 
                                                              
                         319M1 reversed  93   TCACCGTCTCCTCAG  107 
J  100.0% (50/50)  IGHJ4*01              40   TCACCGTCTCCTCAG  54 
                                              <-------------------------FR3-IMGT-------------------------->                              
                          61M3 reversed  2    GAACAACCTGTTCCTGCAAATGAGCAGTCTGAAGTCTGAGGACACGGCCATGTATTACTGTGCAAGACGGGCATATGGTAAAGGGAGCCT  91 
V  97.1% (66/68)   IGHV5-12-2*02         195  GAACACCCTGTACCTGCAAATGAGCAGTCTGAAGTCTGAGGACACGGCCATGTATTACTGTGCAAGAC----------------------  262 
D  100.0% (8/8)    IGHD2-1*01            6    -------------------------------------------------------------------------TATGGTAA---------  13 
 
                                                                                                 
                          61M3 reversed  92   GGCCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG  141 
J  100.0% (48/48)  IGHJ3*01              1    --CCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG  48 
 1	  
                                              <-------------------FR3-IMGT-------------------->                                          2	  
                           5F1 reversed  21   CCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGCAAGACATAAGGACTGGTACTACTTTGACTACTGGGGCCA  110 3	  
V  100.0% (57/57)  IGHV5-9-3*01          240  CCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGCAAGACA---------------------------------  296 4	  
D  100.0% (5/5)    IGHD2-1*01            8    ----------------------------------------------------------------TGGTA---------------------  12 5	  
J  100.0% (48/48)  IGHJ2*01              1    --------------------------------------------------------------------ACTACTTTGACTACTGGGGCCA  22 6	  
 7	  
                                                                         8	  
                           5F1 reversed  111  AGGCACCACTCTCACAGTCTCCTCAG  136 9	  
J  100.0% (48/48)  IGHJ2*01              23   AGGCACCACTCTCACAGTCTCCTCAG  48 10	  
                                              <-------------------------FR3-IMGT-------------------------->                              
                          37M3 reversed  2    GAACACCCTGTTCCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGCAAGACATAAGGACTGGTACTACTTTGA  91 
V  98.6% (68/69)   IGHV5-9-3*01          228  GAACACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGCAAGACA---------------------  296 
D  100.0% (5/5)    IGHD2-1*01            8    ----------------------------------------------------------------------------TGGTA---------  12 
J  100.0% (48/48)  IGHJ2*01              1    --------------------------------------------------------------------------------ACTACTTTGA  10 
 
                                                                                     
                          37M3 reversed  92   CTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAG  129 
J  100.0% (48/48)  IGHJ2*01              11   CTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAG  48 
Alignments 1	  
 2	  
 3	  
                                               <-------------------FR1-IMGT-------------------><--------CDR1-IMGT-------><--------------- 4	  
                           40F1 reversed  44   CCTCGTGAAACCTTCTCAARACTCTGTCCCTCACYTGTTCTGKTCACTGGCGACTCCCATCACCCAGTGGTTACKGRAACTGGATCCSGG  133 5	  
V  93.7% (251/268)  IGHV3-8*02            30   CCTCGTGAAACCTTCTCA-GACTCTGTCCCTCACCTGTTCTG-TCACTGGCGACTCC-ATCACC-AGTGGTTACTGGAACTGGATCC-GG  114 6	  
 7	  
                                               ------FR2-IMGT---------------------><-----CDR2-IMGT-----><-------------------------------- 8	  
                           40F1 reversed  134  AAATTCCCAGGGAAWAAACTTGAATACATGGGGTACATAAACTACAGTKGTAGCACTTACTACAATCCATCTYYCAAAARTMGAATCTCC  223 9	  
V  93.7% (251/268)  IGHV3-8*02            115  AAATTCCCAGGGAATAAACTTGAGTACATGGGGTACATAAGCTACAGTGGTAGCACTTACTACAATCCATCTCTCAAAAGTCGAATCTCC  204 10	  
 11	  
                                               --------------------FR3-IMGT---------------------------------------------------->          12	  
                           40F1 reversed  224  ATCACTCGAGACACATCCAAGAACCAGTACTACCTGCAGTTGAATTCTGTGACTACTGAGGACACAGCCACATATTACTGTGCAAGATGG  313 13	  
V  93.7% (251/268)  IGHV3-8*02            205  ATCACTCGAGACACATCCAAGAACCAGTACTACCTGCAGTTGAATTCTGTGACTACTGAGGACACAGCCACATATTACTGTGCAAGAT--  292 14	  
 15	  
                                                                                                       16	  
                           40F1 reversed  314  GGGAACTGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCAG  368 17	  
J  100.0% (51/51)   IGHJ1*01              3    ----ACTGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCAG  53 18	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Figure 5.8 Subcutaneous transplant into immunocompromised mice.  
a.     b. 
        
c. 
            
d.  
   
a. photograph of subcutaneous tumour  
b. tumour infiltration of recipient spleen  
c. subcutaneous tumour growth 
d. H&E analysis showing tumour infiltrate into skeletal muscle (top left), metastasis to the liver (top 
right), and spleen (bottom left) 
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Figure 5.8 continued Subcutaneous transplant into immunocompromised mice 
e. 
 B220 (x10) B220 (x40) CD3 (x10) CD3(X40) 
Sub-
cutaneous 
tumour  
    
Tumour cells 
in recipient  
liver  
    
 
f. 
 
e. Immunohistochemical analysis of subcutaneous tumour and recipient liver  
f. Amplification of the same IgH V(D)J from primary tumour and secondary transplant (confirmed by 
sequencing) 
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Table 5.7 Clonal abnormalities detected by M-FISH analysis of Atm-/- T cell lymphomas 
Mouse   Description  Number of cells 
Atm-/- F1 der(14)t(1;14) 15/15  
 +15 14/15   
 der(12)t(12;14) 14/15 
 
F1 Clone is der(14)t(1;14), der(12)t(12;14), +15   
   
Atm-/- F2 dup(1) 11/22  
 t(2;14) 11/22  
 der(12) t(12,15) 11/22  
 
F2 Clone 1 is der(12)t(12;15), t(2;14), dup1.   
 der(14)t(14;15) 10/22  
 der(12)t(12;14) 11/22  
 dup (4) 9/22  
 dup (X) 6/22  
 
F2 Clone 2 is der(12)t(12;14), der(14)t(14;15), dup(4) dup(X)  
   
Atm-/- 58M4 der(12)t(12;15) 18/18 
 der(12)t(Y;12) 16/18 
 t(2;14) 16/18 
 -15 8/18 
 t(1;14) 8/18 
 
58M4 clone is der(12)t(12;15),der(12)t(Y;12).t(2;14), -15, t(1;14) 
 
Table describes abnormalities detected in each tumour. An abnormality was considered clonal if it was 
present in 3 or more cells. The number of cells each abnormality is shown out of the total number of 
cells analysed. Aberrations involving chromosome 12, 14 and 15 were the most frequent. Atm-/- 
tumour F2 contains two clones with mutually exclusive translocations. 
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Figure 5.9 Representative 
karyograms showing no 
clonal aberrations 
detected by M-FISH 
analysis of normal 
Atm+/+ spleen 
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Figure 5.10 Representative 
karyograms showing no clonal 
aberrations detected by 
M-FISH analysis of 
normal Atm+/+ spleen 
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Table 5.8 Clonal abnormalities detected by M-FISH analysis of Atm-/-nu-/- B cell 
lymphomas 
 M-FISH Targeted FISH 
Mouse Description  Number of 
Cells 
Copies of Myc IgH 
translocation 
5F3 39~40, XX  3 No (Loss of IgH 
v1 in 1 allele) 
 der(17)t(11;17) 19/20   
 -11 17/20   
 add (6) 15/20   
 der(18)t(15;12;18)* 10/20   
 der(18)t(15;18)* 8/20   
 dup(14) 5/20   
 der(6)t(1;6) 5/20   
 -16 4/20   
 der(1)t(1;16) 3/20   
5F3 clone is 39~40, XX, der(17)t(11;17),-11, -16, add (6), 
dup(14), der(18)t(15;12;18), der(18)t(15;18), der(6)t(1;6), 
der(1)t(1;16) 
  
593 39~40, XY  2 No (Loss of 
IgH) 
 der(17)t(15;17) 19/20   
 der(13)t(3;13) 7/20   
  -Y 6/20   
 dup(4) 6/20   
 add(4)  4/20   
 der(5)t(5;4) 4/20   
 -1 3/20   
 -11 3/20   
593 clone is 39~40, XY, der(17)t(15;17), -Y, -1, -11, dup(4), 
add(4), der(13)t(3;13), der(5)t(5;4) 
  
 
* It is possible that these two abnormalities are the same but due to the technical limitations of the M-
FISH analysis, have been noted separately. 
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Table 5.8 continued Clonal abnormalities detected by M-FISH analysis of Atm-/-nu-/- B 
cell  
 M-FISH Targeted FISH 
Mouse Description  Number of Cells Copies of Myc IgH 
translocation 
37F3 30~41, XY  2 No 
 der(18)t(3;18) 10/40   
 der(18)t(12;18) 6/40   
 -12 5/40   
 t(1,2) 5/40   
 dup(18) 4/40   
 der(18)t(8,18) 4/40   
 der(18)t(5;18) 3/40   
 der(18)t(7;18) 3/40   
 add(1) 3/40   
 add(3) 3/40   
 add(5) 3/40   
 add(11) 3/40   
 
37F3 clone is 30~41, XY, der(18)t(3;18), der(18)t(12;18), 
der(18)t(8;18), der(18)t(5;18), der(18)t(7;18) -12, dup(18), 
add(1), add(3), add(5), add(11), t(1;2) 
  
50F2 37~41, XX  2 No 
 dup(18)der(18)t(7;18) 12/20   
 -19 5/20   
 -5 4/20   
 -7 4/20   
 -8 4/20   
 -9 4/20   
 -2 3/20   
 -12 3/20   
 -16 3/20   
 
50F2 clone is 30~41, XX, dup(18)der(18)t(7;18), -19, -5, -7, -
8, -9, -2, -12, -16 
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Table 5.8 continued Clonal abnormalities detected by M-FISH analysis of Atm-/-nu-/- B 
cell  
 M-FISH Targeted FISH 
Mouse Description  Number of Cells Copies of 
Myc 
IgH 
translocation 
703 36~41, XX  2 No 
 40XX (Normal) 4/36   
 der(X)t(X;13) 11/36   
 der(13)t(13;18) 9/36   
 der(18)t(18;X) 8/36   
  -X 8/36   
 -5 5/36   
 -17 5/36   
 -4 4/36   
 -16 4/36   
 -18 4/36   
 +6 4/36   
 add (6) 4/36   
 der(X)t(X;6) 3/36   
 -3 3/36   
 -13 3/36   
 -15 3/36   
 -19 3/36   
 
703 clone is d36~41, XX, der(X)t(X;13), der(13)t(13;18), 
der(18)t(18;X), +6, -X, -4, -3, -5, -13, -15, -16, -17, -18, -19, 
add(6), der(X)t(X;6) 
  
68F2 40~41, XX  3 Yes 
 40, XX (Normal) 4/12   
 der(12)t(12;15) 8/12   
 -19 5/12   
 +3 5/12   
 +12 (Abnormal) 5/12   
 der(19)t(12;19) 3/12   
 
68F2 clone is 40~41, XX, der(12)t(12;15), -19, +3, +12, 
der(19)t(12;19) 
  
  
 193 
Figure 5.11 Representative karyograms depicting clonal 
aberrations detected by 
M-FISH analysis of Atm-
/-nu-/- lymphoma 5F3 
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Figure 5.12  
Representative 
karyograms depicting 
clonal aberrations 
detected by M-FISH 
analysis of Atm-/-nu-/- 
lymphoma 593 
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Figure 5.13 
Representative 
karyograms depicting 
clonal aberrations 
detected by M-FISH 
analysis of Atm-/-nu-/- 
lymphoma 37F3 
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Figure 5.14 Representative karyograms depicting clonal 
aberrations detected by 
M-FISH analysis of Atm-
/-nu-/- lymphoma 50F2 
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Figure 5.15 Representative karyograms depicting clonal 
aberrations detected by 
M-FISH analysis of Atm-
/-nu-/- lymphoma 703 
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Figure 5.16 
Representative 
karyograms depicting 
clonal aberrations 
detected by M-FISH 
analysis of Atm-/-nu-/- 
lymphoma 68F2 
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Figure 5.17 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma Myc 
targeted FISH 
analysis: 703 
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Figure 5.18 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma Myc 
targeted FISH 
analysis: 5F3 
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Figure 5.19 . 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma Myc 
targeted FISH 
analysis: 593 
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Figure 5.20 . 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma Myc 
targeted FISH analysis: 
37F3 
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Figure 5.21 .Representative cells for 
Atm-/-nu-/- B cell 
lymphoma Myc targeted 
FISH analysis: 68F2 
  
Fi
gu
re
 5
.2
1 
R
ep
re
se
nt
at
iv
e 
ce
lls
 fo
r 
A
tm
-/-
nu
-/-
 B
 c
el
l l
ym
ph
om
a 
c-
M
yc
 ta
rg
et
ed
 F
IS
H
 a
na
ly
si
s 
 
A
tm
-/-
nu
-/-
 B
 c
el
l l
ym
ph
om
a 
68
F2
  
R
es
ul
t: 
3R
 2
G
 
 
 
 
R
ed
: ‘
C
-M
Y
C
’ p
ro
be
 h
yb
rid
is
es
 w
ith
in
 th
e 
c-
M
yc
 g
en
e.
 G
re
en
: I
gH
 v
1 
hy
br
id
is
es
 5
’ o
f t
he
 v
ar
ia
bl
e 
re
gi
on
 o
f I
gH
 (D
is
ta
l).
 
R
= 
R
ed
 p
ro
be
 
G
= 
G
re
en
 p
ro
be
 
 204 
Figure 5.22 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma Myc 
targeted FISH 
analysis: 50F2 
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Figure 5.23 
Representative 
cells for Atm Δ/Δ 
control B cells 
IgH targeted 
FISH analysis 
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Figure 5.24 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma IgH 
targeted FISH 
analysis: 703 
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Figure 5.25 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma IgH 
targeted FISH 
analysis: 5F3 
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Figure 5.26 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma IgH 
targeted FISH 
analysis: 593 
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Figure 5.27 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma IgH 
targeted FISH 
analysis: 50F2 
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Figure 5.28 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma IgH 
targeted FISH 
analysis: 37F3 
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Figure 5.29 
Representative 
cells for Atm-/-
nu-/- B cell 
lymphoma IgH 
targeted FISH 
analysis: 
68F2 
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6 OVERALL DISCUSSION  
The predisposition of ataxia telangiectasia (A-T) patients to developing cancer has long been 
recognised (Morrell et al., 1986). Discovering the ATM gene mutated in the disease in 1995, 
and its product, ATM, a DNA damage repair protein, was the beginning of investigation into 
the association between ATM and cancer. As A-T is a relatively uncommon disease (it affects 
approximately 1 in 330,000 individuals in the UK), it is difficult to perform large scale studies 
of tumour development in these patients (Taylor et al., 1996, Reiman et al., 2011). However, 
shortly after the identification of the human ATM gene in 1995, the mouse Atm gene was 
identified and several mice models were generated in order to investigate the basis of A-T 
further and the relationship of loss of Atm to cancer predisposition (Savitsky et al., 1995, 
Pecker et al., 1996).  
A-T mice that had no Atm protein expression (Barlow et al., 1996, Borghesani et al., 2000, 
Xu et al., 1996, Elson et al., 1996) recapitulated certain phenotypes associated with A-T such 
as immunodeficiency and some aspects of the neurological abnormality, but they did not 
develop the full range of haematological malignancies that have been diagnosed in A-T 
patients. Instead they almost exclusively developed thymoma, albeit at varying age and 
penetrance, depending on the study (See table 1.1)(Barlow et al., 1996, Borghesani et al., 
2000, Xu et al., 1996, Elson et al., 1996).  
The idea, here, of making the Atm-/-nu-/- mouse was to abrogate T cell tumour development 
in order to investigate the development of other tumour types associated with the loss of Atm. 
Indeed, Atm-/-nu-/- mice did not develop thymomas. Instead the Atm-/-nu-/- mice developed 
mostly B cell lymphoma of the spleen. To my knowledge the Atm-/-nu-/- mouse is the only 
mouse model of A-T that completely lacked Atm protein expression in all cells and 
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spontaneously developed B cell lymphoma. Therefore my study gave a unique perspective 
into the development of B cell lymphoma in the absence of Atm protein. 
In addition to the 17 B cell lymphomas I found one T cell lymphoma in the Atm-/-nu-/- mice. 
This is a reversal of the predominance of thymomas in the Atm-/- single knockout animal. It 
is not clear whether analysis of a larger number of Atm-/-nu- tumours would reveal a 
consistent low proportion of T cell tumours, which would be more representative of the 
spectrum of tumour development in patients with A-T. 
Morphological analysis of the B cell lymphoma that developed in the Atm-/-nu-/- mice 
suggested that they were mature B cell lymphoma; mostly diffuse large B cell lymphoma 
(DLBC) and Follicular lymphoma (FL), which both have a germinal centre cell origin 
(Khodabakhshi et al., 2012). Genetic analysis of human DLBCL and FL shows that they both 
have evidence of somatic hypermutation (SHM) in the variable region. In FL especially, 
mutation is on-going and extensive (Swerdlow, 2008). It is unknown if my Atm-/-nu-/- B cell 
lymphoma have SHM. Cases have been described of A-T patients developing DLBCL 
(Machida et al., 2013) but I am not aware of any cases of FL in A-T patients (Taylor et al., 
1996, Machida et al., 2013, Sandoval and Swift, 1998).  
An A-T mouse was generated by Spring and colleagues, that carried the murine equivalent of 
the ataxia telangiectasia mutation 7636del9, in which 44% (19 of 43) developed thymomas 
and in addition, 7 of 43 (16%) mice developed malignancies of non-T cell origin. Of these 7 
mice Spring mice that developed non-T cell tumours, three developed B cell leukaemia after 
10 months of age (Spring et al., 2001). No phenotypic or genetic information was provided 
about the B cell leukaemia that developed apart from that they lacked FasL up-regulation. In 
addition to the B cell leukaemia, ovarian granulosa cell, epithelial carcinoma, ovarian sex 
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cord and stromal cell tumours were also observed in the Spring mice that survived over the 
age of 10 months. The mutation in the Spring mouse, therefore, reduced the frequency of 
thymoma development from 100% - 44% in A-T mice compared to the Barlow mice. In 
addition, the mutation also increased the survival of the mice that did not develop thymoma, 
allowing the development of other tumour types to occur.  
The Spring mice demonstrated that, in the absence of thymoma development, B cell 
leukaemia development could occur in A-T mice. The ataxia telangiectasia 7636del 9 (in 
frame deletion of amino acids SRI) mutation allowed expression of a very low level of ATM 
protein but without measurable activity (see Reiman et al., 2011) and therefore this is a null 
allele with respect to activity; this was also the case for the Spring mice. Another feature 
associated with presence of a null allele is typical increased radiosensitivity of A-T patients. 
This typical increased radiosensitivity is also associated with the 7636del9 allele in ataxia 
telangiectasia, consistent with their being no activity associated with any expressed protein 
from this allele. 
It is not understood why the Spring mice had such a different phenotype compared with Atm 
null mice, but the possibility that some kinase dead Atm protein may have some effect, at 
least in mice, is reminiscent of the work by Yamomoto et al., (2012) and Daniel et al., (2012) 
who demonstrated a different effect of expression of a normal level of kinase dead Atm 
compared with absence of expression of any Atm protein. Another possibility in the Spring 
mice is that the low level of Atm protein expressed from this particular allele does have some 
effective activity but that is undetectable. 
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Approximately, 23% (16 of 71) of my Atm-/-nu-/- mice developed B cell lymphoma. 
Although this is a modest frequency, the Atm-/-nu-/- mouse allows the investigation into the 
development of B cell malignancy in the absence of Atm protein expression.  
 I used the Wynshaw Boris (Barlow) (Barlow et al., 1996) Atm-/- mouse to generate the Atm-
/-nu-/- mouse. The Atm-/- and Atm-/-nu-/- mice were confirmed to be A-T mice as no Atm 
protein could be detected in tissue from either of these genotypes (Figure 3.3) and Atm-/- and 
Atm-/-nu-/- cells were also both unusually radiosensitive (Table 3.4 and 3.5). Despite this, 
introducing the nude (nu-/-) mutation into the Atm-/- mouse could have had the potential to 
alter the A-T phenotype in the Atm-/-nu-/- mice. Nude mice are immunocompromised due to 
abrogated thymic development (Pantelouris, 1968). Haematological comparison of the Atm-/-
nu-/- and Atm-/- relative to wild type mice was undertaken to establish the extent to which 
this mutation affected the A-T phenotype in the Atm-/-nu-/- mice. Relative to wild type mice 
both the Atm-/- and Atm-/-nu-/- were similar. Both the Atm-/- and Atm-/-nu-/- had reduced T 
cell, increased granulocyte and reduced B cell proportions in the bone marrow. However a 
difference was detected. The proportion of transitional B cells (B220 high IgM+) was reduced 
in the spleen of Atm-/-nu-/- mouse compared to wild type, but the transitional (B220high 
IgM+) B cell population in the nude (Atm+/+nu-/-) was normal. Therefore this abnormality 
was unlikely to be a consequence of the nude phenotype. The Atm-/-nu-/- mice had a defect in 
mature B cell development in the spleen and developed mature B cell lymphoma. Therefore, 
the cause of the B cell developmental defect in the Atm-/-nu-/- mice could also be associated 
with subsequent B cell tumourigenesis. 
With regard to the origin of the lymphoid tumours in A-T, cells from A-T patients have been 
found to be sensitive to the effects of ionising radiation, have genetic instability and an 
increase in the number of spontaneous translocations (Meyn, 1999) found in approximately 
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10% of peripheral T cells in A-T patients (Taylor et al., 1996). The translocations usually 
involve chromosome 7 and 14 at the locations of TCR genes. The presence of a translocation 
alone, apparently, could confer a selective growth advantage to the cells. However, for tumour 
growth additional genetic changes were observed associated with development of T cell 
malignancies (T-PLL) (Taylor et al., 1996). I identified translocations involving 
chromosomes that carried immune genes in Atm-/- thymoma cells in the control experiments I 
performed during this study. Liyanage and colleagues detected similar abnormalities; t(12;14) 
and t(12;15) translocations that were each present in 50% of the Atm-/- thymomas. In some 
cases both t(12;14) and t(12;15) were present in the same thymoma (Liyanage et al., 2000). 
Zha and colleagues showed that thymoma from A-T mice had multiple translocations, often 
involving breakage of the immune genes (Zha et al., 2010). Despite being frequently 
associated with the thymoma, it is not known if t(12;15) confers any growth advantage. 
However, it is known that the oncogene Myc is located on chromosome 15, and t(12;15) is 
likely to place the Myc gene under the regulation of the IgH promoter. Chromosome 15 
abnormalities were present in almost all Atm-/- thymomas, whether in the form of t(12;15) or 
another type of chromosome abnormality (Liyanage et al., 2000). The requirement for 
increased Myc expression for tumourigenesis is questionable as abnormalities in chromosome 
15 that result in Myc gene copy number have not been found to correlate with increased levels 
of Myc mRNA (Liyanage et al., 2000). In addition, not all Myc abnormalities involved 
translocations with an immune gene, so it is unlikely that this is the only mechanism that 
enables Atm-/- lymphoma development (Liyanage et al., 2000).  
Recognising the role for Myc deregulation in the development of T cell lymphoma in Atm-/- 
mice and the potential for Atm-/- B cells to develop IgH-Myc complicons in vitro, Tepsuporn 
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and colleagues (2014) generated an A-T mouse to investigate the role of IgH- Myc 
translocation in the development of B cell lymphoma (Tepsuporn et al., 2014). 
Very recently, Tepsuporn and colleagues generated a mouse that could test the involvement of 
aberrant recombination and apoptotic inactivation in the development of B cell lymphoma 
(Tepsuporn et al., 2014). The idea was to introduce mutations into the Atm-/- mouse that 
would promote DSB formation in the oncogene Myc and prevent apoptosis and promote 
survival in response to these abnormal DSBs, by increasing the expression of Bcl2. 
Compound Atm-/- mutant mice were generated that had a Myc gene that contained a RAG1/2 
target sequence, DJβ; other Atm-/- mice were generated with increased Bcl2 expression due 
to the presence of an Eµ-Bcl2 construct. A third Atm-/- mouse was generated with both of 
these constructs. Both the Atm-/- mice with the DJβ sequence and the Atm-/- mice with the 
Eµ-Bcl2 developed B cell lymphomas; tumours occurred in approximately one third of the 
mice and were of peripheral B cell origin. The tumours expressed surface IgM and did not 
show evidence of SHM or CSR. The remaining mice developed thymoma at a similar age as 
Atm-/- mice. All Atm-/- mice that had both the DJβ insertion and Eµ-Bcl2 developed B cell 
lymphoma. B cell lymphoma in these mice had complex translocations involving 
chromosome 12 and 15 and had amplification of Myc. The development of B cell lymphomas 
in mice with both the DJβ insertion and Eµ-Bcl2 supported the idea that aberrant 
recombination of RAG induced breaks in mature B Cells led to lymphoma development as a 
result of increased Myc expression. However, even in the absence of Atm protein aberrant 
recombination alone was not enough to guarantee tumour development, as two thirds of mice 
did not develop B cell lymphoma.  This was caused by apoptosis of the developing B cell 
tumours, since the Atm-/- with both DJβ and Eµ-Bcl2 developed B cell lymphomas. 
Tumourigenesis was likely due to the avoidance of apoptosis and promotion of proliferation 
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by Bcl2 expression from the Eµ-Bcl2 transgene.  This model also reinforced the notion that 
tumour development is a multistep process and also suggested that the loss of Atm, alone, 
may not be sufficient for the development of B cell lymphoma. The suggestion was that Atm 
loss created an environment that enabled accumulation of unrepaired DSB but anti-apoptotic 
signalling was also required for B cell lymphoma development. This study also highlighted 
the observation that the high rate of T cell lymphoma development in Atm-/- mice and the 
absence of B cell lymphoma development may be because it is easier to overcome apoptotic 
signalling in thymic T cell than in mature B cells.  
In keeping with this mechanism of tumour development, translocations involving 
chromosomes (12 or 14) that carry immune system genes were present in half of the Atm-/-
nu-/- B cell lymphomas analysed in my study, but in only one of these tumours did the 
translocation involve the IgH gene. This tumour (68F2) contained der(12)t(12;15) detected by 
M-FISH. In addition, targeted FISH analysis of this lymphoma detected an IgH translocation, 
and 3 copies of the Myc gene (Table 5.8). Morphologically this tumour resembled a small cell 
lymphoma, which are typically of a non-germinal centre origin. The characteristics of this 
lymphoma matched those that were described by Tepsuporn et al, (2014). Tumour 
development in the Tepsuporn mice was accelerated by the genetic manipulation described 
above. Without engineered breaks in an oncogene and the presence of apoptotic resistant cells 
the likelihood of a translocation that leads to tumourigenesis may be lessened and therefore 
tumour development associated with IgH translocations and Myc amplification may be less 
common than the frequency observed in the Tepsuporn mice. In addition, tumourigenesis 
would be likely to take much longer. This is consistent with the tumour development 
observed in the Atm-/-nu-/- mouse 68F2 that was discovered at 6 months of age rather than as 
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early as 7 weeks in the Tepsuporn mice (Atm-/- with both DJβ and Eµ-Bcl2 mice) that 
developed tumours between 7 and 14 weeks of age.   
Most of my Atm-/-nu-/- B cell lymphomas did not have any rearrangement of chromosomes 
containing immune genes. That there was a small proportion of Atm-/-nu-/- tumours with a 
t(12;15) translocation suggests that this was not the only or even the most common 
mechanism of development of B cell lymphoma in Atm-/-nu-/- mice.  Myc deregulation can 
occur via alternative mechanisms in addition to changes to gene copy number (Sewastianik et 
al., 2014). It would be useful to measure the level of Myc mRNA in the Atm-/-nu-/- all B cell 
lymphoma to confirm that Myc protein level is in fact normal.  
Atm-/-nu-/- B cell lymphoma were similar to the Atm-/- DJβ Eµ-Bcl2 B cell lymphomas in 
the Tepsuporn mice in that clonal chromosomal translocations were detected, although 
translocations rarely involved chromosome 12 and 15.  Instead, abnormalities involving 
chromosome 17 and 18 were common in the Atm-/-nu-/- B cell lymphoma. So both the Atm-
/-nu-/- and Tepsuporn mice develop B cell lymphomas associated with clonal chromosomal 
translocation, albeit different chromosomes and presumably different mechanisms.  
Apart from both containing clonal translocations the Atm-/-nu-/- and Atm-/- DJβ Eµ-Bcl2 B 
cell lymphomas are largely different. Atm-/-nu-/- and Atm-/- DJβ Eµ-Bcl2 B cell lymphomas 
differ in their B cell origin. Like Atm-/-nu-/- B cell lymphomas, Atm-/- DJβ Eµ-Bcl2 tumours, 
had expression of IgM, but did not have evidence of somatic hypermutation and therefore 
were suggested to be Pre-GC cell origin. Atm-/-nu-/- B cell lymphoma were likely to be of a 
later differentiation stage. Excluding 68F2, Atm-/-nu-/- B cell lymphomas were mostly 
diffuse large B cell lymphomas (DLBCL) and follicular lymphomas (FL) which are of a 
germinal centre B cell (or post germinal centre in some cases of DLBCL) origin (Swerdlow, 
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2008). The Atm-/-nu-/- B cell lymphomas were not tested for evidence of SHM. If the IgH 
variable gene of the Atm-/-nu-/- lymphomas were mutated this would confirm their germinal 
centre origin (Berek and Milstein, 1987).  
As discussed earlier there are few mouse models that enable investigation into B cell 
lymphoma in the absence of Atm. However, mice lacking the ATM interactor (ATMIN) 
protein specifically in B cells (ATMIN ΔB/ΔB mice), that develop B cell lymphomas (Loizou 
et al., 2011) have been described. ATMIM may possibly play a role in the activation of ATM, 
although the conditions of this activation are not thoroughly understood at this time. ATMIN 
ΔB/ΔB mice are phenotypically similar to Atm-/- and Atm-/-nu-/- mice in that lymphocyte 
development is perturbed in these mice (Loizou et al., 2011, Barlow et al., 1996). The level of 
CSR is also reduced in ATMIN ΔB/ΔB B cells suggesting a role for ATMIN in the repair of 
AID induced DSB. Immunophenotyping of the ATMIN ΔB/ΔB B cell lymphomas suggested 
that they range from the pre B to plasma cell stage of differentiation. Similarly, despite Atm-/-
nu-/- B cell lymphoma being predominantly of germinal centre B cell origin, there is an 
element of phenotypic heterogeneity within the group Atm-/-nu-/- tumours analysed in this 
study. It would be interesting to determine the stage of differentiation of the Atm-/-nu-/- B 
cell lymphoma more definitively by measuring SHM. In addition, as the Atm-/-nu-/- tumours 
have multiple translocations and as AID has been shown to be responsible for the generation 
of DSB and translocations in Atm null B cells it would be interesting to measure AID 
expression levels in the tumours (Callén et al., 2007).  
Both Atm-/- and ATMIN ΔB/ΔB mice have perturbed B cell development, reduced CSR and 
increased genomic instability (Loizou et al., 2011), which suggests that the roles of ATM and 
ATMIN are closely related, and therefore their mechanism of development of B cell 
lymphoma may be similar. M-FISH analysis of the ATMIN ΔB/ΔB B cell lymphoma 
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revealed that they have clonal translocations. These translocations involved both 
chromosomes that contain immune system genes and those without. In addition to this, no 
chromosome 15 abnormalities were detected, in the ATMIN ΔB/ΔB B cell lymphomas. If 
chromosome 15 was normal it is unlikely that Myc gene abnormalities were also present in 
the ATMIN ΔB/ΔB, B cell lymphoma. This differs to the Atm-/- T cell thymoma and 
Tepsuporn tumours that had chromosome 15 abnormalities in almost every tumour (Liyanage 
et al., 2000, Tepsuporn et al., 2014). With exception to the Atm-/-nu-/- B cell lymphoma 68F2 
discussed above, and the 3 copies of Myc gene detected in Atm-/-nu-/- B cell lymphoma 5F3, 
chromosome 15 abnormalities and translocations involving chromosome 12 or 14 were 
infrequent in Atm-/-nu-/- B cell lymphoma.  Thus the ATMIN ΔB/ΔB mice along with the 
Atm-/-nu-/- both demonstrated tumour development in B cells that was unlikely to be 
dependent on deregulation of Myc. Thus, there are features of B cell lymphoma development 
in common between these two models. It is possible that the Tepsuporn mice, requiring both 
DJβ and Eµ-Bcl2 constructs (induced break and resistance to apoptosis) are the exception, 
determined by this additional manipulation. B cell tumour development in Atm-/-nu-/- mice 
may represent a model close to ataxia telangiectasia; as A-T patients develop both B and T 
cell lymphomas.  
In human lymphomas, MYC deregulation is most commonly associated with Burkitt 
lymphoma (BL). In more that 85% of BL IGH-MYC fusions are formed by the t(8;14) 
translocation. This translocation places MYC expression under the influence of the IGH 
promoter and consequently causes constant expression of the gene. Translocations associated 
with MYC are also found in roughly 10% of DLBCL and FL, which is similar to the Myc 
deregulation seen in Atm-/-nu-/- B cell lymphoma (1 in 6). In DLBCL and FL in humans 
MYC abnormalities are usually secondary to translocations involving BCL2 or BCL6 
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(Sewastianik et al., 2014, Swerdlow, 2008). This illustrates that there are other factors to 
consider in addition to IGH-MYC fusions. The Atm-/-nu-/- mouse is a model that enables 
investigation to these other mechanisms of tumour development.  
ATM mutations are frequently found in human B-CLL and MCL (Stankovic et al., 1999, 
Schaffner et al., 2000). Somatic loss of ATM can be caused by deletion of the part of 
chromosome 11 where ATM is located and/or mutation in the ATM gene (Stankovic et al., 
2002). Additional genetic lesions usually accompany ATM inactivation in these tumours. 
Chromosome 17 and 18 translocations were common in Atm-/-nu-/- B cell lymphomas. These 
chromosome breaks could be in areas that are prone to translocation such as fragile sites, but 
the recurrent selection for translocations in 17 and 18 suggests that genes involved in these 
translocations could have a role in tumour progression (Ozeri-Galai et al., 2007). Like the role 
of BCL2 and BCL6 in DLBCL and FL, oncogenes and/or tumour suppressor genes located on 
chromosome 17 and 18 could be candidates for causing tumorigenic transformation in the 
Atm-/-nu-/- mice. Identification of these genes would enable better understanding and 
treatments for B cell lymphoma both in A-T patients and ATM mutated tumours of the 
general population (Sandoval and Swift, 1998, Reiman et al., 2011).  
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